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1 Abstract 
Staphylococcus aureus, both a commensal organism and an important human pathogen, has 
been the objective of basic and clinical research for decades. S. aureus is the leading cause for 
a broad range of diseases, such as pneumonia, endocarditis or toxic shock syndrome. 
Especially nosocomial and community-acquired infections by methicillin-resistant S. aureus 
(MRSA) have become a major health issue. Since there has been an increased emergence of 
microorganisms resistant to various antibiotics, the development of new treatment strategies 
has become a key issue of modern biological and medical science and triggered the need for a 
fundamental knowledge on how these bacteria gain resistance to antibiotics. 
In the first part of this work, the response and putative resistance strategies of S. aureus to the 
lantibiotic mersacidin were studied. Mersacidin is an antimicrobial peptide of 20 amino acids 
that is ribosomally produced by Bacillus sp. strain HIL Y-85,54728. Mersacidin acts by 
complexing the sugar phosphate head group of the peptidoglycan precursor lipid II, thereby 
inhibiting the transglycosylation reaction of peptidoglycan biosynthesis. First, the growth of 
S. aureus in the presence of subinhibitory concentrations of mersacidin was analyzed. 
Transcriptional data revealed an extensive induction of the cell wall stress response which is 
partly controlled by the two-component regulatory system (TCRS) VraSR and which 
predominantly included the transcription of cell wall biosynthesis genes. In contrast to other 
cell wall-active antibiotics, such as the glycopeptide vancomycin, lower concentrations of 
mersacidin were sufficient for induction, probably, because the efficacy of mersacidin is not 
affected by an increased cell wall thickness. However, the cell wall stress response was 
equally induced in the more resistant S. aureus strains SA137/93A and SA137/93G as well as 
in the highly susceptible strain SG511-Berlin. Therefore, the cell wall stress response may not 
account for the different susceptibilities of these strains to mersacidin, but it appears to be a 
general accelerator system of cell wall biosynthesis, thereby contributing to a common 
resistance strategy of S. aureus to cell wall-active antibiotics. Since the transcription of the 
VraDE ABC transporter genes was induced up to 1700-fold in these experiments, the role of 
VraDE in the response to mersacidin was examined. However, a vraE knock-out phenotype 
did not exhibit an increased susceptibility to mersacidin compared to the wild type strain.  
In order to gain further insights into the mechanisms that S. aureus uses to counteract 
antimicrobials like mersacidin, the features of S. aureus SG511-Berlin were identified that 
contribute to its high susceptibility to antimicrobial peptides (AMPs) compared to other  
S. aureus strains. The fairly susceptible strain SG511-Berlin has been extensively used in the 
field of basic research on staphylococci and has represented a standard strain for antimicrobial 
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susceptibility testing for many years. Comparative expression profiling of S. aureus SG511-
Berlin versus the more resistant S. aureus strain SA137/93A revealed a divergent regulation 
of the dltB, mprF and vraFG genes, which are under the control of the TCRS GraRS. These 
transcripts showed significantly lower abundance in strain SG511-Berlin. Sequence analysis 
of graS in strain SG511-Berlin revealed a native nucleotide insertion that generates a stop 
codon at position 64 of the sensor histidine kinase GraS, thereby deleting the entire 
cytoplasmic part of the protein. Quantitative RT-PCR and determination of the whole cell 
surface charge of graS complemented S. aureus SG511-Berlin directly linked its decreased 
dltB transcript level and the resulting increased negative cell surface charge to the nucleotide 
insertion in graS. MIC determinations identified the GraRS TCRS as a resistance factor to the 
lantibiotics mersacidin, nisin and Pep5. In conclusion, mersacidin appears to be a strong 
inducer of the cell wall stress response of S. aureus at very low concentrations, which reflects 
its general mode of action as a cell wall-active peptide as well as its use of a unique target site 
on lipid II. Additionally, mersacidin appeared not to be a substrate for the ABC transporter 
VraDE and therefore may provide directions for the design of future antimicrobials that 
circumvent the action of resistance transporters. Furthermore, the GraRS system represents an 
important resistance factor of S. aureus to counteract AMPs and, due to these findings, the use 
of S. aureus SG511-Berlin for research purposes should be carefully considered, since this 
strain does not reflect the normal response of S. aureus against antibiotics. 
In the second part of this work, the lysis genes of the bacteriophages φ11 and φ12 of S. aureus 
NCTC8325 were characterized to evaluate the potential of endolysins as a novel treatment 
strategy for S. aureus biofilms. Knowledge about the lytic activities of both endolysins is 
limited. Their nucleotide sequences have been published and the φ11 endolysin has been 
shown to possess a D-alanyl-glycyl endopeptidase and an N-acetylmuramyl-L-alanine 
amidase activity on crude cell walls of S. aureus OS2. In this approach, the lytic activities of 
heterologously overexpressed enzymes and their single subdomains were tested on isolated 
cell walls, whole cells and biofilms of staphylococci. The recombinant φ11 endolysin 
hydrolyzed heat-killed staphylococci as well as staphylococcal biofilms. Cell wall targeting 
appeared to be a prerequisite for lysis of whole cells and the combined action of the 
endopeptidase and amidase domains was necessary for maximum activity. In contrast, the φ12 
endolysin was inactive and caused aggregation of the cells. Thus, endolysins may provide 
directions for the development of new biofilm treatment strategies to combat S. aureus 
nosocomial infections. 
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2 Introduction 
 
2.1 The human pathogen Staphylococcus aureus 
In 1884, Friedrich Julius Rosenbach described two differently pigmented colony types of 
staphylococci, namely Staphylococcus aureus (yellow) and Staphylococcus albus (white) 
which had been isolated from bacteriological cultures of the human nose and skin. The latter 
species comprises a growing number of coagulase-negative staphylococci including 
Staphylococcus epidermidis. The designation of the genus Staphylococcus is derived from its 
characteristical form of growth. The spherical cells, which are about 1 µm in diameter, occur 
in microscopic clusters resembling a bunch of grapes (in Greek: staphyle) because 
staphylococci divide in two planes (Fig. 2.1) (Peters and Pulverer, 2001). The configuration 
of the cocci helps to distinguish staphylococci from streptococci, since streptococci only 
divide in one plane, thereby forming slightly oblong cells that usually grow in chains.  
S. aureus is an immotile, non-sporulating bacterium with low GC-content that taxonomically 
belongs to the bacterial family of Staphylococcaceae within the phylum of the Gram-positive 
Firmicutes. The best-known of its nearby phylogenetic relatives are the members of the genus 
Bacillus in the family Bacillaceae. S. aureus can grow at a temperature range of 15 to 45°C 
and at NaCl concentrations as high as 15%. However, the growth optimum of S. aureus is  
30-37°C which correlates with the body temperature of the human host. S. aureus is a 
facultative anaerobe that grows by fermentation which yields principally lactic acid. It forms a 
fairly large yellow colony on rich medium and is often hemolytic on blood agar (Hahn et al., 
2004).  
 
 
 
 
 
 
 
 
 
Figure 2.1: Scanning electron microscope (SEM) image of Staphylococcus aureus. Source: Centers for 
Disease Control and Prevention's Public Health Image Library (PHIL, identification number #6486). Photo 
credit: Janice Carr; content providers: CDC/ Matthew J. Arduino, DRPH; Janice Carr. 
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Although more than 30 species of Staphylococcus are described (Götz et al., 2007), especially 
S. aureus and S. epidermidis appear to be important in their interactions with humans.  
S. aureus colonizes mainly the human nasal passages with a carrier rate of up to 40% (Noble, 
1997), but it may also be found regularly in most other anatomical areas. Noteworthy,  
S. epidermidis is an inhabitant of the human skin. Since S. aureus is relatively tolerant 
towards dehumidified conditions and disinfectants, it also persists outside the human host and 
therefore can be transmitted by smear infections. Actually, S. aureus is the leading cause for a 
broad spectrum of diseases that ranges from superficial skin lesions (furunculosis) and 
invasive inflammations (e.g. otitis and sinusitis) to life-threatening diseases such as 
pneumonia, endocarditis, meningitis or toxic shock syndrome (Hahn et al., 2004). The latter 
belongs to a class of toxin-mediated diseases caused by S. aureus that evokes multisystem 
disorders in the human host due to the staphylococcal toxic shock syndrome toxin (TSST-1). 
Additionally, S. aureus can cause food poisoning by releasing heat-stable enterotoxins (A, B, 
C1-3, D, E, G, H and TSST-1) into food that results in diarrhea and emesis. The pathogenesis 
of S. aureus infections may be divided into three essential steps comprising the adherence to 
the host cell tissue, the invasion of the host and strategies to overcome the host defenses. 
Here, numerous surface proteins of S. aureus, that belong to the MSCRAMM (microbial 
surface components recognizing adhesive matrix molecules) protein family, promote the 
attachment to the host tissue, e.g. the clumping factors A and B (fibrinogen receptors, ClfA 
and ClfB) as well as the fibronectin-binding proteins A and B (FnBPA, FnBPB) of S. aureus 
function as adhesins, thereby initiating the colonization of a new host. The invasion of the 
host tissue involves several extracellular factors produced by S. aureus including membrane-
damaging toxins, e.g. the α-toxin (α-hemolysin) and the β-toxin. Additionally, S. aureus 
produces coagulase and staphylokinase which take part in host invasion and help to survive 
the host defense mechanisms. Coagulase binds to prothrombin forming a complex called 
staphylothrombin that converts fibrinogen into fibrin, thereby coating the bacterial surface 
with fibrin that avoids phagocytosis. Nearly all strains of S. aureus produce coagulase, which 
is also an essential factor to distinguish between S. aureus (coagulase-positive) and S. 
epidermidis, since nearly all strains of S. epidermidis lack this enzyme (coagulase-negative). 
The staphylokinase lyses fibrin allowing the bacteria to escape from the fibrin meshwork that 
is often formed to keep an infection localized. The polysaccaride microcapsule as well as the 
protein A are further prominent factors that contribute to the virulence of S. aureus, since they 
prevent the opsonisation of S. aureus. While protein A is a surface protein that binds to the Fc 
region of immunoglobulins which is usually recognized by the Fc receptor of phagocytes, the 
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polysaccaride microcapsule masks the cells to inhibit phagocytic engulfment (Peters and 
Pulverer, 2001). S. aureus is also able to form small-colony variants (SCVs), which persist 
inside the host cells without causing host-cell damage or being affected by antibiotic 
treatment. Later those SCVs can revert to a more virulent phenotype and therefore contribute 
to persistent and recurrent infection (Proctor and Peters, 1998; Proctor et al., 1998).  
 
2.2 Staphylococcal biofilms 
Bacterial biofilms are currently defined as matrix-enclosed sessile populations of 
microorganisms that adhere to biological or non-biological surfaces which form structurally 
and dynamically complex biological systems. Biofilm formation is part of an intrinsic 
bacterial survival strategy that is usually induced upon suboptimal environmental conditions, 
e.g. by the limitation of nutrients, the presence of lethal concentrations of antibiotics or other 
conditions of stress. The overall development of bacterial biofilms can be divided into 
different stages. The initial stages generally involve the loose and transient association of 
bacteria with the surface and subsequent adhesion. Next, the cells aggregate into 
microcolonies, the structural units of biofilms, followed by growth and maturation. Here, the 
use of scanning electron microscopy and confocal laser scanning microscope techniques 
allowed the in situ examination of vital biofilms (Fig. 2.2). Bacterial biofilms were observed 
to be highly heterogenous and dynamic in structure showing defined cell clusters and water 
channels that permit a hydrodynamic flow through the biofilm which is necessary for an 
adequate supply of nutrients and the removal of waste (Lewandowski, 2000; Dunne, Jr., 
2002). The last stage is a discrete process that is important for the dispersal and structural 
development of biofilms and is defined by transient motility and the detachment of biofilm 
cells (Hall-Stoodley et al., 2004). The bacteria that grow in biofilms are characterized by a 
modified phenotype compared to planktonic cells which includes an altered growth rate and 
the expression of biofilm-specific genes. The initial cell attachment of bacteria triggers the 
transcription of genes controlling the production of bacterial compounds necessary for 
adhesion, biofilm formation and the dispersal of biofilm cells (Donlan and Costerton, 2002). 
Especially regulated cell death and lysis appear to be essential for the development of 
bacterial biofilms, since the genomic DNA, that is released by lysed bacteria, is an important 
structural component of bacterial biofilms and therefore takes part in cellular adhesion and 
biofilm stability (Bayles, 2007; Rice et al., 2007). Bacterial biofilms commonly occur in 
natural aquatic ecosystems and industrial water systems. However, the most serious 
appearance of bacterial biofilms involves device-related and chronic infections. Particularly  
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S. aureus and S. epidermidis are frequently associated with the colonization of medical 
devices like intravenous catheters, joint protheses, cardiac pacemakers or prosthetic heart 
valves (Götz, 2002; Peters et al., 1981; Marrie et al., 1982; von Eiff et al., 1999). Hence, 
biofilm formation may be defined as a virulence factor of S. aureus that contributes to 
infection. The most characteristic feature of staphylococcal biofilms is the extracellular matrix 
that is produced by the bacteria itself and that predominantly consists of polysaccharides or 
proteins. The most common matrix compound represents PIA (polysaccharide intercellular 
adhesion) which is composed of positively or negatively charged, β-1,6-linked  
N-acetylglucosamines that can be deacetylated, phosphorylated or contain esters of succinate 
(Mack et al., 1996a). Interestingly, most of the PIA producers also form a biofilm (Mack et 
al., 1996b). PIA synthesis is regulated by the ica gene cluster (Götz, 2002), a cluster that is 
conserved among staphylococci (Cramton et al., 1999). Most probably, PIA contributes to cell 
aggregation and accumulation of biofilm cells, since mutagenesis of the ica genes prevented 
biofilm formation (Heilmann et al., 1996a; Heilmann et al., 1996b). Additionally, several 
other essential factors have been identified to take part in staphylococcal biofilm formation, 
e.g. the AtlE murein hydrolase as well as the net charge of teichoic acids (Heilmann et al., 
1997; Gross et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Scanning electron micrograph (SEM) of the polysaccharide matrix of a Staphylococcus 
biofilm. Here, the staphylococcal biofilm is located on the inner surface of a needleless connector. Biofilms are 
characterized by the presence of an extracellular matrix consisting of polymeric substances, primarily 
polysaccharides, that surround and encase the cells. Source: Hardin Library for the Health Sciences, University 
of Iowa (http://www.lib.uiowa.edu/ hardin/md/cdc/staph/). 
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Furthermore, the surface proteins Bap (biofilm-associated protein), AAP (accumulation-
associated protein) and Eap (extracellular adherence protein) have been implicated in a 
protein-associated biofilm of S. aureus (Cucarella et al., 2001; Hussain et al., 1997; Hussain 
et al., 2002). Beside the colonization of artificial surfaces, staphylococci also settle on the 
extracellular matrix of the host tissue. To this end, receptors of the bacterial cell surface 
recognize host molecules like glycoprotein components and mediate the adhesion to host cell 
tissue (Götz, 2002). These receptors, called adhesins, belong to the family of staphylococcal 
MSCRAMMs which include FnBPA and FnBPB, the collagen-binding protein (Cna) as well 
as ClfA and ClfB. Furthermore, the α-toxin of S. aureus seems to contribute to cell-cell 
interactions during biofilm formation (Caiazza and O'Toole, 2003). 
An intrinsic feature of staphylococcal biofilms is the increased resistance to antibiotic 
treatment, disinfectants and host defenses which contributes to the persistance of biofilm 
infections (Mah and O'Toole, 2001; Stewart, 2002). A combination of several factors like 
poor antibiotic penetration, an altered microenvironment as well as adaptive responses 
appears to account for the protective mechanism of cells living in a biofilm. In this context, 
the extracellular matrix of biofilms might decelerate the diffusion rate of antimicrobial agents 
through the biofilm and antibiotic-matrix interactions may affect the activity of antibiotic 
compounds (Duguid et al., 1992a; Suci et al., 1994; Souli and Giamarellou, 1998). 
Furthermore, an altered growth rate of biofilm cells has an impact on the susceptibility to 
antibiotics (Stewart, 2002). Biofilm-associated cells are characterized by a decreased growth 
rate compared to planktonic cells which concomitantly leads to a decelerated uptake of 
antimicrobial substances and a decreased efficiency of specific antibiotics, e.g. β-lactams, that 
particularly act on growing cells. Indeed, a decreased growth rate had a direct influence on the 
susceptibility of S. epidermidis biofilms to fluorchinolones (Duguid et al., 1992b). Especially 
persister cells, which represent a phenotypic variant of microorganisms living in a biofilm, 
appear to contribute to antibiotic resistance (Anderson and O'Toole, 2008). In regions of 
substrate limitation, normal cells fail to grow and slowly convert to the persister state which is 
assumed to be incapable of growth. Persisters are generated at a fixed rate, which is not 
dependend on the presence of antimicrobial agents, and they are able to revert from the 
persister state after antibiotic treatment and allow the biofilm to regrow (Roberts and Stewart, 
2005; Shah et al., 2006). As a consequence of the increased antibiotic resistance, 
staphylococcal biofilms are of severe clinical relevance and about 65% of the nosokomial 
infections are due to the formation of biofilms (Mah and O'Toole, 2001). Biofilms are 
involved in various human infections like endocarditis, otitis media, osteomyelitis and 
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prostatitis as well as the colonization of medical devices like catheters and artificial heart 
valves. Considering the increased resistance of biofilms to conventionally used antibiotics, 
there is an urgent need to develop new strategies to combat biofilm infections. 
 
2.3 The cell wall envelope of S. aureus 
The cell wall of Gram-positive bacteria constitutes a structural entity that is located outside 
the bacterial plasma membrane and completely covers the cell. The bacterial cell wall 
comprises a multi-layer heteropolymer that predominantly consists of the sugar-peptide 
polymer peptidoglycan (up to 70%) with attached accessory molecules such as teichoic acids, 
teichuronic acids, polyphosphates, carbohydrates and proteins. The main structural features of 
the peptidoglycan are linear glycan chains of alternating units of β-1,4 linked N-acetyl-
glucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) interlinked by short peptides 
(Fig. 2.3). These peptide side chains are bound to the D-lactyl moiety of the MurNAc and are 
additionally cross-linked with peptides of neighboring glycan strands. The peptide side chain 
of S. aureus consists of L-alanine (L-Ala), D-glutamic acid (D-Glu), L-lysin (L-Lys) and  
D-alanine (D-Ala), in which the ε amino group of L-Lys is further modified by the addition of 
five glycine residues that form a characteristical interpeptide bridge to neighboring peptides. 
Thereby, a three-dimensional, elastic molecular network is generated that is intimately 
involved in the cell division process as well as the maintenance of the cell shape and the cell 
integrity by withstanding the internal osmotic pressure (Navarre and Schneewind, 1999; van 
Heijenoort, 2001).  
Cell wall biosynthesis occurs in three distinct subcellular compartments, the cytoplasm, the 
membrane and the cell wall itself (Fig. 2.3). In the first stage, several cytoplasmic steps lead 
to the formation of the soluble UDP-MurNAc-pentapeptide precursor (Park`s nucleotide). The 
assembly of UDP-MurNAc from UDP-GlcNAc and phosphoenolpyruvate as well as the 
consecutive attachment of the pentapeptide side chain (L-Ala, D-Glu, L-Lys and the D-Ala-
D-Ala dipeptide) are mediated by MurA to MurF. In the second stage, the MurNAc-
pentapeptide is phosphodiester linked via MraY to the membrane-bound undecaprenyl-
phosphate carrier molecule generating lipid I. Subsequently, MurG and FemXAB mediate the 
linkage of GlcNAc and five glycine residues, respectively, to produce the disaccharide 
precursor lipid II (van Heijenoort, 2001; Navarre and Schneewind, 1999). Finally, lipid II is 
translocated across the cytoplasmic membrane to the outside surface by a yet unknown 
mechanism. The third stage of cell wall biosynthesis comprises the incorporation of lipid II 
into the nascent peptidoglycan which is catalyzed by penicillin-binding proteins (PBPs). 
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Figure 2.3: S. aureus peptidoglycan structure and biosynthesis pathway of cell wall assembly. The original 
diagram was designed by Dr. T. Schneider and has been modified by P. Sass. 
 
 
The bifunctional PBPs promote both the polymerization of glycan from the lipid II precursors 
as well as the transpeptidation (cross-linkage) of the peptide side chains which results in the 
removal of a D-Ala at the C-terminal end of the pentapeptide (van Heijenoort, 2001; Navarre 
and Schneewind, 1999). The peptidoglycan is a structure that is unique for bacteria and 
therefore represents an effective target site for antimicrobial agents, e.g. β-lactam antibiotics 
imitate the structure of the D-alanyl-D-alanine and bind to the active site of PBPs, whereby 
the polymerization of new peptidoglycan is inhibited and the cell wall becomes vulnerable to 
lysis (Yocum et al., 1979; Yocum et al., 1980).  
 
2.4 Role of S. aureus in hospital-associated infections – MRSA / VISA / VRSA 
Infections with S. aureus are normally endogenous, i.e. the causative organism originates 
from the flora of the patient itself. However, hospital-aquired infections are often exogenous 
and are promoted by the extensive use of anti-infective agents among post-operative and 
immune suppressed patients. Here, the widespread use of anti-infective agents can lead to the 
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dissemination of multiresistant organisms that are spread among the patients via the medical 
and nursing staff. In fact, S. aureus is probably the most dangerous multiresistant bacterial 
organism in hospital settings which is due to its ability to easily acquire resistance to 
antibiotics. The accessory genome represents 25% of the whole genome of S. aureus and 
includes mobile elements, e.g. plasmids, bacteriophages, transposons, cassette chromosomes 
and genetic islands, which harbour genetic determinants for antibiotic resistance and virulence 
(Lindsay and Holden, 2004). 
In the 1940s, the first β-lactam resistant S. aureus strains have been described shortly after the 
implementation of penicillin treatment in hospitals (Barber, 1947; North and Christie, 1946). 
Today, more than 80% of S. aureus produce penicillin-degrading enzymes, the so-called  
β-lactamases (Peters and Pulverer, 2001). The introduction of semi-synthetic, β-lactamase-
stable penicillin derivatives, e.g. methicillin and oxacillin, was followed by the isolation of 
the first methicillin-resistant S. aureus (MRSA) in the early 1960s (Barber, 1961). Methicillin 
resistance is based on the acquisition of the staphylococcal cassette chromosome mec 
(SCCmec) by horizontal transfer from a yet unidentified donor (Gordon and Lowy, 2008). 
SCCmec contains the mecA gene encoding an additional PBP2, namely PBP2a. PBP2a is 
characterized by a decreased affinity for β-lactam antibiotics and thus it ensures the cross-
linking of the bacterial peptidoglycan when the endogenous PBP2 is inhibited by methicillin. 
Actually, hospital-acquired MRSA strains (HA-MRSA) represent a serious problem in 
hospital settings due to the eventuality of antibiotic treatment failure with severe 
consequences for the patient. Currently, 20% of the hospital isolates of S. aureus in Germany 
are MRSA (Hahn et al., 2004) and even 40-60% of MRSA were recorded in the United States 
and Japan (Lindsay and Holden, 2004). More recently, community-acquired MRSA  
(CA-MRSA) infections occurred among individuals in Australia and in the United States 
without health care contact (Udo et al., 1993; Tenover et al., 2006) and the number of  
CA-MRSA infections appears to be increasing (Vandenesch et al., 2003). From 1997 to 1999, 
four children died in the United States because of aggressive CA-MRSA infections caused by 
S. aureus strain MW2 (USA400) which were rapidly fatal involving necrotizing pneumonia 
or pulmonary abscesses and sepsis (Gordon and Lowy, 2008). The increased emergence of 
CA-MRSA has been proposed to be due to numerous factors like increased fitness, improved 
evasion of the host immune system and unique toxin production compared to HA-MRSA 
(Gordon and Lowy, 2008).  
Infections with MRSA are currently treated with vancomycin, a glycopeptide antibiotic that 
inhibits bacterial cell wall biosynthesis by binding to the D-alanyl-D-alanine terminus of the 
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cell wall precursor lipid II. However, in the last years, strains with decreased susceptibility to 
vancomycin (VISA – “vancomycin-intermediate resistance”, MIC 4-16 µg/ml) have emerged 
worldwide (Ruef, 2004) that are associated with clinical treatment failure of glycopeptide 
therapy (Song et al., 2004; Woods et al., 2004; Bierbaum et al., 1999). The VISA phenotype 
is variable and the genotypes of VISA strains have not yet been well understood. A common 
feature of VISA is a thickened cell wall as a cause of an elevated cell wall metabolism (Cui et 
al., 2000; Cui et al., 2003; Reipert et al., 2003; Cui et al., 2006; Hanaki et al., 1998a). In some 
strains, the cell wall cross-linking is decreased, resulting in a higher concentration of free  
D-alanyl-D-alanine termini in the cell wall that are able to complex vancomycin (Cui et al., 
2000; Hanaki et al., 1998b; Sieradzki and Tomasz, 2003; Reipert et al., 2003). Many strains 
are characterized by a decreased activity of autolysins, which may contribute to the increased 
cell wall thickness (Utaida et al., 2006; Boyle-Vavra et al., 2003; Koehl et al., 2004; Sakoulas 
et al., 2005). Alterations of the teichoic acids, which are able to complex vancomycin in an 
ionic interaction, may also augment vancomycin resistance (Peschel et al., 2000). For the 
development of high resistance, the loss of SSCmec has been described (Sieradzki and 
Tomasz, 1999; Reipert et al., 2003; Adhikari et al., 2004). In 2002, the first high level 
vancomycin resistant S. aureus strains (VRSA, MIC >32µg/ml) were isolated in the United 
States (Miller et al., 2002; Sievert et al., 2002). Probably, VRSA emerged by the acquisition 
of the vanA operon from an Enterococcus faecalis strain that colonized the same location 
(Chang et al., 2003). VanA-type resistance is due to the synthesis of modified cell wall 
precursors which do not complex vancomycin. However, high level vancomycin resistance is 
rare in S. aureus and appears to be incompatible with methicillin resistance (Perichon and 
Courvalin, 2006). In this context, there is a demand to establish new effective treatment 
strategies to treat MRSA. 
 
2.5 S. aureus strain SG511 
S. aureus strain SG511 is rather susceptible to most antibiotics and has been extensively used 
in the field of basic research on staphylococci and the screening for new antimicrobial agents 
for many years. Widespread use of strain SG511 in the first half of the last century resulted in 
the appearance of several strains named SG511 which could be divided into three different 
lysotypes (Pöhn, 1959), namely type “Berlin” (lysotype I), type “Hoechst” (lysotype II) and 
type “Duesseldorf” (lysotype III). Despite the differences concerning their lysotypes, 
pigmentation and hemolysis, all three subtypes displayed a concordant spectrum of 
susceptibility to antibiotics, which might be one of the reasons for their common designation 
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SG511 (Pulverer and Grün, 1960). Especially, the type “Berlin”, from the Robert Koch 
institute (Berlin, Germany), and the type “Hoechst”, originating from the strain collection of 
the “Farbwerke Hoechst AG” (Frankfurt am Main, Germany), have experienced intensive use 
in antibiotic susceptibility testing of new antimicrobial substances and basic microbiological 
research (Chatterjee et al., 1992a; Wink, 2002; Lampilas and Vogel, 1999; Garrard and 
Lascelles, 1968; Maidhof et al., 1989; de Jonge et al., 1993; Sass et al., 2008b; Pag et al., 
2008; Brötz et al., 1997). 
 
2.6 Lantibiotics – lanthionine containing peptide antibiotics 
Antimicrobial peptides (AMPs) are produced by a large variety of organisms as a part of their 
first line of defense. AMPs are generally regarded to be relatively short in length (up to 100 
amino acids) and have been isolated from microorganisms, insects, plants, amphibians, birds, 
fish and mammals, including humans (Jenssen et al., 2006). Some AMPs have been shown to 
be potent antimicrobial agents (Jack et al., 1995), however, these peptides also seem to play 
an important role as effector molecules of the innate immune system, e.g. by enhancing 
phagocytosis or recruitment and accumulation of various immune cells at inflammatory sites 
(Bowdish et al., 2005; Yang et al., 2002). The lantibiotics form a particular group among the 
AMPs and are characterized by unique structural features. These result from extensive 
posttranslational modifications that are mostly based on the amino acids serine (Ser), 
threonine (Thr) and cysteine (Cys) of the ribosomally produced precursor peptide. Here, the 
selective dehydration of serine and threonine yields the α,β-unsaturated amino acids 
didehydroalanine (Dha) and didehyrobutyrine (Dhb), respectively. Dha and Dhb are usually 
targets for the nucleophilic addition of the SH-groups of suitable positioned Cys residues that 
results in the formation of the ring forming thioether amino acids lanthionine (Lan, from Dha) 
and 3-methyllanthionine (MeLan, from Dhb) (Fig. 2.4). In fact, the designation “lantibiotics” 
is derived from “lanthionine containing peptide antibiotics”. Since the number of suitable 
reaction partners is limited, mature lantibiotics usually contain one or more dehydroamino 
acids that did not undergo nucleophilic addition. Furthermore, Cys residues located at the  
C-terminus may be oxidized and decarboxylated before the addition of Dha or Dhb resulting 
in 2-aminovinyl-D-cysteine (AviCys) or 2-aminovinyl-3-methyl-D-cysteine (AviMeCys) in 
the case of mersacidin (Sahl and Bierbaum, 1998). The ring structures contribute to enhanced 
resistance towards proteolysis (Bierbaum et al., 1996) and to increased tolerance to oxidizing 
conditions (Sahl et al., 1995). Mature lantibiotics are synthesized from gene encoded 
precursor peptides. The structural gene encoding the prepeptide (lanA) as well as the genes 
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coding for the postranslational modification of the prepeptide (lanM or lanB and lanC), export 
of the prepeptide and subsequent activation by cleavage of its N-terminal leader sequence 
(lanP, lanT), the regulation of the biosynthesis (lanK, lanQ, lanR) and the genes encoding 
producer self protection (lanE, lanF, lanG, lanI) are organized in gene clusters (Sahl and 
Bierbaum, 1998). So far (November, 2008), more than 60 lantibiotics have been described 
(Table 2.1) all of which are produced by and predominantly act against Gram-positive 
bacteria, thereby exerting multiple modes of action like pore formation and/or inhibition of 
cell wall biosynthesis (Chatterjee et al., 1992b; Willey and van der Donk, 2007; Bierbaum 
and Sahl, 2009).  
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Figure 2.4: Structure of the lantibiotics nisin, Pep5, mersacidin and cinnamycin. Nisin and Pep5 represent 
type-AI lantibiotics with elongated and flexible configurations. Mersacidin and cinnamycin belong to the type-B 
lantibiotics that are characterized by a rather globular structure. 
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Table 2.1: Overview of lantibiotics 
Lantibiotic Mass (Da) Producer strain Reference 
Type-AI lantibiotics
nisin group 
nisin A 3353 Lactococcus lactis Gross & Morell (1971) 
nisin Z 3330 Lactococcus lactis Mulders et al. 1991 
nisin Q 3327 Lactococcus lactis Zendo et al (2003) 
nisin U 3029 Streptococcus uberis Wirawan et al (2006) 
nisin F not determined Lactococcus lactis de Kwaadsteniet et al (2008) 
subtilin 3317 Bacillus subtilis Gross et al (1973) 
ericin A 2986 Bacillus subtilis Stein et al (2002) 
ericin S 3442 Bacillus subtilis Stein et al (2002) 
microbisporicin 2246/2230 Microbiospora sp. Castiglione et al. (2008) 
epidermin group 
epidermin 2164 Staphylococcus epidermidis Allgaier et al. (1986) 
[Val1, Leu6]-epidermin 2151 Staphylococcus epidermidis Israil et al. (1996) 
gallidermin 2164 Staphylococcus gallinarum Kellner et al. (1988) 
staphylococcin T 2166 Staphylococcus cohnii Furmanek et al. (1999) 
mutacin B-Ny266 2270 Streptococcus mutans Mota-Meira et al. (1997) 
mutacin 1140 2263 Streptococcus mutans Hillman et al. (1998) 
mutacin I 2364 Streptococcus mutans Qi et al. (2000) 
mutacin III 2266 Streptococcus mutans Qi et al. (1999) 
streptin 2424 Streptococcus pyogenes Wescombe & Tagg (2003) 
Pep5 group 
Pep5 3488 Staphylococcus epidermidis Kaletta et al. (1989) 
epilancin K7 3032 Staphylococcus epidermidis van de Kamp et al. (1995) 
epicidin 280 3133 Staphylococcus epidermidis Heidrich et al. (1998) 
epilancin 15X 3173 Staphylococcus epidermidis Ekkelenkamp et al. (2005) 
Type-AII lantibiotics
lacticin 481 group 
lacticin 481 2901 Lactococcus lactis Piard et al. (1993) 
mutacin II 3245 Streptococcus mutans Novak et al. (1994) 
streptococcin A-FF22 2795 Streptococcus pyogenes Jack et al. (1994) 
salivaricin A 2315 Streptococcus salivarius Ross et al. (1993) 
salivaricin A1 2321 Streptococcus salivarius Simpson et al. (1995) 
salivaricin A2 2364 Streptococcus salivarius Wescombe et al. (2006) 
salivaricin A3 2312 Streptococcus salivarius Wescombe et al. (2006) 
salivaricin A4 2340 Streptococcus salivarius Wescombe et al. (2006) 
salivaricin A5 2328 Streptococcus salivarius Wescombe et al. (2006) 
salivaricin B 2740 Streptococcus salivarius Hyink et al. (2007) 
variacin 2658 Micrococcus varians Pridmore et al. (1996) 
macedocin 2795 Streptococcus macedonicus Georgalaki et al. (2002) 
nukacin ISK-1 2960 Staphylococcus warneri Sashihara et al. (2000) 
nukacin KQU-131 3004 Staphylococcus hominis Wilaipun et al. (2008) 
plantaricin C 2880 Lactobacillus plantarum Turner et al. (1999) 
mutacin K8 2734 Streptococcus mutans Robson et al. (2007) 
butyrivibriocin not determined Butyrivibrio fibrisolvens Kalmokoff et al. (1999) 
continued on following page 
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Table 2.1 - Continued 
Lantibiotic Mass (Da) Producer strain Reference 
ruminococcin A 2675 Ruminococcus gnavus Dabard et al. (2001) 
Type-B lantibiotics
mersacidin group 
mersacidin 1825 Bacillus ssp. Chatterjee et al. (1992) 
actagardine 1890 Actinoplanes liguriae Zimmermann et al. (1995) 
Ala(O)-actagardine 1961 Actinoplanes liguriae Vertesy et al. (1999) 
michiganin A 2145 Clavibacter michiganensis Holtsmark et al. (2006) 
cinnamycin group 
cinnamycin 2042 Streptomyces cinnamoneus Fredenhagen et al. (1990) 
duramycin 2014 Streptomyces cinnamoneus Fredenhagen et al. (1990) 
duramycin B 1951 Streptoverticillium sp. Fredenhagen et al. (1990) 
duramycin C 2008 Streptomyces griseoluteus Fredenhagen et al. (1990) 
ancovenin 1959 Streptomyces ssp. Kido et al. (1983) 
Others
class III morphogenic peptides 
SapB 2026 Streptomyces coelicolor Kodani et al. (2004) 
SapT 2032 Streptomyces tendae Kodani et al. (2005) 
AmfS not determined Streptomyces griseus Ueda et al. (2002) 
two peptide lantibiotics 
lacticin 3147 3322/2847 Lactococcus lactis ssp. Martin et al. (2004) 
staphylococcin C55 3339/2993 Staphylococcus aureus C55 Navaratna et al. (1998) 
plantaricin W 3223/3099 Lactobacillus plantarum Holo et al. (2001) 
haloduracin 2332/3046 Bacillus halodurans McClerren et al. (2006) 
Smb not determined Streptococcus mutans GS5 Yonezawa & Kiramitsu (2005) 
BHT 3375/2802 Streptococcus ratus BHT Hyink et al. (2005) 
cytolysin LL/LS 4164/2631 Enterococcus faecalis Booth et al. (1996) 
peptides which have not yet been assigned to a group 
planosporicin 2194 Planomonospora sp. Castiglione et al., 2007 
cypemycin 2094 Streptomyces ssp. Komiyama et al. (1993) 
lactocin S 3764 Lactobacillus sake Skaugen et al. (1994) 
sublancin 168 3877 Bacillus subtilis Paik et al. (1998) 
pediocin PD-1 2866 Pediococcus damnosus Bauer et al. (2005) 
carnocin UI 49 4635 Carnobacterium piscicola Stoffels et al. (1993) 
bovicin HJ50 3428 Streptococcus bovis HJ50 Xiao et al. (2004) 
paenibacillin 2983 Paenibacillus polymyxa He et al. (2007) 
 
 
According to their configuration and mode of action, the lantibiotics can be subdivided into 
several types. Nisin, subtilin, epidermin and Pep5 belong to the type-AI lantibiotics with an 
elongated and flexible configuration that predominantly disturb bacterial membranes. Nisin 
probably represents the most prominent lantibiotic which is commonly employed as a food 
preservative (Galvez et al., 2007). Nisin is biologically active in nanomolar concentrations. It 
binds specifically to lipid II and causes pore formation in bacterial membranes as well as 
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inhibition of cell wall biosynthesis (Wiedemann et al., 2001). The type-B lantibiotics 
comprise rather globular peptides including mersacidin that act by inhibition of the cell wall 
biosynthesis since they tightly bind to lipid II. The type-AII lantibiotics combine features of 
the type-AI and type-B lantibiotics, e.g. lacticin 481 is characterized by a linear N-terminus 
and a globular C-terminus and its modification system is analogous to the type-B lantibiotics. 
Furthermore, there are lantibiotics that cannot be classified into the established types. Some 
lantibiotics like SapB exert a morphogenic rather than a bactericidal effect (Kodani et al., 
2004) and others function optimally as a consequence of the synergistic activity of two 
peptides (Lawton et al., 2007). 
 
2.7 The lantibiotic mersacidin 
Mersacidin is the smallest lantibiotic known so far (1825 Da) and belongs to the type-B 
lantibiotics. It is an uncharged molecule of 20 amino acids forming four intramolecular 
thioether bridges (3 x MeLan, 1 x AviMeCys) which confer a globular structure to the peptide 
(Fig. 2.4) (Prasch et al., 1997). The mersacidin gene cluster (12.3 kb) is located on the 
chromosome of the producer Bacillus sp. strain HIL Y-85,54728. For the biosynthesis of 
biologically active mersacidin, a precursor peptide consisting of the N-terminal leader peptide 
and the C-terminal propeptide is ribosomally synthesized from its structural gene mrsA 
(Bierbaum et al., 1995). The posttranslational modification of the precursor peptide is 
catalyzed by two distinct enzymes, namely MrsM and MrsD. MrsM consists of 1062 amino 
acids and confers the dehydration of the serine and threonine residues as well as the formation 
of the thioether bridges, thereby generating the characteristic MeLan residues. MrsD is a 
FAD-containing enzyme of 194 amino acids that oxidatively decarboxylizes the C-terminal 
Cys residue to produce AviMeCys (Altena et al., 2000; Majer et al., 2002). Proteolytic 
activation of the modified precurser peptide by cleavage of the leader peptide is performed 
concomitantly with export by the ABC transporter MrsT that contains an N-terminal protease 
domain (Havarstein et al., 1995; Altena et al., 2000). Producer self-protection is also mediated 
by an ABC transporter (MrsFEG) that confers immunity to exogenous mersacidin and 
prohibits binding of mersacidin to the producer strain. MrsE and MrsG both form membrane-
spanning subunits while MrsF contains an ATP binding site that is responsible for ATP 
hydrolysis and drives the active extrusion of mersacidin (Guder et al., 2002). The active 
transport of antibiotics away from the bacterial cell by membrane-associated ABC 
transporters, or so-called drug resistance transporters, is a mechanism that is often utilized by 
bacteria to escape from the effects of antimicrobial agents. Hence, intrinsic and aquired 
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resistance transporters play an important role in the antimicrobial resistance of several 
pathogens, including S. aureus. Drug resistance transporters usually respond to specific 
classes of antimicrobial compounds and decrease their concentration at the bacterial 
membrane below a critical level to prevent killing of the cell (Putman et al., 2000). Since 
ABC transporters appear to be energy consuming systems, they are subject to tight 
modulation by regulatory pathways including two-component regulatory systems (TCRS). 
The TCRS constitutes a type of phosphotransfer-mediated signalling pathway and consists of 
two conserved modular proteins: a sensor histidine protein kinase and a corresponding 
response regulator. Upon specific environmental stimuli, the histidine kinase undergoes 
autophosphorylation at a conserved histidine residue followed by transfer of the phosphoryl 
group to a conserved aspartate residue of the regulatory domain of the cognate response 
regulator resulting in its activation. The response regulator again is regulated by the 
phosphatase activity of the histidine kinase or the response regulator itself (Mascher et al., 
2006; Mascher, 2006). Commonly, the activated response regulator functions as transcription 
regulator of specific target genes. In the case of mersacidin biosynthesis, the immunity 
transporter MrsFGE is controlled by the TCRS MrsR2/K2 in which MrsR2 belongs to the 
family of OmpR/PhoB winged helix binding domain response regulators and MrsK2 
represents the sensor histidine kinase (Guder et al., 2002; Altena et al., 2000). The 
biosynthesis cluster of mersacidin comprises a second regulatory protein with lower similarity 
to the Omp/PhoB family of response regulators, namely MrsR1, which appears to be essential 
for the biosynthesis of mersacidin (Guder et al., 2002). However, a gene encoding a 
corresponding histidine kinase is not present (Altena et al., 2000). Further, the biosynthesis of 
mersacidin seems to be regulated by an autoinducing mechanism (Schmitz et al., 2006).  
Mersacidin exerts bactericidal activity by the selective inhibition of the transglycosylation 
reaction of bacterial cell wall biosynthesis. To this end, it complexes the sugar phosphate head 
group of the peptidoglycan precursor lipid II (Fig. 2.3), thereby preventing the incorporation 
of the peptidoglycan precursor molecule into the nascent peptidoglycan (Brötz et al., 1998). 
Interestingly, the efficiency of mersacidin is dependent on the presence of divalent cations, 
since Ca2+-ions dramatically increase the bactericidal effect of mersacidin in vitro (Barrett et 
al., 1992). Furthermore, mersacidin undergoes conformational changes upon substrate binding 
which is due to a hinge region (Ala-12 and Abu-13) in between the second and the third ring 
structure (Hsu et al., 2003). Probably, mersacidin binds to a Ca2+-ion located at the 
diphosphate group of lipid II which is followed by the enclosure of the lipid II disaccharide 
domain as a result of conformational reconfiguration of mersacidin. In addition, the lipid II-
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binding mechanism of mersacidin is assumed to depend on electrostatic interactions, since the 
carboxylic acid residue at position Glu-17 of the third ring structure appeared to be essential 
for biological activity (Szekat et al., 2003). In fact, this ring represents the putative lipid II-
binding motif and it is conserved among other lantibiotics, e.g the lacticin 481 group 
lantibiotics, the two-peptide lantibiotics and plantaricin C (Willey and van der Donk, 2007). 
Importantly, mersacidin uses a target binding site that is different from any other clinically 
applied antibiotic. It has been shown to successfully inhibit the growth of Gram-positive 
bacteria including MRSA in vitro and in vivo (Hoffmann et al., 2002; Kruszewska et al., 
2004; Chatterjee et al., 1992a) as well as enterococci expressing the VanA vancomycin 
resistance phenotype (Brötz et al., 1997). Considering the emergence of VISA since the late 
1990s (Ruef, 2004), new effective treatment strategies for MRSA are urgently needed. In this 
context, lantibiotics could represent alternatives for clinical applications (Willey and van der 
Donk, 2007) and mersacidin might be a blueprint for the development of new antibiotics to 
control nosocomial infections (Brötz et al., 1998; Kruszewska et al., 2004).  
 
2.8 Antibacterial activities of phage-encoded cell wall hydrolases  
Temperate bacteriophages, which integrate as prophages into the genome of the bacterial host 
without propagation and induction of host lysis, represent a common feature of bacteria 
including S. aureus. Upon specific environmental conditions, the prophage is able to switch 
from the lysogenic stage to the lytic cycle which involves the production of new phage 
particles and lysis of the host cell. Newly synthesized phage particles are usually released 
from bacterial host cells by the synergistic action of phage-encoded two-component lysis 
systems. Here, a hydrophobic membrane protein, termed holin, oligomerizes in the bacterial 
membrane to form disruptive lesions, thereby promoting the access of a cell wall hydrolase 
(endolysin) to its substrate, the peptidoglycan of the bacterial host, at a programmed time of 
the phage’s life cycle (Young et al., 2000; Ronda-Lain et al., 1977).  
Usually, endolysins are multi-domain proteins that belong to the late gene products which are 
produced towards the end of the phage’s lytic cycle. An example represents the temperate 
bacteriophage φ11 of S. aureus NCTC8325 (Iandolo et al., 2002). The φ11 endolysin consists 
of an N-terminal, a central and a C-terminal domain which give rise to multiple enzymatic 
activities that cleave the bacterial peptidoglycan at two distinct sites. The N-terminal domain 
displays D-alanyl-glycyl endopeptidase activity and therefore cleaves the peptide bond 
between the D-Ala of the pentapeptide and the glycine of the interpeptide bridge. The central 
domain represents an N-acetylmuramyl-L-alanine amidase which hydrolyzes the peptide bond 
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between N-acetylmuramyl and L-Ala (Navarre et al., 1999). The C-terminus is homologous to 
the cell wall binding domain of lysostaphin (Loessner et al., 1998), a staphylolytic bacteriocin 
secreted by Staphylococcus simulans biovar staphylolyticus (Schindler and Schuhardt, 1964) 
with glycyl-glycine endopeptidase activity. The cell wall binding domain directs the 
endolysin to its target in the bacterial cell wall. Since the cell wall binding domain has been 
shown to distinguish between different peptidoglycan cross-bridges (Lu et al., 2006), it 
confers high specificity, in this case to S. aureus, which appears to be a common 
characteristic among endolysins. Phage φ12 is another temperate bacteriophage of S. aureus 
NCTC8325 (Iandolo et al., 2002) that has not yet been studied in detail.  
Due to the antibacterial properties of endolysins, endolysin therapy is intensively discussed as 
an alternative to common antibiotic therapy for clinical treatment or the prevention of 
infectious disease (Parisien et al., 2008). Endolysins possess several important features, e.g. a 
narrow antibacterial spectrum, activity against bacteria regardless of their antibiotic 
sensitivity, a low probability of developing resistance and a novel mode of action. In fact, first 
clinical studies indicated that the therapeutic use of endolysins should not be prevented by 
potential problems with endolysin therapy, e.g. their immunogenicity or the release of 
proinflammatory components during bacteriolysis (Borysowski et al., 2006). Additionally, the 
specificity of endolysins makes them more appealing today compared to broad-spectrum 
antibiotics, since they should not affect the microbial flora of the host. 
 
2.9 Objectives of this work 
In times of increased antibiotic treatment failure, which can lead to severe clinical infections, 
there is an obvious need to understand how bacteria respond to the presence of antibacterial 
compounds and develop resistance. Additionally, new treatment strategies need to be 
explored to counteract microorganisms that are multi-resistant to conventionally applied 
antibiotics. 
The first part of this work was conceived to analyze the response and to identify putative 
resistance mechanisms of S. aureus to the lantibiotic mersacidin, an antimicrobial peptide 
with potential for clinical application. To this end, gene expression profiling by using full 
genome S. aureus microarrays and quantitative Real-Time PCR techniques was conducted to 
elucidate the transcriptional response of S. aureus to subinhibitory concentrations of 
mersacidin. For this purpose, three S. aureus strains providing varying susceptibility 
characteristics were employed, namely the vancomycin- and methicillin-susceptible (VSSA / 
MSSA) strain S. aureus SG511-Berlin as well as the heterogeneous VISA / MRSA strain  
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S. aureus SA137/93A and the closely related VISA / MSSA strain S. aureus SA137/93G 
(Reipert et al., 2003; Maki et al., 2004). To further identify probable constitutive resistance 
mechanisms of S. aureus to mersacidin and other antimicrobials, the gene expression profile 
of the susceptible strain SG511-Berlin was compared to that of the more resistant S. aureus 
strain SA137/93A in the absence of antibiotics. 
In the second part of this work, the in vitro activity of endolysins was evaluated to hydrolyze 
staphylococcal biofilms. Since conventional antibiotics predominantly affect the metabolism 
of bacteria, they have no effect on non-growing persister cells of bacterial biofilms. In 
contrast, endolysins are enzymes that hydrolyze the bacterial peptidoglycan and, thus, should 
target growing and non-growing cells. For this purpose, the endolysins of the staphylococcal 
bacteriophages φ11 and φ12 were heterologously overexpressed in Escherichia coli, purified 
via immobilized metal affinity chromatography (IMAC) and subsequently applied to 
staphylococcal cells and biofilms growing on polystyrene surfaces. Additionally, the lytic 
activities of the single subdomains of the φ11 endolysin were further characterized in order to 
gain deeper insights into the mode of action of endolysins. 
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3 Materials and methods 
 
3.1 Bacterial strains, plasmids and growth conditions 
Bacterial strains used in this thesis are listed in Table 3.1. Staphylococci were cultured in 
tryptic soy broth (TSB; Oxoid, Wesel, Germany), brain heart infusion (BHI) medium 
(Becton-Dickinson GmbH, Heidelberg, Germany) or half concentrated BHI as indicated. 
Escherichia coli was cultivated in lysogeny broth (LB; 10 g/L tryptone, 5 g/L yeast extract, 
10 g/L NaCl (Bertani, 2004; Bertani, 1951)). The growth conditions were 37°C with aeration 
unless indicated otherwise. Plasmids used in this thesis are listed in Table 3.2. S. aureus 
strains harbouring the pTX15 vector, which comprises a xylose-inducible promoter, or its 
derivatives were grown in the presence of 12.5 µg/ml tetracycline and 0.5% of xylose was 
routinely used to induce expression from the plasmid. For the maintenance of pCU1 
derivatives, S. aureus cultures were grown with 20 µg/ml chloramphenicol. E. coli strains 
carrying pUC19, pCU1 or the pET22b derivatives were grown with 40 µg/ml ampicillin. 
 
3.2 S. aureus typing methods 
 
3.2.1 Pulsed field gel electrophoresis (PFGE) 
Purification of chromosomal DNA for the SmaI restriction digest and PFGE were performed 
as described previously (Goering and Duensing, 1990). PFGE was carried out on the Chef 
DRIII System (BioRad, München, Germany) using Pulsed Field Certified Agarose (1%)  
(Bio-Rad), 6 V/cm, a field angle of 120°, and switch times of 5-15 s for 7 h and 15-60 s for a 
further 19 h. A chromosomal DNA SmaI digest of S. aureus NCTC8325 served as mass 
standard. 
 
3.2.2 Multi locus sequence typing (MLST) 
MLST of S. aureus strain SG511-Berlin and strain SA137/93A was performed as previously 
described (Enright et al., 2000). The sequence types (ST) were determined using the MLST 
database via http://saureus.mlst.net/. 
 
3.2.3 Phage typing 
The identity of S. aureus SG511-Berlin was confirmed by phage typing. Phage typing was 
conducted using the international set for phage typing employed at the routine test dilution 
and 100 times the routine test dilution in accordance with the standard rules agreed on by the 
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International Union of Microbiological Societies Subcommittee on Phage Typing of 
Staphylococci. Phage typing was kindly performed by M. Oedenkoven (IMMIP). 
 
 
Table 3.1: Bacterial strains and bacteriophages used in this thesis. 
Abbreviations: hVISA, heterogeneous vancomycin intermediately resistant S. aureus; MRSA, methicillin-
resistant S. aureus; MET, methicillin; r, resistant; s, susceptible. 
Strain / phage Relevant characteristic(s) Reference(s) or source 
Staphylococcus  
aureus 
  
SG511-Berlin Susceptible control strain RKI Berlin, 
Germany 
SG511∆vraE vraE-defective mutant of strain SG511-Berlin Sass V. et al. 
(2008) 
SA137/93A Clinical hVISA isolate; METr, Northern German epidemic MRSA Reipert et al. 
(2003) 
SA137/93G Spontaneous mutant of SA137/93A, ∆SCCmec (METs), ∆tcaA Reipert et al. 
(2003), Maki et 
al. (2004) 
NCTC8325 Biofilm-positiv, laboratory strain with defect rsbU, lysogenic for 
phages φ11, φ12and φ13 
Iandolo et al. 
2002 
RN4220 Restriction-negative derivative of S. aureus NCTC8325 Kreiswirth et al. 
(1983) 
RN1”HG” S. aureus  NCTC8325 with repaired rsbU F. Götz, 
Tübingen 
MRSA252 U.K. hospital-acquired MRSA strain Holden et al. 
(2004) 
N315 Japan hospital-acquired MRSA strain Kuroda et al. 
(2001) 
Cowan I MSSA, catheter infections by binding of fibrinogen and fibronectin Juuti et al. 
(2004) 
Newman MSSA Wolz et al. 
(1996) 
Wood 46 Protein A-deficient, alpha-toxin producing strain Delmi et al. 
(1994) 
Staphylococcus 
simulans 
  
22 Penicillin-resistant, lysostaphin susceptible Kloos and 
Schleifer (1975) 
Staphylococcus 
epidermidis 
  
 O-47 Biofilm-positiv, clinical isolate causing central venous catheter-
associated infections 
Rupp et al. 
(2001) 
Escherichia  
coli 
  
K12 JM109 Subcloning host Yanisch-Perron 
et al. (1985) 
Bl21(DE3) λDE3 lysogen harbouring the T7 RNA-polymerase gene; protein 
expression host 
Studier and 
Moffatt (1986) 
Bacteriophages 
  
φ11 Siphoviridae; temperate bacteriophage of S. aureus NCTC8325 Iandolo et al. 
2002 
φ12 Siphoviridae; temperate bacteriophage of S. aureus NCTC8325 Iandolo et al. 
2002 
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Table 3.2: Plasmids used in this thesis. 
Abbreviations: Tet, tetracycline; Amp, ampicillin; Cm, chloramphenicol; r, resistant; s, susceptible. 
Plasmid Relevant characteristic(s) Reference(s) or source 
pTX15 Xylose-inducible staphylococcal expression vector; Tetr Peschel et al. 
(1996) 
pTX16 Derivative of pTX15 lacking the lipase gene downstream of xylAR Peschel et al. 
(1996) 
pTXgraS 
(MRSA252) 
pTX15 derivative with the graS gene of S. aureus MRSA252 
(SAR0670) under the control of xylAR 
This thesis 
pTXgraS  
(N315) 
pTX15 derivative with the graS gene of S. aureus N315 (SA0615) 
under the control of xylAR 
This thesis 
pCU1 high copy shuttle vector, Ampr, Cmr, MCS-lacZ` Augustin et al. 
(1992) 
pCU1graXRS 
(MRSA252) 
pCU1 derivative carrying the SAR0668-70 genes of S. aureus 
MRSA252  
This thesis 
pCU1graXRS 
(N315) 
pCU1 derivative carrying the SA0613-15 genes of S. aureus N315 This thesis 
pUC19 high copy vector, Ampr, MCS-lacZ` Vieira and 
Messing (1982) 
pUC19gyrB pUC19 (Ampr), carrying a 560 bp internal fragment of gyrB (SA0005); 
external plasmid standard for qRT-PCR 
Jansen et al. 
(2007) 
pUC19dltB pUC19 (Ampr), carrying a 1354 bp internal fragment of dltB 
(SA0794); external plasmid standard for qRT-PCR 
This thesis 
pUC19vraF pUC19 (Ampr), carrying a 761 bp internal fragment of vraF (SA0616); 
external plasmid standard for qRT-PCR 
This thesis 
pET22b 
    
C-terminal 6xHis-tag expression vector, T7 lac promoter, Ampr Studier and 
Moffatt (1986) 
pET22b∆pelB 
    
pET22b without pelB-leader tag Sass, 2005 
pETer∆11 pET22b + ORF 53 of φ11 (aa 1-490, 56.5 kDa) [I/II] Sass, 2005 
pETendo/ami11 pET22b + ORF 53 of φ11 (aa 1-371, 43.2 kDa) [I/IX] This thesis 
pETendo11 pET22b + ORF 53 of φ11 (aa 1-180, 22.1 kDa) [I/V] This thesis 
pETendoCBD11 pET22b + ORF 53 of φ11 (∆aa 181-370, 35.2 kDa) [I/V; VI/VII] This thesis 
pETami11 pET22b + ORF 53 of φ11 (aa 180-371, 22.8 kDa) [VIII/IX] This thesis 
pETamiCBD11 pET22b + ORF 53 of φ11 (aa 180-490, 36.1 kDa) [VIII/II] This thesis 
pETer∆12 pET22b + ORF 49 of φ12 (aa 1-484, 55.3 kDa) [III/IV] Sass, 2005 
pETer∆12mut mutated pETer∆12 for the expression of T780G substituted φ12mut 
endolysin 
This thesis 
Roman numerals in parentheses are primer pairs (see Table 3.3)  used for amplification of ORFs [for/rev].  
 
 
3.3 Antimicrobial susceptibility testing 
Determination of the minimal inhibitory concentration (MIC) was performed in polystyrene 
round bottom microtiter plates (Greiner, Frickenhausen, Germany) using BHI broth or half 
concentrated BHI broth as indicated. An inoculum of 5 × 105 CFU/ml was employed in the 
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arithmetic broth microdilution method. All experiments were done in triplicate. For MIC 
testing of mersacidin (Hoechst, Frankfurt am Main, Germany), CaCl2 was added to all 
cultures to a final concentration of 1 mM unless indicated otherwise, since Ca2+-ions enhance 
the bactericidal effect of mersacidin (Barrett et al., 1992; Schneider et al., 2000). 
 
3.4 Growth conditions of S. aureus for the preparation of total RNA 
For the analysis of the mersacidin induced transcriptional response of S. aureus, the cultures 
were diluted 200-fold from overnight precultures and grown to exponential phase until they 
reached an optical density at 600 nm (OD600) of 0.5 in BHI broth. Then, mersacidin was 
added as indicated, and the cultures were further grown to an OD600 of 1.0 for total RNA 
preparations (~30 minutes) or longer to assess growth behavior.  
For the comparative analysis of S. aureus SG511-Berlin with S. aureus SA137/93A via DNA 
microarrays, 10 ml cultures were diluted 200-fold from fresh BHI broth overnight precultures 
and were further incubated until they reached an OD600 of 1.0.  
For the extraction of total RNA for dltB and vraF expression analysis, overnight cultures were 
diluted 200-fold into 10 ml half concentrated BHI and grown to exponential phase until they 
reached an OD600 of 0.5. Then, the cationic antimicrobial peptide (CAMP) indolicidin was 
added to a final concentration of 0.5 µg/ml in order to induce dltB and vraF expression via the 
GraRS two-component regulatory system (Li et al., 2007a). The cultures were further grown 
for 30 minutes to an OD600 of  approximately 1.0.  
 
3.5 Preparation of total RNA 
For RNA preparation, S. aureus cultures were grown as aforementioned and aliquots of 10 ml 
were stabilized by incubation with two volumes of prewarmed RNAprotect Bacteria Reagent 
(Qiagen, Hilden, Germany) for 5 min at 37°C. The culture was subsequently harvested by 
centrifugation and the pellets were shock-frozen in liquid nitrogen and kept at -70°C. The 
cells were lysed in the presence of 400 µg/ml lysostaphin (Genmedics, Reutlingen, Germany) 
and total RNA was extracted using the PrestoSpin R bug kit including DNase I treatment 
(Molzym, Bremen, Germany) following the manufacturer’s instructions. Quality and quantity 
of total RNA were determined by agarose gel electrophoresis and measured by using the 
Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, USA). 
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3.6 Synthesis of CyDye-3 and CyDye-5 labeled cDNA for microarray experiments 
 
3.6.1 Direct cDNA labeling 
For the analysis of the mersacidin induced response of S. aureus, fluorescence-labeled single-
stranded cDNA was obtained by reverse transcription of total RNA. To this end, aliquots of 
total RNA preparations from three different cultures of each condition were pooled to a total 
amount of 9 µg (3 µg each) and transcribed into cDNA using 100 units (U) of BioScript 
reverse transcriptase (Bioline, Luckenwalde, Germany) following the manufacturer’s 
instructions. The total reaction volume of 40 µl contained 75 µg/ml pd(N)6 random hexamers 
(GE Healthcare, Freiburg, Germany), 0.1 mM CyDye3- or CyDye5-dCTPs (GE Healthcare) 
aside from 0.2 mM dCTP, 0.5 mM dATP, 0.5 mM dTTP, 0.5 mM dGTP and 25 U/ml RNase-
OUT (Invitrogen, Karlsruhe, Germany). RNA was degraded by alkaline hydrolysis at 65°C 
and fluorescence-labeled cDNA was purified using the MinElute PCR purification kit 
(Qiagen). cDNA synthesis and CyDye3 / CyDye5 incorporation were verified by using the 
Nanodrop spectrophotometer (Nanodrop Technologies). 
 
3.6.2 Indirect cDNA labeling 
For the comparative analysis of S. aureus SG511-Berlin and S. aureus SA137/93A, 
fluorescence-labeled DNA was obtained by reverse transcription of total RNA. Therefore, 
total RNA preparations (3 µg) were transcribed into cDNA using BioScript reverse 
transcriptase (Bioline) and pd(N)6 random hexamers (GE Healthcare) following the 
manufacturers’ instructions. For fluorescence-labeling, three different aliquots of cDNA 
preparations from separate cultures of the respective experiment were pooled to a total 
amount of 300 ng (100 ng each) and were subsequently used in the labeling reaction using the 
BioPrime(R) DNA Labeling System (Invitrogen) according to the instruction manual using 
pd(N)6 random hexamers (Invitrogen), 0.1 mM CyDye3- or CyDye5-dCTPs aside from 0.2 
mM dCTP, 0.5 mM dATP, 0.5 mM dTTP, 0.5 mM dGTP (GE Healthcare). 
 
3.7 Microarray hybridization and analysis 
Microarray-based transcriptional profiling by competitive hybridization of fluorescence-
labeled cDNA was performed by using the custom PCR product full-genome chip sciTracer 
(Scienion, Berlin, Germany) containing 2338 unique open reading frames representing 90% 
of the S. aureus N315 genome (NC_002745). Additional information on the microarray 
platform has been deposited in NCBI’s Gene Expression Omnibus (see below). Each 
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experiment was performed 4 times including a dye swap resulting in four chips per 
competitive comparison to increase reproducibility. S. aureus SA137/93G incubated with 
0.15 x MIC of mersacidin for the analysis of the mersacidin induced response of S. aureus as 
well as the microarray experiments for the comparative analysis of S. aureus SG511-Berlin 
with S. aureus SA137/93A were only reproduced in duplicate. All hybridizations were done 
with equal amounts of cDNA probes displaying similar picomoles of incorporated dye. 
Fluorescence-labeled cDNA probes were mixed in hybridization buffer (Scienion) in a total 
volume of 55 µl, denatured at 95°C for 2 min and subsequently applied to the microarray slide 
followed by incubation at 42°C for 72 hours under humidified conditions according to the 
manufacturer’s instructions. Hybridized microarrays were washed at room temperature in 
SSC buffer with decreasing salt concentrations (1 x SSC / 0.3% SDS for 5 min, 0.2 x SSC for 
5 min, 0.06 x SSC for 30s). For image capture, the microarrays were scanned with a GenePix 
4000B scanner (Axon Instruments / Distribution by Biozyme Scientific GmbH, Hessisch 
Oldendorf, Germany). The TIFF images were analyzed with GenePixPro4.1 software (Axon 
Instruments). The actual signal intensity was calculated by using the mean of the “median of 
ratios” of the individual spot. The data sets were then normalized by using Acuity 3.1 
software (Axon Instruments) and by applying the LOWESS algorithm. For the analysis of the 
mersacidin induced response of S. aureus, significant changes of gene expression were 
determined by implementing SAM (significance analysis of microarrays; http://www-
stat.stanford.edu/~tibs/SAM/) (Tusher et al., 2001) using the one class response and a false 
discovery rate of <1% with a medium number of falsely called significant genes of <1.  
 
3.8 Microarray data accession number 
Additional information on the microarray platform as well as the processed and raw 
microarray data of this thesis have been deposited in NCBI’s Gene Expression Omnibus 
(GEO) (http://www.ncbi.nlm.nih.gov/geo/) to be found under the GEO Series accession 
numbers GSE9261 and GSE12016. 
 
3.9 Transcript quantification by Real-Time PCR (qRT-PCR) 
The LightCycler instrument (Roche Diagnostics, Mannheim, Germany) was employed to 
generate quantitative transcription data by measuring sample amplification during the log-
linear phase of the PCR. Therefore, total RNA preparations (3 µg) were transcribed into 
cDNA using BioScript reverse transcriptase (Bioline) and pd(N)6 random hexamers  
(GE Healthcare) following the manufacturers’ instructions. Quantitative RT-PCR was 
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performed by using the LightCycler FastStart DNA Master SYBR Green I kit (Roche 
Diagnostics) according to the manufacturer’s instructions. For all experiments, the amount of 
transcripts was determined from the appropriate standard curve and the target concentration 
was expressed in relation to the concentration of the constitutively expressed housekeeping 
gene gyrB. Each standard curve was generated by assaying gene specific PCR product or 
plasmid templates. The specific primers, which were used for the synthesis of external 
LightCycler standards or for qRT-PCR of the target genes and the endogenous control gyrB, 
are listed in Table 3.3. To control quality and reproducibility of the qRT-PCR data, at least 
two different cDNA probes were synthesized employing RNA preparations from independent 
cultures for every condition. The PCR products were verified by melting curve analysis and 
ethidium bromide staining on agarose gels. 
 
3.10 Nucleotide sequence analysis of vraDE, vraS and graXRS 
The nucleotide sequences of vraDE and vraS as well as graXRS (SA0613-5, of the genomic 
sequence of S. aureus N315) in S. aureus SG511-Berlin, SA137/93A and SA137/93G were 
determined from PCR fragments, which were amplified from genomic DNA using a standard 
PCR protocol and the primers described in Table 3.3. For graXRS sequencing of strain 
SG511-Berlin, the PCR products were amplified from at least two different long-term 
glycerol stock cultures for each strain. The nucleotide sequences were obtained by Sanger 
sequencing including quality editing of the automatically determined sequence (Sequiserve, 
Vaterstetten, Germany). In silico analysis of sequence data was performed using world wide 
web-based online analysis tools (http://molbiol-tools.ca/). 
 
3.11 Molecular cloning procedures 
 
3.11.1 Isolation of genomic DNA 
For genomic DNA preparations of S. aureus, 2-4 ml overnight cultures were harvested and 
lysed in the presence of 125 µg/ml lysostaphin (Genmedics) followed by genomic DNA 
extraction using the PrestoSpin D bug kit (Molzym) according to the manufacturer’s 
instructions. Quality and quantity of genomic DNA were determined by agarose gel 
electrophoresis and measured by using the Nanodrop spectrophotometer (Nanodrop 
Technologies). 
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    Table 3.3: Oligonucleotide primers used in this thesis. 
Primer Primer sequence 5’-3’ Anneal.Temp. 
Reference(s) 
or source 
a) Oligonucleotide primers used for the synthesis of external vraE and vraS qRT-PCR standards 
vraE-1 TCTCATATGACATTTAACCATATCGTTTTC (NdeI) 64.5°C This thesis 
vraE-2 TAACTCGAGAATGGTTTTCTTAATCAATTTGTTTG (XhoI) 64.5°C This thesis 
vraS-1 TTACATATGAACCACTACATTAGAACAAT (NdeI) 63.2°C This thesis 
vraS-2 AATAAGCTTATCGTCATACGAATCCTCCT (HindIII) 63.2°C This thesis 
b) Oligonucleotide primers used to construct the external qRT-PCR standards pUC19dltB and pUC19vraF 
dltBfor-Xba1 AAATCTAGATGCAGAGGTAATTAACGGATGA (Xba1) 62°C This thesis 
dltBrev-Pst1 ATACTGCAGTCTTCAAAAATTTCTACGTCTGGA (Pst1) 62°C This thesis 
vraFfor-Xba1 AAATCTAGAGGTAAGCGTGCCAAATTGAAT (Xba1) 62°C This thesis 
vraFrev-Pst1 TTACTGCAGTGCTATGCGTATATTTTAGTGCT (Pst1) 62°C This thesis 
c) Oligonucleotide primers used for qRT-PCR 
gyrB-297 TTAGTGTGGGAAATTGTCGATAAT 52°C Goerke et al. (2006) 
gyrB-547 AGTCTTGTGACAATGCGTTTACA 52°C Goerke et al. (2006) 
vraE-1-RT2 GTAACTGTATTGTGTTTCGCGGC 52°C This thesis 
vraE-2-RT2 TGATGGCATTGTTGCCTGTTACC 52°C This thesis 
vraS-1-RT GTTGGTTCGGTACTCGCATA 52°C This thesis 
vraS-2-RT CTCGAGCTAGTCTTTGACGTTC 52°C This thesis 
dltB-RT1 CATGGTTAGGTGGACATCAGA 52°C This thesis 
dltB-RT2 CGATATTCATTGCCTGTTGG 52°C This thesis 
vraF-RT1 TCCATCCGAATTGTCTGGT 52°C This thesis 
vraF-RT2 CCGTGAATATTTGCCCATC 52°C This thesis 
d) Oligonucleotide primers used for vraDE sequencing 
vraDprom_for TCCAATCAACCAGGTAATAGCA 62°C This thesis 
vraDint_rev TTGGAAGATGAAACCTAATGATTCT 62°C This thesis 
vraEfor CAATCAGTATTAGGTGGTGTC 62°C This thesis 
vraEint_rev GCGTTTCACGAATAAATGATTG 62°C This thesis 
vraErev CTCAATGAAGCATCTTTTAATCG 62°C This thesis 
e) Oligonucleotide primers used for vraS sequencing 
vraSfor CGTTTATCGGAGACGTAGAG 62°C This thesis 
vraSrev GTACCATTTCATGATCATCCAC 62°C This thesis 
f) Oligonucleotide primers used for graXRS (SA0613-5) sequencing 
SA0613_for CTAACTCTACGTATAATATGGGC 64°C This thesis 
SA0613int_rev GTGTTATTTTGGCAGAATTCTTTGT 64°C This thesis 
continued on following page 
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   Table 3.3 - Continued 
Primer Primer sequence 5’-3’ Anneal. Temp. 
Reference(s) 
or source 
graRint_rev ATACCAGCAACATTAAAATCCCATT 64°C This thesis 
graSintern_rev GCGCTGAGATTTGACGATATAAATAA 64°C This thesis 
graS_rev CAATTCTAAGTAACAAAACGCATG 64°C This thesis 
g) Oligonucleotide primers used for the construction of pTXgraS 
graSpTX-BamH1 GTAGGATCCGGATATATGGCACATGAATAATTTG (BamHI) 64°C This thesis 
graSpTX-Mlu1 ATGACGCGTCAATTCTAAGTAACAAAACGCATG (Mlu1) 64°C This thesis 
h) Oligonucleotide primers used for the construction of pCU1graXRS 
SA0613pCU-Xba1 TCTTCTAGACTAACTCTACGTATAATATGGGC (XbaI) 64°C This thesis 
graSpCU-Pst1 ATGCTGCAGCAATTCTAAGTAACAAAACGCATG (PstI) 64°C This thesis 
i) Oligonucleotide primers for the mapping of Tn551 transposon insertion  
Tn551-P1 TCCGAGAGTGATTGGTCTTG 60°C This thesis 
Tn551-P2 AAATTTCTCGTAGGCGCTCG 60°C This thesis 
Tn551-P2.2 GTTTGGATCTCGCAATACACG 62°C This thesis 
k) Oligonucleotide primers used for the construction of pET22b derivatives 
I. phi11F TTTGGATCCAATGAGTATCATCATGGAGGTG (BamHI) 62°C This thesis 
II. phi11R GTCAAGCTTACTGATTTCTCCCCATAAGTCA (HindIII) 62°C This thesis 
III. phi12F GTGGGATCCAATGTTGATAACAAAAAACCAA (BamHI) 62°C This thesis 
IV. phi12R TAAAAGCTTAATCGTGCTAAACTTACCAAAAC (HindIII) 62°C This thesis 
V. endo11R TTGAAGCTTAGCTGTTTCTTTTTTAGGT (HindIII) 62°C This thesis 
VI. CBD11F ATGAAGCTTAAAATACCGGTTGCCACTGT (HindIII) 69.3°C This thesis 
VII. CBD11R GTCCTCGAGACTGATTTCTCCCCATAAGTCA (XhoI) 69.3°C This thesis 
VIII. ami11F GAACATATGAAGCCACAACCTAAAGCAGTAG (NdeI) 64°C This thesis 
IX. ami11R CGGAAGCTTACCATCCATGTACGCCCTAA (HindIII) 64°C This thesis 
l) Oligonucleotide primers used for the construction of mutated φ12 endolysin 
phi12mutFor “Phos“-ACAGGGGTATGACATTGTTCTAGAGA 62°C This thesis 
phi12mutRev “Phos“-GATTTAACCCAATATAAGCCATAA 62°C This thesis 
    Restriction sites are underlined and in brackets. Mutated primer nucleotides are underlined and in italics. 
 
 
3.11.2 Isolation of plasmid DNA 
For plasmid DNA preparations, 2-4 ml overnight cultures were harvested followed by 
plasmid DNA extraction using the QIAprep® Spin Miniprep kit (Qiagen) according to the 
manufacturer’s instructions. Lysis of S. aureus cultures was supported by the presence of 125 
µg/ml lysostaphin (Genmedics). Quality and quantity of genomic DNA were determined by 
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agarose gel electrophoresis and measured by using the Nanodrop spectrophotometer 
(Nanodrop Technologies). 
 
3.11.3 Purification of DNA fragments and extraction from agarose gels 
DNA fragments were excised from agarose gels under UV light using a scalpel and purified 
by employing the MinElute™ PCR Purification kit (Qiagen) or the QIAquick™ Gel 
Extraction kit (Qiagen) depending on the target’s size and according to the manufacturer’s 
instructions. 
 
3.11.4 Agarose gel electrophoresis 
The electrophoretic separation of RNA and DNA fragments was performed on a horizontal 
electrophoresis apparatus (Peqlab, Erlangen, Germany) using Top Vision™ LE GQ agarose 
(Fermentas, St. Leon-Rot, Germany) with concentrations of 0.8-2% depending on the 
molecular weight of the specific fragments. TAE (Tris-Acetate-EDTA) buffer was used for 
the preparation of agarose gels and as an electrophoresis running buffer according to standard 
procedures (Sambrook et al., 1989). RNA and DNA fragments were visiualized by ethidium 
bromide staining and documented using the ImageMaster VDS system (GE Healthcare/ 
Pharmacia). 
 
3.11.5 Polymerase chain reaction (PCR) 
PCR was performed on the PCRexpress Thermal Cycler (Thermo Fisher Scientific, Waltham, 
USA; formerly Hybaid) or the SensoQuest Labcycler (Sensoquest, Göttingen, Germany). 
GoTaq DNA polymerase (Promega, Mannheim, Germany) or Phusion™ HF DNA 
polymerase (NEB, Frankfurt am Main, Germany) were used for DNA amplification following 
the manufacturers’ instructions and according to standard PCR procedures. The primers used 
for PCR are listed in table 3.3. 
 
3.11.6 Enzymatic modification of DNA 
Digestion of DNA by FastDigest® restriction enzymes (Fermentas), vector dephosphorylation 
using FastAP™ thermosensitive alkaline phosphatase (Fermentas), filling of 5`-protruding 
ends for blunt end DNA ligation using Klenow fragment (Fermentas) and ligation of DNA 
fragments using T4-ligase (Roche) were performed following the manufacturers’ instructions 
and according to standard procedures (Sambrook et al., 1989). 
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3.11.7 Site-directed mutagenesis 
The Phusion™ Site-Directed Mutagenesis kit (NEB) was employed to introduce single point 
mutations into the coding sequence of target genes located on the pET22b plasmid (Fig. 3.1). 
According to the manufacturer’s instructions, PCR amplification of the target plasmid was 
performed using two 5`-phosphorylated primers, comprising the desired mutation, which 
anneal back to back to the plasmid. Circularization of the mutated PCR products was 
achieved by blunt end ligation followed by transformation of the mutated plasmid into E. coli 
by electroporation (see below). 
 
 
 
 
 
 
 
 
Amplified target 
plasmid with 
desired mutation 
Plasmid 
circularization by 
ligation 
High Fidelity PCR 
amplification 
Figure 3.1: Schematic representation of site-directed mutagenesis. Derived from www.finnzymes.com. 
 
 
3.11.8 Mapping of Tn551 transposon insertion 
Chromosomal DNA of S. simulans 22 Tn551-7 was isolated as aforementioned and digested 
with HpaI (Roche). The digest was purified using the E.Z.N.A.® Cycle Pure kit (Peqlab), 
diluted 1:5 and religated. A PCR was performed employing the outgoing primers Tn551-P1 
and Tn551-P2 (Table 3.3) that anneal within the 5`-terminal 278 bp HpaI fragment of Tn551 
and Phusion™ HF DNA polymerase (NEB) using a standard PCR protocol. The PCR 
products were analyzed on 1% agarose gels and new bands appearing compared to the wild 
type were extracted from the gel, purified and sequenced (Sequiserve). 
 
 
 
genomic sequence 
of S. simulans 22 Tn551 
genomic sequence 
of S. simulans 22 
P2
P1
HpaI HpaI
 
 
 
Figure 3.2: Schematic representation of mapping the Tn551 transposon insertion. 
 
 
Materials and methods  32 
3.11.9 Transformation of E. coli and S. aureus by electroporation 
The transformation of bacteria by electroporation is based on a significant increase of 
electrical conductivity and permeability of the cell plasma membrane caused by an externally 
applied electrical field which allows the introduction of DNA into the cell. For the preparation 
of electrocompetent cells, the bacteria were grown to an OD600 of 0.5 and were subsequently 
washed several times with destilled water and resuspended in 10% glycerol for 
cryoprotection. Electroporation was performed as described previously for S. aureus (Schenk 
and Laddaga, 1992) and E. coli (Sass, 2005). 
 
3.11.10 Transformation of S. aureus by phage transduction 
The pCU1 vector derivatives were transduced into S. aureus SG511-Berlin by phage 
transduction using bacteriophage 85 as described previously (Berger-Bächi and Kohler, 1983) 
including a heat shock at 52°C for 2 min to inactivate the host restriction system. 
 
3.12 Cytochrome c assay 
For the determination of the whole-cell surface charge, stationary-phase bacteria (OD600 of  
3-5) were harvested and washed twice with 20 mM 3-[N-morpholino] propanesulfonic acid 
(MOPS; pH 7.0; Sigma-Aldrich, Taufkirchen, Germany). Six absorbance units (e.g. bacteria 
from 2 ml of a culture with an OD600 of 3) were resuspended in 500 µl equine heart 
cytochrome c (0.5 mg/ml; Sigma) dissolved in MOPS buffer. After an incubation for 10 min 
at room temperature, the samples were pelleted and the supernatant was assayed 
photometrically at 530 nm using a control (buffer without cells) and a cytochrome c standard 
curve as a reference. The data represent the mean values of at least three independent studies 
unless indicated otherwise. 
 
3.13 C-terminal six-His-tagged proteins 
 
3.13.1 The pET22b C-terminal six-His-tag protein expression vector 
The pET22b C-terminal six-His-tag protein expression vector belongs to the pET system 
family (Merck-Novagen, Darmstadt, Germany) which are employed for the cloning and 
expression of recombinant proteins in E. coli (Fig. 3.3). Target genes are cloned into pET22b 
under the control of the strong bacteriophage T7lac promoter and the lac operator. In the 
pET22b vector, the coding sequence of six histidine residues is located downstream the 
multiple cloning site (mcs) that enables the C-terminal fusion of a six-His-tag to any target 
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gene which allows its purification via Ni-NTA affinity chromatography. Expression is 
induced by providing a source of T7 RNA polymerase in the host cell and by the addition of 
isopropyl-β-D-thiogalactopyranoside (IPTG) to the bacterial culture. The expression host  
E. coli BL21(DE3) is lysogenic for bacteriophage DE3 and therefore carries a copy of the  
T7 RNA polymerase gene under the control of the lacUV5 promoter. E. coli BL21(DE3) also 
harbours the lac repressor gene lacI which blocks the transcription of the T7 RNA polymerase 
gene and the target gene on pET22b until IPTG induction. Furthermore, the pET22b vector 
offers the pelB signal sequence, which is co-transcribed with the target gene and mediates the 
transport of the six-His-tagged protein into the periplasm of E. coli.  
 
 
 
Figure 3.3: The pET22b C-terminal six-His-tag protein expression vector. Source: www.novagen.com 
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3.13.2 Expression and purification of C-terminal six-His-tagged proteins 
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3.13.3 Sodium dodecyl sulfate polyacrylamide gel electro
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Table 3.4: Chemical ingredient
Chemicals Resolving gel (12%) Stacking gel (4%) 
Acrylamide/bisacrylamide (19:1) 2.25 ml 0.238 ml 
Solution A 1.25 ml ------- 
Solution D ------- 0.3 ml 
APS 2.0 ml 0.8 ml 
Distilled water 2.7 ml 1.03 ml 
SDS (20%) 50 µl ------- 
Tetramethylethylendiamin (TEMED) 5 µl 5 µl 
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3.13.4 Determination of protein concentrations according to Bradford 
um supplemented with 
.25% D-(+)-glucose to a final volume of 200 µl in each well of a flat-bottomed 96-well 
polystyrene microtiter plate (Nunc, Wiesbaden, Germany). The plates were incubated for 24 h 
or 48 h at 37°C under aerobic conditions or in 5% CO2 incubation atmosphere, respectively. 
Afterwards, the wells were washed twice with incubation buffer [50 mM Tris-HCl, 100 mM 
NaCl, pH 7.5]. The biofilm-containing wells were then filled with incubation buffer plus 
endolysin. Fresh medium and incubation buffer alone or incubation buffer plus lysostaphin or 
lysozyme were employed as controls. Lysostaphin was used as a positive control, since it is 
able to lyse S. aureus and S. epidermidis biofilms (Wu et al., 2003). Following incubation for 
two hours at 37°C, the wells were washed again and stained with 0.1% safranin.  
 
3.15 Sodium metaperiodate and proteinase K treatment of staphylococcal biofilms 
Staphylococcal biofilms were obtained as aforementioned and treated with either 40 mM 
sodium periodate or 1 mg/ml proteinase K dissolved in incubation buffer [50 mM Tris-HCl, 
100 mM NaCl, pH 7.5] for 24 h. Distilled water was used as a control. 
 
The sample protein concentration was determined by the Bradford method (Bradford, 1976) 
using the Protein Assay Reagent (BioRad) as described previously (Sass, 2005). 
 
3.14 Activity testing of C-terminal six-His-tagged proteins 
 
3.14.1 Photometric assay 
A photometric assay was employed to analyze the lytic activities of the six-His-tagged 
endolysins (each applied in a concentration of 20 µg/ml). To this end, the turbidity of  purified 
SDS cell walls of S. simulans 22 (Bierbaum and Sahl, 1987) or heat-inactivated staphylococci 
(pasteurized for 10 minutes at 80°C), both resuspended in incubation buffer [50 mM  
Tris-HCl, 100 mM NaCl, pH 7.5] to an OD600 of ~0.3, was measured over time. All lysis 
experiments were performed in triplicates. 
 
3.14.2 Biofilm assay 
The influence of six-His-tagged endolysins on staphylococcal biofilms was determined by a 
modified biofilm plate assay (Wu et al., 2003). To obtain staphylococcal biofilms, an 
overnight culture of the desired strain was diluted 1:200 in TSB medi
0
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4 Results 
 
Part I – Response and resistance of S. aureus to the lantibiotic mersacidin 
 
4.1 Antimicrobial susceptibility testing of S. aureus SA137/93A, S. aureus SA137/93G 
and S. aureus SG511-Berlin to mersacidin 
In this thesis, three S. aureus strains with different susceptibility characteristics were 
employed, namely the vancomycin- and methicillin-susceptible (VSSA / MSSA) strain  
S. aureus SG511-Berlin as well as the heterogeneous VISA / MRSA strain S. aureus 
SA137/93A and the closely related VISA / MSSA strain S. aureus SA137/93G (Reipert et al., 
2003; Maki et al., 2004). The three strains displayed considerable differences in their 
susceptibilities to mersacidin. While the growth of S. aureus SG511-Berlin was already 
inhibited by 1 µg/ml mersacidin in BHI, the minimal inhibitory concentrations (MIC) of 
mersacidin against SA137/93A and SA137/93G were 35 µg/ml and 30 µg/ml in BHI broth, 
respectively. To assess suitable mersacidin concentrations for microarray experiments, the 
lantibiotic was added to an exponentially growing S. aureus culture at an OD600 of ~0.5 (time 
point “a”; Fig. 4.1). In the microarray experiments, the cells were harvested at an OD600 of ~1 
(time point “b”; Fig. 4.1) before the reduced growth rates of the cultures became visible. The 
slight variation of the MIC values between the two VISA strains was also reflected by the 
growth curve of strain SA137/93G showing a stronger decrease of its growth rate after 
addition of 16 µg/ml mersacidin. 
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Figure 4.1: In vitro growth of S. aureus in the presence of mersacidin. S. aureus SG511-Berlin (¡ 1 µg/ml, 
 control); S. aureus SA137/93A (S 16 µg/ml, U control); S. aureus SA137/93G ( 16 µg/ml,  4 µg/ml,  
control). 
 
Results     37 
4.2 PFGE, MLST and phage typing of S. aureus strains SA137/93A and SG511-Berlin 
Since the PFGE patterns and lysotypes of S. aureus SA137/93A and SA137/93G have been 
previously described (Bierbaum et al., 1999; Reipert et al., 2003), S. aureus SG511-Berlin 
was also analyzed via PFGE (Fig. 4.2). However, the PFGE pattern of S. aureus SG511-
Berlin was dissimilar from the patterns of the strains SA137/93A, SA137/93G and all other  
S. aureus strains typed via PFGE at the reference center for staphylococci at the Institute for 
Medical Microbiology in Bonn (Marion Oedenkoven, IMMIP; personal communication). 
This might be due to the fact that PFGE is commonly used to study the international spread of 
MRSA epidemic clones rather than MSSA strains. 
 
 1  2 
~200 kb 
~100 kb
 
 
 
 
 
 
 
 
 
Figure 4.2: Pulsed field gel electrophoresis (PFGE) of S. aureus SG511-Berlin. (1) S. aureus SG511-Berlin; 
(2) S. aureus NCTC8325 (reference strain). 
 
 
To further characterize S. aureus strain SA137/93A and strain SG511-Berlin, the sequence 
type (ST) of each strain was determined by MLST (Fig. 4.3 and Fig. 4.4). Since S. aureus 
SA137/93G is isogenic to strain SA137/93A (Reipert et al., 2003), this strain was not tested. 
MLST is a molecular typing technique that has become the predominant method to study the 
epidemiology of S. aureus because of its high discrimination and inter-laboratory 
reproducibility (Enright et al., 2000). MLST of S. aureus involves sequencing DNA 
fragments (~500-600 bp) of seven housekeeping genes, namely arcC (carbamate kinase), 
aroE (shikimate dehydrogenase), glpF (putative glycerol uptake facilitator protein SAR1274), 
gmk (guanylate kinase), pta (phosphate acetyltransferase), tpiA (triosephosphate isomerase) 
and yqi (acetyle coenzyme A acetyltransferase). The nucleotide sequences of these genes are 
then trimmed to standard sequence lengths (trimmed sequences) and are compared to known 
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alleles at each locus via the MLST database (http://saureus.mlst.net/). Here, every isolate is 
described by a seven-integer allelic profile that defines a sequence type. 
S. aureus SA137/93A could be assigned to the allele type 3-3-1-12-4-4-16 (ST247) and is 
therefore closely related to the Northern German epidemic MRSA strain SA1450/94 
(Cookson et al., 2007). S. aureus SG511-Berlin had the allele type 2-2-2-2-6-3-2 (ST30) 
which is considered to be the ancestral type of the MRSA clonal complex (CC) 30 (Robinson 
and Enright, 2003) and is therefore closely related to S. aureus MRSA252 (ST-36) (Johnson 
et al., 2001; Enright et al., 2000). 
 
 
 
S. aureus SA137/93A – arcC – allele number  3 
TTATTAATCCAACAAGCTAAATCGAACAGTGACACAACGCCGGCAATGCCATTGGATACTTGTGGTGCAATGTCACAGGGTATGATAGGCTATT
GGTTGGAAACTGAAATCAATCGCATTTTAACTGAAATGAATAGTGATAGAACTGTAGGCACAATCGTTACACGTGTGGAAGTAGATAAAGATGA
TCCACGATTTGATAACCCAACTAAACCAATTGGTCCTTTTTATACGAAAGAAGAAGTTGAAGAATTACAAAAAGAACAGCCAGACTCAGTCTTT
AAAGAAGATGCAGGACGTGGTTATAGAAAAGTAGTTGCGTCACCACTACCTCAATCTATACTAGAACACCAGTTAATTCGAACTTTAGCAGACG
GTAAAAATATTGTCATTGCATGCGGTGGTGGCGGTATTCCAGTTATAAAAAAAGAAAATACCTATGAAGGTGTTGAAGCG 
 
S. aureus SA137/93A – aroE – allele number 3 
AATTTTAATTCTTTAGGATTAGATGATACTTATGAAGCTTTAAATATTCCAATTGAAGATTTTCATTTAATTAAAGAAATTATTTCGAAAAAAG
AATTAGAAGGCTTTAATATCACAATTCCTCATAAAGAACGTATCATACCGTATTTAGATTATGTTGATGAACAAGCGATTAATGCAGGTGCAGT
TAACACTGTTTTGATAAAAGATGGCAAGTGGATAGGGTATAATACAGATGGTATTGGTTATGTTAAAGGATTGCACAGCGTTTATCCAGATTTA
GAAAATGCATACATTTTAATTTTGGGCGCAGGTGGTGCAAGTAAAGGTATTGCTTATGAATTAGCAAAATTTGTAAAGCCCAAATTAACTGTTG
CGAATAGAACGATGGCTCGTTTTGAATCTTGGAATTTAAATATAAACCAAATTTCATTAGCAGATGCTGAAAAGTATTTA 
 
S. aureus SA137/93A – glpF – allele number 1 
GGTGCTGATTGGATTGTCATCACAGCTGGATGGGGATTAGCGGTTACAATGGGTGTGTTTGCTGTCGGTCAATTCTCAGGTGCACATTTAAACC
CAGCGGTGTCTTTAGCTCTTGCATTAGACGGAAGTTTTGATTGGTCATTAGTTCCTGGTTATATTGTTGCTCAAATGTTAGGTGCAATTGTCGG
AGCAACAATTGTATGGTTAATGTACTTGCCACATTGGAAAGCGACAGAAGAAGCTGGCGCGAAATTAGGTGTTTTCTCTACAGCACCGGCTATT
AAGAATTACTTTGCCAACTTTTTAAGTGAGATTATCGGAACAATGGCATTAACTTTAGGTATTTTATTTATCGGTGTAAACAAAATTGCCGATG
GTTTAAATCCTTTAATTGTCGGAGCATTAATTGTTGCAATCGGATTAAGTTTAGGCGGTGCTACTGGTTATGCAATCAACCCAGCACGT 
 
S. aureus SA137/93A – gmk – allele number 12 
CGAATATTTGAAGATCCAAGTACATCATATAAGTATTCTATTTCAATGACAACACGTCAAATGCGTGAAGGTGAAGTTGATGGCGTAGATTACT
TTTTTAAAACTAGGGATGCGTTTGAAGCTTTAATCAAAGATGACCAATTTATAGAATATGCTGAATATGTAGGCAACTATTATGGTACACCAGT
TCAATATGTTAAAGATACAATGGACGAAGGTCATGATGTATTTTTAGAAATTGAAGTAGAAGGTGCAAAGCAAGTTAGAAAGAAATTTTCAGAT
GCGCTATTTATTTTCTTAGCACCTCCAAGTTTAGAACACTTGAGAGAGCGATTAGTAGGTAGAGGAACAGAATCTGATGAGAAAATACAAAGTC
GTATTAACGAAGCGCGTAAAGAAGTTGAAATGATGAATTTATACGATTACGTT 
 
S. aureus SA137/93A – pta – allele number 4 
GCAACACAATTACAAGCAACAGATTATGTTACACCAATCGTGTTAGGTGATGAGACTAAGGTTCAATCTTTAGCGCAAAAACTTGATCTTGATA
TTTCTAATATTGAATTAATTAATCCTGCGACAAGTGAATTGAAAGCTGAATTAGTTCAATCATTTGTTGAACGACGTAAAGGTAAAGCGACTGA
AGAACAAGCACAAGAATTATTAAACAATGTGAACTACTTCGGTACAATGCTTGTTTATGCTGGTAAAGCAGATGGTTTAGTTAGTGGTGCAGCA
CATTCAACAGGCGACACTGTGCGTCCAGCTTTACAAATCATCAAAACGAAACCAGGTGTATCAAGAACATCAGGTATCTTCTTTATGATTAAAG
GTGATGAACAATACATCTTTGGTGATTGTGCAATCAATCCAGAACTTGATTCACAAGGACTTGCAGAAATTGCAGTAGAAAGTGCAAAATCAGC
ATTA 
 
S. aureus SA137/93A – tpiA – allele number 4 
CACGAAACAGATGAAGAAATTAACAAAAAAGCGCACGCTATTTTCAAACATGGAATGACTCCAATTATATGTGTTGGTGAAACAGACGAAGAGC
GTGAAAGTGGTAAAGCTAACGATGTTGTAGGTGAGCAAGTTAAGAAAGCTGTTGCAGGTTTATCTGAAGATCAACTTAAATCAGTTGTAATTGC
TTATGAACCAATCTGGGCAATCGGAACTGGTAAATCATCAACATCTGAAGATGCAAATGAAATGTGTGCATTTGTACGTCAAACTATTGCTGAC
TTATCAAGCAAAGAAGTATCAGAAGCAACTCGTATTCAATATGGTGGTAGTGTTAAACCTAACAACATTAAAGAATACATGGCACAAACTGATA
TTGATGGGGCATTAGTAGGTGGCGCA 
 
S. aureus SA137/93A – yqi – allele number 16 
GCGTTTAAAGACGTGCCAGCCTATGATTTAGGTGCGACTTTAATAGAACATATTATTAAAGAGACGGGTTTGAATCCAAGTGAGATTGATGAAG
TTATCATCGGTAACGTACTACAAGCAGGACAAGGACAAAATCCAGCACGAATTGCTGCTATGAAAGGTGGCTTGCCAGAAACAGTACCTGCATT
TACGGTGAATAAAGTATGTGGTTCTGGGTTAAAGTCGATTCAATTAGCATATCAATCTATTGTGACTGGTGAAAATGACATCGTGCTAGCTGGC
GGTATGGAGAATATGTCTCAATCACCAATGCTTGTCAACAACAGTCGCTTTGGTTTTAAAATGGGACATCAATCAATGGTTGATAGCATGGTAT
ATGATGGTTTAACAGATGTATTTAATCAATATCATATGGGTATTACTGCTGAAAATTTAGCAGAGCAATATGGTATTTCAAGAGAAGAACAAGA
TACATTTGCTGTAAACTCACAACAAAAAGCAGTACGTGCACAGCAA 
 
Figure 4.3: Trimmed nucleotide sequences for MLST analysis of S. aureus SA137/93A.  
 
 
Results     39 
 
 
S. aureus SG511-Berlin – arcC – allele number 2 
TTATTAATCCAACAAGCTAAATCGAACAGTGACACAACGCCGGCAATGCCATTGGATACTTGTGGTGCAATGTCACAAGGTATGATAGGCTATT
GGTTGGAAACTGAAATCAATCGCATTTTAACTGAAATGAATAGTGATAGAACTGTAGGCACAATCGTAACACGTGTGGAAGTAGATAAAGATGA
TCCACGATTTGATAACCCAACTAAACCAATTGGTCCTTTTTATACGAAAGAAGAAGTTGAAGAATTACAAAAAGAACAGCCAGGCTCAGTCTTT
AAAGAAGATGCAGGACGTGGTTATAGAAAAGTAGTTGCGTCACCACTACCTCAATCTATACTAGAACACCAGTTAATTCGAACTTTAGCAGACG
GTAAAAATATTGTCATTGCATGCGGTGGTGGCGGTATTCCAGTTATAAAAAAAGAAAATACCTATGAAGGTGTTGAAGCG 
 
S. aureus SG511-Berlin – aroE – allele number 2 
AATTTTAATTCTTTAGGATTAGATGATACTTATGAAGCTTTAAATATTCCAATTGAAGATTTTCATTTAATTAAAGAAATTATTTCAAAAAAAG
AATTAGATGGCTTTAATATCACAATTCCTCATAAAGAGCGTATCATACCGTATTTAGATCATGTTGATGAACAAGCGATTAATGCAGGTGCAGT
TAACACTGTTTTGATAAAAGATGGCAAGTGGATAGGGTATAATACAGATGGTATTGGTTATGTTAAAGGATTGCACAGCGTTTATCCAGATTTA
GAAAATGCATACATTTTAATTTTGGGAGCAGGTGGTGCAAGTAAAGGTATTGCTTATGAATTAGCAAAATTTGTAAAGCCCAAATTAACTGTTG
CGAATAGAACGATGGCTCGTTTTGAATCTTGGAATTTAAATATAAACCAAATTTCATTGGCAGATGCTGAAAAGTATTTA 
 
S. aureus SG511-Berlin – glpF – allele number 2 
GGTGCTGATTGGATTGTCATCACAGCTGGATGGGGATTAGCGGTTACAATGGGTGTGTATGCTGTTGGTCAATTCTCAGGTGCACATTTAAACC
CAGCGGTGTCTTTAGCTCTTGCATTAGACGGAAGTTTTGATTGGTCATTAGTTCCTGGTTATATTGTTGCTCAAATGTTAGGTGCAATTGTCGG
AGCAACAATTGTATGGTTAATGTACTTGCCACATTGGAAAGCGACAGAAGAAGCTGGCGCGAAATTAGGTGTTTTCTCTACAGCACCGGCTATT
AAGAATTACTTTGCCAACTTTTTAAGTGAAATTATCGGAACAATGGCATTAACTTTAGGTATTTTATTTATCGGTGTAAACAAAATTGCTGATG
GTTTAAATCCTTTAATTGTCGGAGCATTAATTGTTGCAATCGGATTAAGTTTAGGCGGTGCTACTGGTTATGCAATCAACCCAGCACGT 
 
S. aureus SG511-Berlin – gmk – allele number 2 
CGAATATTTGAAGATCCAAGTACATCATATAAGTATTCTATTTCAATGACAACACGTCAAATGCGTGAAGGTGAAGTTGATGGCGTAGATTACT
TTTTTAAAACTAGGGATGCGTTTGAAGCTTTAATTAAAGATGACCAATTTATAGAATATGCTGAATATGTAGGCAACTATTATGGTACACCAGT
TCAATATGTTAAAGATACAATGGACGAAGGTCATGATGTATTTTTAGAAATTGAAGTAGAAGGTGCAAAGCAAGTTAGAAAGAAATTTCCAGAT
GCGTTATTTATTTTCTTAGCACCTCCAAGTTTAGATCACTTGAGAGAGCGATTAGTAGGTAGAGGAACAGAATCTGATGAGAAAATACAAAGTC
GTATTAACGAAGCACGTAAAGAAGTCGAAATGATGAATTTATACGATTACGTT 
 
S. aureus SG511-Berlin – pta – allele number 6 
GCAACACAATTACAAGCAACAGATTATGTTACACCAATCGTGTTAGGTGATGAGACTAAGGTTCAATCTTTAGCGCAAAAACTTAATCTTGATA
TTTCTAATATTGAATTAATTAATCCTGCGACAAGTGAATTGAAAGCTGAATTAGTTCAATCATTTGTTGAACGACGTAAAGGTAAAGCGACTGA
AGAACAAGCACAAGAATTATTAAACAATGTGAACTACTTCGGTACAATGCTTGTTTATGCTGGTAAAGCAGATGGTTTAGTTAGTGGTGCAGCA
CATTCAACAGGCGACACTGTGCGTCCAGCTTTACAAATCATCAAAACGAAACCAGGTGTATCAAGAACATCAGGTATCTTCTTTATGATTAAAG
GTGATGAACAGTACATCTTTGGTGATTGTGCAATCAATCCAGAACTTGATTCACAAGGACTTGCAGAAATTGCAGTAGAAAGTGCAAAATCAGC
ATTA 
 
S. aureus SG511-Berlin – tpiA – allele number 3 
CACGAAACAGATGAAGAAATTAACAAAAAAGCGCACGCTATTTTCAAACATGGAATGACTCCAATTATTTGTGTTGGTGAAACAGACGAAGAGC
GTGAAAGTGGTAAAGCTAACGATGTTGTAGGTGAGCAAGTTAAGAAAGCTGTTGCAGGTTTATCTGAAGATCAACTTAAATCAGTTGTAATTGC
TTATGAACCAATCTGGGCAATCGGAACTGGTAAATCATCAACATCTGAAGATGCGAATGAAATGTGTGCATTTGTACGTCAAACTATTGCTGAC
TTATCAAGCAAAGAAGTATCAGAAGCAACTCGTATTCAATATGGTGGTAGTGTTAAACCTAACAACATTAAAGAATACATGGCACAAACTGATA
TTGATGGGGCATTAGTAGGTGGCGCA 
 
S. aureus SG511-Berlin – yqi – allele number 2 
GCGTTTAAAGACGTGCCAGCCTATGATTTAGGTGCGACTTTAATAGAACATATTATTAAAGAGACGGGTTTGAATCCAAGTGAGATTAATGAAG
TCATCATCGGTAACGTACTACAAGCAGGACAAGGACAAAATCCAGCACGAATTGCTGCTATGAAAGGTGGCTTGCCAGAAACAGTACCTGCATT
TACAGTGAATAAAGTATGTGGTTCTGGGTTAAAGTCGATTCAATTAGCATATCAATCTATTGTGACTGGTGAAAATGACATCGTGCTAGCTGGC
GGTATGGAGAATATGTCTCAATCACCAATGCTTGTCAACAACAGTCGCTTTGGTTTTAAAATGGGACATCAATCAATGGTTGATAGCATGGTAT
ATGATGGTTTAACAGATGTATTTAATCAATATCATATGGGTATTACTGCTGAAAATTTAGTAGAGCAATATGGTATTTCAAGAGAAGAACAAGA
TACATTTGCTGTAAACTCACAACAAAAAGCAGTACGTGCACAGCAA 
 
Figure 4.4: Trimmed nucleotide sequences for MLST analysis of S. aureus SG511-Berlin. 
 
 
 
Phage typing was used to confirm the identity of S. aureus SG511-Berlin, since this strain has 
been previously assigned to lysotype I (Pöhn, 1959). The identity of strain SG511-Berlin 
could be confirmed using the international set for phage typing, since its lysis pattern 
comprised the phages 29/52/52A/80. Strain SG511-Berlin additionally reacted with the 
phages 42E/77/84/85 of lysotype III, phage 96 of lysotype V and phage 95 of lysotype M.  
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4.3 Transcriptional response of the S. aureus strains SA137/93A, SA137/93G and SG511-
Berlin in the presence of mersacidin using DNA-microarrays 
S. aureus SA137/93A and SA137/93G were grown in BHI broth to an OD600 of 0.5, then 
subinhibitory concentrations of mersacidin (16 µg/ml, 0.5 x MIC) were added. Samples were 
taken 30 minutes after addition of mersacidin (OD600 of ~1), before the decreased growth rate 
became apparent (Fig. 4.1). S. aureus SG511-Berlin was grown with 1 x MIC of mersacidin 
to induce a mersacidin-dependent transcriptional response, since the profile of the growth 
curve of S. aureus SG511-Berlin at 1 x MIC was comparable to that recorded for the strains 
SA137/93A and SA137/93G at 0.5 x MIC (Fig. 4.1). Additionally, the transcriptional 
response of S. aureus SA137/93G was recorded at even lower concentrations of mersacidin  
(4 µg/ml, 0.15 x MIC; Table 5.1 and Table S1 in the supplemental material). Gene expression 
profiles of the mersacidin-treated S. aureus strains were compared to non-treated control cells 
and displayed extensive changes in gene expression. These changes were similar for all three 
tested strains and involved the transcript levels of 380 genes that were significantly changed 
(>2.5-fold) upon mersacidin treatment in at least one of the tested strains, with 207 genes 
exhibiting increased transcript levels (Table 4.1) and 173 genes showing decreased transcript 
levels (Table 4.2). Mersacidin-treatment resulted in the considerable regulation of genes 
referring to different cellular processes like cell wall biosynthesis, adaptation to atypical 
conditions, membrane bioenergetics, metabolism-related functions, pathogenic factors, 
protein and RNA synthesis, protein transport and binding as well as signal transduction. 
 
4.3.1 Regulation of cell wall biosynthesis genes 
Significance analysis of the microarray data (SAM) revealed an extensive induction of a 
subset of genes that has been previously described as the “cell wall stress stimulon” of  
S. aureus that is partly triggered by the VraSR two-component regulatory system (TCRS). 
This system coordinates the induction of cell wall biosynthesis genes upon treatment with 
cell-wall-active antibiotics like bacitracin, D-cycloserine, oxacillin and vancomycin (Utaida et 
al., 2003; Kuroda et al., 2003). Accordingly, vraSR gene transcription (SA1700/SA1701) was 
induced up to 17-fold among all tested strains in the presence of mersacidin. Additionally, the 
cell wall metabolism related genes murZ, uppS, bacA, pbp2, sgtB, the proline/betaine 
transporter homologue gene proP, the tcaA gene, the protein folding catalyst gene prsA, the 
autolysin gene atl and the drug responsive protein 35 gene (drp35) were significantly 
regulated in response to mersacidin treatment. The genes coding for the TcaA protein and the 
drug resistance protein 35 (drp35) were shown to be involved in the development of 
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teicoplanin and β-lactam resistance (Brandenberger et al., 2000; Murakami et al., 1999), while 
their definitive physiological function remains unknown yet. Gene expression for cell wall 
lytic enzymes (atl, SA0423, SA2100) was negatively affected.  
 
4.3.2 Regulation of genes belonging to the adaptation to atypical conditions 
Several chaperone/protease genes of the Clp-family (caseinolytic proteases) were found to be 
upregulated like clpC, clpP, cplB and clpL which are also part of the S. aureus response to 
heat-shock, vancomycin stress and acid shock (Anderson et al., 2006; Kuroda et al., 2003; 
Bore et al., 2007) and may play a role in targeting heat-denatured proteins for proteolysis. 
Suitably, the cold shock protein gene cspC and the alkaline shock protein gene asp23 were 
significantly downregulated in strain SG511-Berlin. 
 
4.3.3 Regulation of genes with metabolism-related functions 
Here, a strong induction of the acetyl-CoA c-transferase gene vraB was observed, which is 
involved in the biosynthesis of lipids and degradation of amino acids to feed catabolic 
pathways. In other studies, vraB was also induced upon mupirocin treatment (stringent 
response) and in response to D-cycloserine (inhibitor of alanine racemase) (Anderson et al., 
2006; Utaida et al., 2003). Furthermore, mersacidin treatment induced the transcription of 
genes involved in the amino acid biosynthesis of glutamate (gltB, rocA), lysine (asd, dapAB, 
dhoM, lysA), threonine (thrBC), cysteine (cysK), serine (serA) and valine/isoleucine (ilvE). 
The metabolism of carbohydrates was affected especially in strain SG511-Berlin, where the 
succinate dehydrogenase genes sdhBC were downregulated.  
 
4.3.4 Regulation of genes related to the metabolism of nucleotides. 
The pyrimidine synthesis gene cluster SA1043-48 was extremely downregulated in strain 
SG511-Berlin (up to 33-fold) but remained rather unaffected in strains SA137/93A and 
SA137/93G. The repression of the pyrimidine synthesis genes was also observed in studies on 
the S. aureus response to acid stress and modulations on the cell wall biosynthesis gene murF 
(Bore et al., 2007; Sobral et al., 2007). Interestingly, the putative GTP-pyrophosphokinase 
gene SA2297, which catalyses the formation of guanosine 3'-diphosphate 5'-triphosphate, was 
upregulated over 9-fold in all strains which is reported to be also upregulated by vancomycin 
and oxacillin treatment (Kuroda et al., 2003; Utaida et al., 2003) and downregulated by the 
GraRS TCRS (Herbert et al., 2007) and upon stringent response (Anderson et al., 2006). 
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Table 4.1: Genes with significantly increased expression upon mersacidin treatment1
Fold change2
N315 
ORF Gene Gene product function 137/93A 
(0.5xMIC) 
137/93G 
(0.5xMIC) 
SG511 
(1xMIC) 
 
Adaptation to atypical conditions    
SA0483 clpC endopeptidase  1.2 2.7 6.6 
SA0659  hypothetical protein, similar  to CsbB stress response protein  2.1 3.5 3.0 
SA0723 clpP ATP-dependent Clp protease proteolytic subunit homologue  1.3 3.0 3.4 
SA0755  hypothetical protein, similar to general stress protein 170  1.7 4.0 2.8 
SA0835 clpB ClpB chaperone homologue  1.5 6.9 16.4 
SA1146 bsaA glutathione peroxidase  2.1 2.7 2.7 
SA1410 grpE GrpE protein  0.9 3.1 5.3 
SA1549  hypothetical protein, similar to serine proteinase Do, heat-shock protein htrA  7.1 4.6 5.6 
SA2175  hypothetical protein, similar to small heat shock protein  2.4 3.0 3.1 
SA2336 clpL ATP-dependent Clp proteinase chain clpL  0.9 4.0 1.3 
Cell division     
SA1023 ftsL cell division protein  2.4 1.6 3.0 
Cell wall related genes    
SA0205  hypothetical protein, similar to lysostaphin precursor  6.0 4.5 13.6 
SA0244  hypothetical protein, similar to teichoic acid biosynthesis protein F  1.6 1.4 2.8 
SA0265 lytM peptidoglycan hydrolase  4.0 2.1 1.7 
SA0638 bacA bacitracin resistance protein (putative undecaprenol kinase) homologue  3.0 1.9 1.8 
SA1103 uppS undecaprenyl pyrophosphate synthetase  2.5 3.0 2.0 
SA1266  hypothetical protein, similar to cell wall enzyme EbsB  3.4 1.9 3.7 
SA1283 pbp2 penicillin binding protein 2  3.4 2.3 3.5 
SA1691 sgtB hypothetical protein, similar to penicillin-binding protein 1A/1B  13.1 8.8 9.7 
SA1926 murZ UDP-N-acetylglucosamine 1-carboxylvinyl transferase 2  3.2 4.4 6.1 
SA2481  conserved hypothetical protein  2.4 3.5 7.0 
Detoxification     
SA0128 sodM superoxide dismutase  1.0 - 1.0 
SA0681  hypothetical protein, similar to multidrug resistance protein  1.2 3.1 1.0 
SA1170 katA Catalase  1.6 2.7 1.9 
SA1238  hypothetical protein, similar to tellurite resistance protein  2.6 3.2 3.3 
SA1382 sodA superoxide dismutase SodA  1.1 3.0 1.8 
DNA replication, modification, recombination and repair    
SA1282 recU recombination protein U homologue  3.6 2.5 2.5 
SA1313  probable ATP-dependent DNA helicase RecQ  2.0 2.2 2.7 
SA1485 radC truncated hypothetical protein, similar to DNA repair protein  1.5 1.4 6.3 
SA1711  hypothetical protein, similar to DNA-damage inducible protein P  2.2 1.6 3.4 
SA2335 adaB probable methylated DNA-protein cysteine methyltransferase  1.7 2.8 2.2 
Membrane bioenergetics (electron transport chain and ATP synthase)    
SA0211  hypothetical protein, similar to NADH-dependent dehydrogenase  2.2 1.3 4.0 
SA0411 ndhF NADH dehydrogenase subunit 5  1.6 1.0 2.9 
SA0817  hypothetical protein, similar to NADH-dependent flavin oxidoreductase  2.1 3.4 2.4 
SA1221  thioredoxine reductase  1.2 2.6 1.2 
SA2324  hypothetical protein, similar to thioredoxin  1.3 2.6 3.0 
Metabolism of amino acids    
SA0011  hypothetical protein, similar to homoserine-o-acetyltransferase  1.6 2.0 2.8 
SA0430 gltB glutamate synthase large subunit  2.8 2.0 1.3 
SA0471 cysK cysteine synthase (o-acetylserine sulfhydrylase) homologue  1.6 3.4 1.8 
SA0512 ilvE branched-chain amino acid aminotransferase homologue  2.1 2.5 2.1 
SA0829  hypothetical protein, similar to 5-oxo-1,2,5-tricarboxilic-3-penten  
acid decarboxylase  
2.1 3.2 3.1 
SA0902  HisC homologue 2.2 1.8 4.2 
SA0942 pdf1 formylmethionine deformylase homologue 1.7 1.6 2.9 
SA1164 dhoM homoserine dehydrogenase  2.5 2.7 6.2 
SA1165 thrC threonine synthase  1.6 2.0 3.9 
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Table 4.1 - Continued 
Fold change2
N315 
ORF Gene Gene product function 137/93A 
(0.5xMIC) 
137/93G 
(0.5xMIC) 
SG511 
(1xMIC) 
 
SA1166 thrB homoserine kinase homologue 1.4 1.7 3.9 
SA1216  hypothetical protein, similar to oligoendopeptidase  1.8 1.7 2.8 
SA1226 asd aspartate semialdehyde dehydrogenase  2.2 3.8 2.2 
SA1227 dapA dihydrodipicolinate synthase  2.3 3.0 2.0 
SA1228 dapB dihydrodipicolinate reductase  2.3 2.6 1.9 
SA1232 lysA diaminopimelate decarboxylase  2.1 2.4 2.7 
SA1531 ald alanine dehydrogenase  2.1 1.5 4.2 
SA1545 serA D-3-phosphoglycerate dehydrogenase  2.1 1.6 2.8 
SA1861 ilvC alpha-keto-beta-hydroxylacil reductoisomerase  1.9 2.5 1.2 
SA2341 rocA 1-pyrroline-5-carboxylate dehydrogenase  1.2 1.4 3.1 
Metabolism of carbohydrates    
SA0528  hypothetical protein, similar to hexulose-6-phosphate synthase  1.5 3.4 3.3 
SA0658  hypothetical protein, similar to plant-metabolite dehydrogenases  1.5 3.3 2.6 
SA0958  myo-inositol-1(or 4)-monophosphatase homologue 1.8 3.1 3.1 
SA1142 glpD aerobic glycerol-3-phosphate dehydrogenase  1.4 2.0 3.8 
SA1566  endo-1,4-beta-glucanase homologue 2.0 2.9 2.4 
SA1599  hypothetical protein, similar to transaldolase  1.7 2.7 3.1 
SA1736 aldH aldehyde dehydrogenase  2.0 2.3 3.3 
SA1924  hypothetical protein, similar to aldehyde dehydrogenase  1.3 3.4 2.4 
SA1925  conserved hypothetical protein  3.5 3.8 4.7 
SA2104  hypothetical protein, similar to suppressor protein SuhB  1.4 2.0 2.9 
SA2266  hypothetical protein, similar to oxidoreductase  2.0 3.4 1.6 
SA2346  hypothetical protein, similar to D-specific D-2-hydroxyacid  
dehydrogenase ddh homologue  
1.9 2.2 3.8 
SA2490  hypothetical protein, similar to N-hydroxyarylamine O-acetyltransferase  3.6 6.0 5.4 
Metabolism of coenzymes and prosthetic groups    
SA0915 folD FolD bifunctional protein  1.3 2.7 1.8 
SA2412  hypothetical protein, similar to uroporphyrin-III C-methyltransferase  1.9 2.3 2.7 
SA2438  hypothetical protein, similar to N-carbamoylsarcosine amidohydrolase  2.3 2.7 3.7 
Metabolism of lipids    
SA0534 vraB acetyl-CoA c-acetyltransferase  18.5 8.5 12.9 
SA0572  hypothetical protein, similar to esterase/lipase  0.9 3.3 1.8 
SA1435  hypothetical protein, similar to acetyl-CoA carboxylase  
(biotin carboxyl carrier subunit), accB homologue  
0.9 1.3 3.4 
SA1542  hypothetical protein, similar to glycerophosphoryl diester phosphodiesterase  2.3 2.8 4.6 
SA2240  hypothetical protein, similar to para-nitrobenzyl esterase chain A  1.8 4.1 2.2 
Metabolism of nucleotides and nucleic acids    
SA0864  GTP pyrophosphokinase  1.6 1.8 2.8 
SA1172  hypothetical protein, similar to GMP reductase  1.8 3.0 2.4 
SA1308  30S ribosomal protein S1  2.0 3.5 3.2 
SA2297  hypothetical protein, similar to GTP-pyrophosphokinase  9.1 14.1 10.3 
Metabolism of phosphate    
SA1237  hypothetical protein, similar to 5-bromo-4-chloroindolyl phosphate  
hydrolysis protein XpaC  
2.5 4.1 6.0 
SA2301  hypothetical protein, similar to alkaline phosphatase  2.7 2.7 3.3 
Pathogenic factors (toxins and colonization factors)    
SA0382 set6 exotoxin 6 [Pathogenicity island SaPIn2] 2.4 2.7 5.1 
SA0610  hypothetical protein, similar to lipase LipA  1.2 0.7 3.9 
SA0909 fmtA FmtA, autolysis and methicillin resistant-related protein  9.3 3.8 6.3 
SA2006  hypothetical protein, similar to MHC class II analogue  3.4 7.3 4.4 
SA2323  conserved hypothetical protein  1.9 2.4 2.9 
Phage-related functions    
SA1760  holin homologue [Bacteriophage phiN315] 3.8 3.2 17.5 
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Fold change2
N315 Gene Gene product function 137/93G SG511 137/93A ORF 
(0.5xMIC) (0.5xMIC) (1xMIC) 
 
Protein modification, folding and secretion    
spsA SA0825 type-I signal peptidase  1.4 2.2 3.9 
spsB SA0826 type-1 signal peptidase 1B  1.5 2.4 2.9 
SA1257  peptide methionine sulfoxide reductase MsrA2 6.0 11.0 17.1 
SA1530  Xaa-Pro dipeptidase homologue  1.8 3.1 2.2 
SA1409 dnaK DnaK protein  0.9 2.1 4.6 
SA1659 prsA peptidyl-prolyl cis/trans isomerase homologue  10.8 18.1 33.3 
SA1836 groEL GroEL protein  1.2 3.9 4.5 
Protein transport and binding    
SA0166  hypothetical protein, similar to nitrate transporter  2.0 2.4 2.6 
SA0531 proP proline/betaine transporter homologue  2.4 2.7 0.6 
SA0640  hypothetical protein, similar to ABC transporter required  
for expression of cytochrome bd  
1.6 1.5 2.6 
SA0677  hypothetical protein, similar to choline transport ATP-binding protein  1.2 1.1 2.8 
SA0769  ABC transporter ATP-binding protein homologue  0.9 1.4 3.6 
SA0845 oppB oligopeptide transport system permease protein  1.4 3.6 3.5 
SA0846  hypothetical protein, similar to oligopeptide transport  
system permease protein OppC  
1.8 3.1 3.4 
SA0847 oppD oligopeptide transport system ATP-binding protein OppD homologue  1.5 3.0 2.6 
SA0848 oppF oligopeptide transport system ATP-binding protein OppF homologue  2.3 3.9 2.1 
SA1255  PTS system, glucose-specific enzyme IIA component  4.7 10.7 13.1 
SA1478  hypothetical protein, similar to transporter PAB2175 from Pyrococcus abyssi  3.8 3.7 4.9 
SA1654  hypothetical protein, similar to ABC transporter EcsB  2.3 2.0 2.9 
SA1655  ABC transporter EcsA homologue  1.5 2.4 5.1 
SA1848 nrgA probabale ammonium transporter  1.4 1.4 4.1 
SA1948 czrB cation-efflux system membrane protein homologue  0.9 1.9 2.7 
SA2112  hypothetical protein, similar to sodium-dependent transporter  1.9 1.3 2.9 
SA2114 glvC PTS system, arbutin-like IIBC component  3.7 5.6 4.7 
SA2148  hypothetical protein, similar to membrane protein  1.4 1.6 4.1 
 SA2396 hypothetical protein, similar to amino acid transporter  1.9 1.3 3.0 
 SA2416 hypothetical protein, similar to ABC transporter (ATP-binding protein)  2.3 2.3 2.7 
vraD SA2492 hypothetical protein, similar to ABC transporter  59.4 72.2 52.7 
vraE SA2493 hypothetical protein, similar to ABC transporter (permease)  52.7 39.6 42.4 
RNA synthesis - regulation    
ctsR SA0480 transcription repressor of class III stress genes homologue  1.1 4.2 5.0 
msrR SA1195 peptide methionine sulfoxide reductase regulator MsrR  4.2 3.6 5.5 
hrcA SA1411 Heat-inducible transcriptional repressor  1.3 3.3 5.1 
vraR SA1700 two-component response regulator  13.3 8.0 17.3 
SA1947 czrA repressor protein  1.2 2.5 3.5 
SA2103  hypothetical protein, similar to lyt divergon expression attenuator LytR  6.4 6.1 8.0 
SA2159  hypothetical protein, similar to transcription repressor of sporulation,  
septation and degradation PaiA  
1.8 2.1 3.4 
SA2296  hypothetical protein, similar to transcriptional regulator, MerR family  8.1 10.4 5.5 
SA2458 icaR ica operon transcriptional regulator IcaR  1.4 2.6 1.6 
Sensors (signal transduction)    
SA1701 vraS two-component sensor histidine kinase  11.7 8.9 17.0 
Transformation competence    
SA0857  hypothetical protein, similar to negative regulator of genetic competence MecA 3.0 3.4 7.0 
Hypothetical proteins    
SA0165  hypothetical protein, similar to alpha-helical coiled-coil protein SrpF  1.8 3.4 3.5 
SA0192  hypothetical protein, similar to ABC transporter ATP-binding protein  23.6 31.7 26.6 
SA0358  conserved hypothetical protein  10.6 15.4 39.3 
SA0359  conserved hypothetical protein  1.9 6.1 4.3 
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Fold change2
N315 
ORF Gene Gene product function 137/93A 
(0.5xMIC) 
137/93G 
(0.5xMIC) 
SG511 
(1xMIC) 
 
SA0481  conserved hypothetical protein  1.8 5.3 8.0 
SA0482  hypothetical protein, similar to creatine kinase  1.2 4.5 5.8 
SA0509  conserved hypothetical protein  1.1 2.8 0.8 
SA0529  conserved hypothetical protein  1.4 3.0 3.7 
SA0530  hypothetical protein, similar to indigoidine synthesis protein  2.5 2.4 1.3 
SA0535 vraC hypothetical protein  25.7 11.3 18.9 
SA0536  hypothetical protein  30.2 17.1 26.6 
SA0591  hypothetical protein  11.3 8.9 10.9 
SA0608  hypothetical protein  2.7 3.8 9.2 
SA0611  hypothetical protein  1.2 0.8 4.6 
SA0612  conserved hypothetical protein  2.0 2.5 2.4 
SA0637  conserved hypothetical protein  2.5 4.0 1.5 
SA0647  hypothetical protein  2.3 1.2 3.6 
SA0648  conserved hypothetical protein  2.4 1.5 3.6 
SA0707  conserved hypothetical protein  4.8 9.7 2.5 
SA0721  conserved hypothetical protein  1.0 3.1 1.9 
SA0725  conserved hypothetical protein  2.9 2.9 1.8 
SA0750  conserved hypothetical protein  1.9 1.7 4.9 
SA0770  conserved hypothetical protein  0.8 1.2 3.8 
SA0771  conserved hypothetical protein  1.2 1.4 2.8 
SA0772  conserved hypothetical protein  2.4 4.5 0.8 
SA0782  conserved hypothetical protein  2.1 1.6 2.9 
SA0824  conserved hypothetical protein  4.1 2.4 3.9 
SA0833  conserved hypothetical protein  1.8 2.6 1.8 
SA0856  conserved hypothetical protein  2.0 2.6 2.1 
SA0903  conserved hypothetical protein  3.2 1.4 5.3 
SA0908  conserved hypothetical protein  2.2 1.5 3.1 
SA0914  hypothetical protein, similar to chitinase B  14.2 3.9 15.3 
SA0931  hypothetical protein  4.9 3.2 6.2 
SA0943  conserved hypothetical protein  3.2 3.2 4.5 
SA0957  conserved hypothetical protein  1.8 2.2 3.2 
SA0962  conserved hypothetical protein  1.8 1.4 2.8 
SA1018  conserved hypothetical protein  1.7 2.2 3.0 
SA1019  conserved hypothetical protein  3.9 6.9 6.5 
SA1022  conserved hypothetical protein  2.2 2.1 2.8 
SA1050  conserved hypothetical protein  2.0 2.6 1.1 
SA1173  conserved hypothetical protein  2.7 2.8 3.7 
SA1185  conserved hypothetical protein  2.0 1.9 3.2 
SA1186  conserved hypothetical protein  1.9 1.4 3.4 
SA1256  conserved hypothetical protein  7.9 16.1 18.8 
SA1280  conserved hypothetical protein  1.7 2.8 2.8 
SA1281  conserved hypothetical protein  1.9 3.0 2.9 
SA1293  conserved hypothetical protein  1.7 2.3 3.5 
SA1419  conserved hypothetical protein  1.3 1.4 4.6 
SA1436  conserved hypothetical protein  0.7 1.0 3.4 
SA1476  hypothetical protein  11.5 11.3 15.9 
SA1532  conserved hypothetical protein  2.5 9.1 5.5 
SA1543  conserved hypothetical protein  2.8 3.9 6.0 
SA1544  hypothetical protein, similar to soluble hydrogenase 42 kD subunit  1.8 2.0 4.9 
SA1546  hypothetical protein  2.3 1.7 3.2 
SA1606  plant metabolite dehydrogenase homologue  1.9 3.5 2.6 
SA1649  conserved hypothetical protein  1.9 1.1 3.0 
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N315 
ORF Gene Gene product function 137/93A 
(0.5xMIC) 
137/93G 
(0.5xMIC) 
SG511 
(1xMIC) 
 
SA1680  conserved hypothetical protein  2.3 2.7 3.0 
SA1682  conserved hypothetical protein  2.4 2.9 1.8 
SA1686  conserved hypothetical protein  2.1 2.1 3.5 
SA1690  conserved hypothetical protein  2.0 2.1 4.0 
SA1692  conserved hypothetical protein  1.3 3.1 0.8 
SA1702  conserved hypothetical protein  10.4 9.4 12.2 
SA1703  hypothetical protein  31.6 24.8 45.4 
SA1712  conserved hypothetical protein  24.7 21.0 29.4 
SA1743  hypothetical protein  2.7 4.3 2.6 
SA1942  conserved hypothetical protein  1.7 3.7 2.5 
SA1990  conserved hypothetical protein  1.9 2.6 3.9 
SA2004  conserved hypothetical protein  2.1 2.2 2.5 
SA2049  hypothetical protein  4.3 5.8 6.5 
SA2113  hypothetical protein  14.9 11.8 11.4 
SA2138  conserved hypothetical protein  3.1 4.2 5.3 
SA2139  hypothetical protein  2.7 2.8 3.4 
SA2146 tcaA TcaA protein  3.3 1.6 4.0 
SA2158  hypothetical protein, similar to TpgX protein  2.1 2.7 2.3 
SA2220  conserved hypothetical protein  7.0 12.2 21.4 
SA2221  hypothetical protein  25.6 18.3 42.7 
SA2366  conserved hypothetical protein  0.9 2.7 1.1 
SA2367  conserevd hypothetical protein  1.0 3.3 1.1 
SA2480 drp35 drug responsive protein 35 2.7 3.4 2.8 
 
 
 
1 Significant changes of gene expression were determined by implementing SAM (significance analysis of    
   microarrays; http://www-stat.stanford.edu/~tibs/SAM/) (Tusher et al., 2001). 
2 Fold change in transcript level of at least 2.5-fold is indicated as mean of the “median of ratios” compared to  
   control cells. Fold change in bold = classified as "significantly" regulated in this strain by SAM. 
 
 
4.3.5 Regulation of genes related to protein synthesis 
Mersacidin treatment reduced the transcription of 30 genes coding for 30S and 50S ribosomal 
proteins. To date, only acid shock treatment of S. aureus cells has been shown to induce such 
a response (Bore et al., 2007). The loss of ribosomal proteins and pyrimidines (see section 
4.3.4) may be one of the reasons for the retarded growth of S. aureus after addition of 
mersacidin. Furthermore, the chaperone genes groEL, prsA and dnaK and the signal peptidase 
genes spsAB were upregulated.  
 
4.3.6 Regulation of genes related to signal transduction and global regulators 
Besides the induction of the VraSR TCRS, the global regulators pyrR, rot, agrA, agrC and 
sarR were downregulated. Further, the GraRS antimicrobial peptide-sensing system of  
S. aureus (Li et al., 2007a) was not induced upon mersacidin treatment, as many genes 
reported to be positively controlled by GraRS were downregulated, like dltABC and vraFG 
(Li et al., 2007a; Herbert et al., 2007; Meehl et al., 2007). 
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Table 4.2: Genes with significantly decreased expression upon mersacidin treatment1
Fold change2
N315 
ORF Gene Gene product function 137/93A 
(0.5xMIC) 
137/93G 
(0.5xMIC) 
SG511 
(1xMIC) 
 
Adaptation to atypical conditions    
SA0747 cspC cold-shock protein C  0.65 0.84 0.40 
SA1984 asp23 alkaline shock protein 23, ASP23  0.64 2.24 0.32 
Cell division     
SA0905 atl autolysin  0.42 0.49 0.18 
SA2499 gidB glucose inhibited division protein B  0.57 0.36 0.56 
SA2500 gidA glucose inhibited division protein A  0.55 0.34 0.51 
Cell wall related genes    
SA0423  hypothetical protein, similar to autolysin  0.58 0.20 0.20 
SA0793 dltA D-alanine-D-alanyl carrier protein ligase  0.63 0.22 0.24 
SA2100  hypothetical protein, similar to autolysin E  0.46 0.32 0.30 
SA2354  hypothetical protein, similar to acyltransferase  0.73 0.37 0.47 
Membrane bioenergetics (electron transport chain and ATP synthase)    
SA0910  hypothetical protein, similar to quinol oxidase polypeptide IV QoxD  0.41 0.20 0.12 
SA0911 qoxC Quinol oxidase polypeptide III QoxC  0.34 0.19 0.14 
SA0912 qoxB Quinol oxidase polypeptide I QoxB  0.37 0.21 0.11 
SA0913  hypothetical protein, similar to quinol oxidase polypeptide II QoxA  0.40 0.24 0.19 
SA0965 ctaB cytochrome caa3 oxidase (assembly factor) homologue  0.57 0.40 0.35 
SA1909 atpF ATP synthase B chain  0.72 0.38 0.49 
SA1910 atpE ATP synthase C chain  0.79 0.43 0.38 
SA1911 atpB ATP synthase A chain  0.66 0.43 0.39 
Metabolism of amino acids    
SA0180  hypothetical protein, similar to branched-chain amino acid  
transport system carrier protein  
0.54 0.34 0.33 
SA2095  hypothetical protein, similar to D-octopine dehydrogenase  0.45 0.49 0.33 
Metabolism of carbohydrates    
SA0562 adh1 alcohol dehydrogenase I  2.23 1.59 0.30 
SA0994 sdhC succinate dehydrogenase cytochrome b-558  0.58 0.62 0.35 
SA0996 sdhB succinate dehydrogenase iron-sulfur protein subunit  0.62 0.58 0.32 
SA2008 alsS alpha-acetolactate synthase  0.73 0.39 0.29 
SA2102  formate dehydrogenase homologue  0.47 0.86 0.23 
Metabolism of coenzymes and prosthetic groups    
SA0665  coenzyme PQQ synthesis homologue  0.73 0.38 0.54 
SA0666  hypothetical protein 6-pyruvoyl tetrahydrobipterin synthase homologue 0.61 0.34 0.38 
SA1494 hemC porphobilinogen deaminase  0.65 0.33 0.42 
SA1495 hemX HemA concentration negative effector HemX  0.68 0.37 0.37 
SA1537  hypothetical protein, similar to thiamine biosynthesis protein ThiI  0.65 0.35 0.43 
SA1538  hypothetical protein, similar to iron-sulfur cofactor synthesis protein NifZ  0.52 0.31 0.48 
SA1919  hypothetical protein, similar to protoporphyrinogen oxidase (HemK)  0.44 0.39 0.39 
Metabolism of lipids    
SA0820 glpQ glycerophosphoryl diester phosphodiesterase  1.11 0.47 0.29 
Metabolism of nucleotides and nucleic acids    
SA0373 xprT xanthine phosphoribosyltransferase  0.41 0.13 0.43 
SA0511  hypothetical protein, similar to UDP-glucose 4-epimerase related protein  0.57 0.52 0.33 
SA0927  conserved hypothetical protein  0.75 0.69 0.22 
SA1043 pyrB aspartate transcarbamoylase chain A  0.92 2.22 0.05 
SA1044 pyrC dihydroorotase  0.98 2.06 0.03 
SA1045 pyrAA carbamoyl-phosphate synthase small chain  1.05 1.58 0.07 
SA1046 pyrAB carbamoyl-phosphate synthase large chain  0.87 1.58 0.08 
SA1047 pyrF orotidine-5-phosphate decarboxylase  0.81 1.65 0.05 
SA1048 pyrE orotate phosphoribosyltransferase  0.87 1.43 0.07 
SA1461 apt adenine phosphoribosyl transferase  0.71 0.62 0.39 
SA1921 tdk thymidine kinase  0.61 0.50 0.39 
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SA2027 adk adenylate kinase  0.53 0.31 0.33 
Pathogenic factors (toxins and colonization factors)    
SA0270  hypothetical protein, similar to secretory antigen precursor SsaA  0.67 0.51 0.13 
SA0276  conserved hypothetical protein, similar to diarrheal toxin  0.84 0.34 0.99 
SA0519 sdrC Ser-Asp rich fibrinogen-binding, bone sialoprotein-binding protein  0.53 0.27 0.08 
SA0521 sdrE Ser-Asp rich fibrinogen-binding, bone sialoprotein-binding protein  1.74 1.40 0.32 
SA0587  lipoprotein, streptococcal adhesin PsaA homologue  0.76 1.21 0.25 
SA0742 clfA fibrinogen-binding protein A, clumping factor  0.80 1.21 0.22 
SA0746  staphylococcal nuclease  0.99 0.26 0.65 
SA1645 yent1 enterotoxin Yent1 [Pathogenicity island SaPIn3] 1.28 1.30 0.39 
SA1647 sem enterotoxin SEM [Pathogenicity island SaPIn3] 1.47 1.31 0.36 
SA2093 ssaA secretory antigen precursor SsaA homologue  0.57 0.23 0.34 
SA2206 sbi IgG-binding protein SBI  0.87 0.33 1.30 
SA2290 fnbB fibronectin-binding protein homologue  0.49 0.27 1.29 
SA2291 fnb fibronectin-binding protein homologue  0.51 0.32 1.15 
SA2353  hypothetical protein, similar to secretory antigen precursor SsaA  0.69 0.38 0.78 
SA2356 isaA immunodominant antigen A  0.73 0.51 0.36 
SA2423 clfB clumping factor B  0.81 0.90 0.17 
Phage-related functions    
SA1798  hypothetical protein [Bacteriophage phiN315] 0.57 0.38 0.36 
Protein modification, folding and secretion    
SA2028 secY preprotein translocase SecY subunit  0.58 0.32 0.34 
SA2446  hypothetical protein, similar to preprotein translocase SecY  0.87 0.39 1.08 
Protein synthesis - initation and termination    
SA1504 infC translation initiation factor IF-3 InfC  0.72 0.40 0.53 
SA1920 prfA peptide chain release factor 1  0.47 0.37 0.41 
Protein synthesis - ribosomal proteins and aminoacyl-tRNA synthases    
SA0354 rpsR 30S ribosomal protein S18  0.73 0.48 0.29 
SA0486 gltX glutamyl-tRNA synthetase  0.57 0.35 0.53 
SA0497 rplJ 50S ribosomal protein L10 (BL5) 0.48 0.28 0.32 
SA0498 rplL 50S ribosomal protein L7/L12  0.51 0.37 0.30 
SA0503 rpsL 30S ribosomal protein S12  0.48 0.28 0.40 
SA0504 rpsG 30S ribosomal protein S7  0.42 0.28 0.44 
SA1081 rpsP 30S ribosomal protein S16  0.55 0.52 0.31 
SA1471 rpmA 50S ribosomal protein L27  0.46 0.37 0.59 
SA1922 rpmE 50S ribosomal protein L31  0.61 0.48 0.38 
SA2022 rplQ 50S ribosomal protein L17  0.45 0.22 0.26 
SA2024 rpsK 30S ribosomal protein S11  0.44 0.31 0.30 
SA2029 rplO 50S ribosomal protein L15  0.50 0.29 0.31 
SA2030 rpmD 50S ribosomal protein L30  0.53 0.25 0.32 
SA2031 rpsE 30S ribosomal protein S5  0.66 0.29 0.39 
SA2032 rplR 50S ribosomal protein L18  0.49 0.25 0.29 
SA2033 rplF 50S ribosomal protein L6  0.43 0.26 0.28 
SA2034 rpsH 30S ribosomal protein S8  0.50 0.26 0.35 
SA2035 rplE 50S ribosomal protein L5  0.47 0.24 0.26 
SA2036 rplX 50S ribosomal protein L24  0.41 0.25 0.26 
SA2037 rplN 50S ribosomal protein L14  0.43 0.22 0.28 
SA2038 rpsQ 30S ribosomal protein S17  0.42 0.24 0.25 
SA2039 rpmC 50S ribosomal protein L29  0.41 0.22 0.25 
SA2040 rplP 50S ribosomal protein L16  0.53 0.24 0.31 
SA2041 rpsC 30S ribosomal protein S3  0.43 0.25 0.24 
SA2042 rplV 50S ribosomal protein L22  0.58 0.31 0.31 
SA2043 rpsS 30S ribosomal protein S19  0.54 0.28 0.29 
continued on following page
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Table 4.2 - Continued 
Fold change2
N315 
ORF Gene Gene product function 137/93A 
(0.5xMIC) 
137/93G 
(0.5xMIC) 
SG511 
(1xMIC) 
 
SA2045 rplW 50S ribosomal protein L23  0.46 0.26 0.36 
SA2046 rplD 50S ribosomal protein L4  0.46 0.27 0.36 
SA2048 rpsJ 30S ribosomal protein S10  0.43 0.31 0.48 
SAS052 rpsD 30S ribosomal protein S4  0.71 0.47 0.38 
SAS079 rpsN 30S ribosomal protein S14  0.51 0.27 0.27 
Protein transport and binding    
SA0183 glcA PTS enzyme II, glucose-specific, factor IIA homologue  0.34 0.21 0.09 
SA0272  hypothetical protein, similar to transmembrane protein Tmp7  0.47 0.33 0.97 
SA0295  hypothetical protein, similar to outer membrane protein precursor  0.65 0.31 0.26 
SA0374 pbuX xanthine permease  0.52 0.11 0.50 
SA0479 nupC pyrimidine nucleoside transport protein  0.33 0.24 0.10 
SA0616 vraF ABC transporter ATP-binding protein  0.64 0.36 1.46 
SA0617 vraG ABC transporter permease  0.92 0.38 1.49 
SA0688  hypothetical protein, similar to ferrichrome ABC transporter permease  1.26 0.75 0.32 
SA0689  hypothetical protein, similar to ferrichrome ABC transporter permease  0.88 0.69 0.26 
SA0690  hypothetical protein, similar to ferrichrome ABC transporter  
ATP-binding protein  
0.44 0.52 0.37 
SA0794 dltB DltB membrane protein  0.79 0.26 0.31 
SA0796 dltD poly D-alanine transfer protein  0.75 0.24 0.30 
SA0928  hypothetical protein, similar to cation ABC transporter  0.90 0.90 0.23 
SA0950 potA spermidine/putrescine ABC transporter, ATP-binding protein homologue  0.62 0.31 0.30 
SA0951 potB   0.58 0.44 0.28 
SA0952 potC spermidine/putrescine ABC transporter homologue  0.51 0.23 0.28 
SA1042 pyrP uracil permease  1.16 2.02 0.07 
SA1224  ABC transporter (ATP-binding protein) homologue  0.48 0.35 0.36 
SA1979  hypothetical protein, similar to ferrichrome ABC transporter (binding protein)  0.46 0.55 0.32 
SA2094  hypothetical protein, similar to Na+/H+ antiporter  0.46 0.33 0.81 
SA2117  hypothetical protein, similar to Na+/H+ antiporter 0.82 0.36 0.76 
SA2132  hypothetical protein, similar to ABC transporter (ATP-binding protein)  0.34 0.22 0.21 
SA2135  hypothetical protein, similar to sodium/glutamate symporter  0.71 0.65 0.23 
SA2142  hypothetical protein, similar to multidrug resistance protein  0.40 0.42 0.23 
SA2191  hypothetical protein, similar to NirC  0.54 0.31 0.67 
SA2300  hypothetical protein, similar to glucarate transporter  0.81 0.83 0.22 
SA2302  hypothetical protein, similar to ABC transporter  1.12 0.83 0.27 
SA2303  hypothetical protein, similar to membrane spanning protein  1.15 0.65 0.18 
SA2326 ptsG PTS system, glucose-specific IIABC component  0.64 0.42 0.32 
RNA synthesis - regulation, elongation and modification    
SA0501 rpoC RNA polymerase beta-prime chain  0.81 0.39 0.54 
SA1041 pyrR pyrimidine operon repressor chain A  0.72 1.28 0.13 
SA1082 rimM probable 16S rRNA processing protein  0.40 0.31 0.32 
SA1083 trmD tRNA-(guanine-N1)-methyltransferase  0.44 0.32 0.38 
SA1583 rot repressor of toxins Rot  0.55 0.64 0.23 
SA1844 agrA accessory gene regulator A  0.33 0.22 0.53 
SA2023 rpoA DNA-directed RNA polymerase alpha chain  0.43 0.23 0.25 
SA2089 sarR staphylococcal accessory regulator A homologue  0.53 0.36 0.31 
Sensors (signal transduction)    
SA1843 agrC accessory gene regulator C  0.51 0.27 0.70 
Hypothetical proteins    
SA0121  hypothetical protein  0.64 - 0.34 
SA0213  conserved hypothetical protein  0.33 0.39 0.37 
SA0231  hypothetical protein, similar to flavohemoprotein  0.90 0.90 0.36 
SA0262  hypothetical protein  0.51 0.47 0.20 
continued on following page
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Table 4.2 - Continued 
Fold change2
N315 
ORF Gene Gene product function 137/93A 
(0.5xMIC) 
137/93G 
(0.5xMIC) 
SG511 
(1xMIC) 
 
SA0266  conserved hypothetical protein  1.47 1.03 0.34 
SA0267  hypothetical protein  1.13 0.78 0.35 
SA0268  hypothetical protein  1.05 0.90 0.39 
SA0269  hypothetical protein  1.10 1.18 0.03 
SA0291  hypothetical protein  0.31 0.36 0.11 
SA0292  hypothetical protein  0.26 0.23 0.07 
SA0406  hypothetical protein  0.70 0.98 0.35 
SA0499  conserved hypothetical protein  0.54 0.28 0.53 
SA0555  conserved hypothetical protein  0.74 0.53 0.27 
SA0588  conserved hypothetical protein  0.63 1.26 0.30 
SA0667  conserved hypothetical protein  0.79 0.21 0.40 
SA0739  conserved hypothetical protein  0.27 0.29 0.04 
SA0890  conserved hypothetical protein  0.42 0.20 0.58 
SA0929  conserved hypothetical protein  0.73 0.94 0.34 
SA0949  conserved hypothetical protein  0.73 0.31 0.52 
SA1002  hypothetical protein  1.01 0.55 0.20 
SA1049  hypothetical protein  1.11 1.44 0.13 
SA1056  hypothetical protein  0.62 0.53 0.35 
SA1265  conserved hypothetical protein  0.49 0.19 0.36 
SA1275  conserved hypothetical protein  0.64 0.57 0.39 
SA1536  conserved hypothetical protein  0.55 0.35 0.53 
SA1693  conserved hypothetical protein  0.73 0.60 0.35 
SA1840  conserved hypothetical protein  0.62 0.39 0.57 
SA1912  hypothetical protein  0.55 0.45 0.33 
SA1985  hypothetical protein  0.53 1.74 0.20 
SA1986  hypothetical protein  0.49 1.56 0.19 
SA2050  conserved hypothetical protein  0.59 0.29 0.44 
SA2133  conserved hypothetical protein  0.51 0.31 0.21 
SA2143  conserved hypothetical protein  0.46 0.53 0.30 
SA2328  conserved hypothetical protein  0.90 1.38 0.37 
SA2329  conserved hypothetical protein  0.26 0.22 0.21 
SA2355  conserved hypothetical protein  0.80 0.39 0.72 
SA2371  conserved hypothetical protein  0.69 0.80 0.29 
SA2372  hypothetical protein  0.58 0.74 0.34 
SA2443  hypothetical protein  0.84 0.37 1.00 
 
 
 
 
1 Significant changes of gene expression were determined by implementing SAM (significance analysis of  
   microarrays; http://www-stat.stanford.edu/~tibs/SAM/) (Tusher et al., 2001). 
2 Fold change in transcript level of at least 2.5-fold is indicated as mean of the “median of ratios” compared to  
   control cells. Fold change in bold = classified as "significantly" regulated in this strain by SAM. 
 
 
4.3.7 Regulation of genes related to protein transport and binding 
In this thesis, the most prominent event of gene regulation comprised the upregulation of the 
genes coding for the hypothetical ABC transporter VraDE in the presence of mersacidin. The 
vraSR genes were induced 40 to 70-fold in the microarray studies in all three strains tested. 
This transporter has been previously shown to be induced by vancomycin and cationic AMPs 
(Kuroda et al., 2000; Li et al., 2007a) and seems to be involved in the increased resistance 
towards bacitracin and the human β-defensin 3 (hBD3) in S. aureus (Sass et al., 2008b). 
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Furthermore, the oppBCDF gene cluster coding for an oligopeptide transport system and the 
components of the phospho-transferase system (PTS), notably ORF SA1255 (specific to 
glucose), glvC, as well as glcA and ptsG (both specific to glucose), displayed increased 
expression. Only few genes coding for transport proteins were differently expressed in the 
VISA strains SA137/93A and SA137/93G compared to the sensitive strain SG511-Berlin. 
Among these, the proline/betaine transporter homologue gene proP, coding for a transporter 
of osmoprotectants, was upregulated in both VISA strains while downregulated in strain 
SG511-Berlin. Interestingly, the genes coding for the ABC transporter VraFG, which have 
recently been shown to be positively controlled by the GraRS TCRS and seem to support 
vancomycin-intermediate resistance (Meehl et al., 2007) as well as resistance to cationic 
AMPs (Li et al., 2007a), were slightly downregulated in strains SA137/93A and SA137/93G 
compared to strain SG511-Berlin.  
 
4.4 Quantitative Real-Time PCR (qRT-PCR) of vraS and vraE marker gene 
transcription in response to mersacidin 
Quantitative RT-PCR of the sensor histidine kinase gene vraS was employed to further 
analyze the induction of the VraSR-triggered cell wall stress stimulon (Fig. 4.5A). In the 
presence of 0.5 x MIC of mersacidin, a strong induction of vraS transcription (16 to 26-fold) 
was recorded for all strains tested. Even 0.15 x MIC of mersacidin considerably induced vraS 
transcription in strain SA137/93G (5.6-fold; incubated with 4 µg/ml of mersacidin 
corresponding to 2.175 µM) and strain SG511-Berlin (3.4-fold; incubated with 0.2 µg/ml of 
mersacidin corresponding to 0.116 µM) (strain SA137/93A not tested). As a control, strain 
SA137/93G was incubated with subinhibitory concentrations of vancomycin (4 µg/ml, 2.75 
µM, 0.5 x MIC). Here, no induction was visible by qRT-PCR. However, the transcript levels 
of untreated or treated conditions, respectively, did not vary significantly between the tested 
strains. Interestingly, vraS transcription was not significantly affected in strain SA137/93G 
when incubated with 0.5 µg/ml that corresponds to 0.02 x MIC mersacidin for this strain.  
The induction of vraDE gene transcription was also verified using qRT-PCR (Fig. 4.5B). 
Upon incubation with 0.5 x MIC of mersacidin, vraDE transcription was induced 76 to  
79-fold in strain SA137/93A and SA137/93G, respectively. In the susceptible strain SG511-
Berlin, the transcript level of the vraDE genes rose almost 1700-fold upon incubation with 
mersacidin. 
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Figure 4.5: Gene regulatory response of the S. aureus strains SA137/93A, SA137/93G and SG511-Berlin to 
the lantibiotic mersacidin. A. qRT-PCR of vraS gene induction in response to subinhibitory concentrations of 
mersacidin and vancomycin (control). B. qRT-PCR of vraE gene expression upon mersacidin treatment. The 
qRT-PCR values represent the mean of at least two independent experiments. Quantitative data are presented in 
relation to 106 copies of the housekeeping gene gyrB. Fold changes were calculated in relation to the untreated 
control cells, i.e. transcription levels in the absence of mersacidin. 
 
 
4.5 Susceptibility testing of a vraDE deletion mutant of S. aureus SG511-Berlin against 
mersacidin 
In this thesis, microarray profiling and qRT-PCR of different S. aureus strains revealed the 
extensive upregulation of the genes coding for the hypothetical ABC transporter VraDE in 
response to mersacidin treatment. In the producer strain of mersacidin, resistance is conferred 
y an ABC transporter (Guder et al., 2002). For this reason, the participation of an ABC 
ansporter in the decreased susceptibility of S. aureus seemed to be likely. To test whether 
raDE is able to transport mersacidin out of the cell membrane and therefore supports a 
sistance phenotype, the growth behaviour and MICs of a vraE knock-out mutant of  
. aureus SG511-Berlin (Sass et al., 2008b) and its parent strain were examined in the 
resence of the lantibiotic. Unexpectedly, S. aureus SG511∆vraE was characterized by a 
wered growth rate but did not show increased susceptibility towards mersacidin neither in 
rowth curve recordings (Fig. 4.6) nor in MIC studies (MIC of SG511∆vraE: 1 µg/ml; 
G511-Berlin: 1 µg/ml). 
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Figure 4.6: In vitro growth curve recordings of S. aureus SG511∆vraE in the presence of mersacidin.  
S. aureus SG511-Berlin wild type (S 0.5 µg/ml, U control); S. aureus SG511∆vraE ( 0.5 µg/ml,  control). 
 
 
4.6 Nucleotide sequence analysis of vraDE and vraS 
For further characterization of VraDE and VraS in S. aureus SA137/93A and S. aureus 
SG511-Berlin, the nucleotide sequences of the vraDE genes plus the corresponding promoter 
region as well as the vraS gene were determined in both strains. Sequencing of the vraDE 
genes revealed single differences in the overall nucleotide sequence, however, the -35 and the 
-10 region, the ribosomal binding site (Fig. 4.7) as well as the vraD gene (for protein 
sequence alignment see Fig. 4.8) were highly conserved in strains SA137/93A and SG511-
Berlin showing 100% sequence identity. The vraE gene still showed 95.7% sequence identity 
with mostly conservative amino acid substitutions (for protein sequence alignment see  
Fig. 4.8). Noteworthy, the vraDE sequence of S. aureus SA137/93G was identical to that of 
strain SA137/93A (data not shown). In silico analysis of putative transmembrane helices of 
VraE using online analysis tools (http://www.cbs.dtu.dk/services/TMHMM-2.0/) assumed 
that these amino acid substitutions predominantly occurred in the C-terminal loop of VraE 
that is located in the periplasmic space between the plasma membrane and the thick 
peptidoglycan layer of S. aureus. Protein sequence analysis of VraDE via Basic Local 
Alignment Search Tool (BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to 
determine the homology of VraDE of strain SA137/93A and strain SG511-Berlin to other  
S. aureus species. Conserved domain analysis using BLAST linked VraDE to the SalXY-like 
ABC_ATPase superfamily. Here, VraD of S. aureus SA137/93A and strain SG511-Berlin 
showed 100% sequence identity to all other S. aureus VraD protein sequences of the NCBI 
database (http://www.ncbi.nlm.nih.gov/) except for S. aureus MRSA252 which was 
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characterized by a single conservative amino acid substitution (E236K). The VraE protein 
sequence of S. aureus SA137/93A also showed 100% sequence identity to the VraE 
sequences of S. aureus strain COL, strain USA300 and strain Newman. Less homology was 
noted for S. aureus strain NCTC8325 (2 conservative amino acid (aa) substitutions), strain 
Mu50, strain N315, strain JH9 (each 1 conservative and 4 non-conservative aa substitutions), 
strain MW2, strain MSSA476, (each 1 conservative and 5 non-conservative aa substitutions), 
strain RF122 (8 conservative and 12 non-conservative aa substitutions) and strain MRSA252 
(15 conservative and 13 non-conservative aa substitutions). Interestingly, the homology 
pattern of S. aureus SG511-Berlin was reversed. The closest homology was detected with  
S. aureus strain MRSA252 (1 non-conservative aa substitution; S441I), followed by strain 
RF122 (9 conservative and 7 non-conservative aa substitutions), strain MW2, strain 
SSA476 (each 14 conservative and 9 non-conservative aa substitutions), strain NCTC8325 
5 conservative and 12 non-conservative aa substitutions), strain Mu50, strain N315, strain 
, strain 
 
7/93A, 
 other  
 except for 
rvative 
CTACTAAGT 172 
511-Berlin       GCTCAAATTAGTTGAACTGCTTTCCAATAATCCAAATTCACCCGAGAAAATC-ACGATAT 179 
                    ***    ** **  ** *   * * *  ****   ** * * *   ****** ** *  * 
M
(1
JH9 (each 17 conservative and 11 non-conservative aa substitutions), strain COL
Newman and strain USA300 (each 15 conservative and 12 non-conservative aa substitutions).
The protein sequence of the histidine sensor kinase VraS of S. aureus strain SA13
strain SA137/93G and strain SG511-Berlin showed 100% sequence identity to all
S. aureus protein sequences of the NCBI database (http://www.ncbi.nlm.nih.gov/)
S. aureus strain Mu50 and strain Mu3 which were characterized by a single non-conse
amino acid substitution (I5N; Fig. 4.9). 
 
 
 
SA137/93A        AACAATCAATTCCTTTCAAATAAAACCCTCTTTTAATTTTTACAAAAAAT-TTATTATAC 59 
SG511-Berlin       AACAATCATTTCCTTTCAAACAACGCCTTCTTTATATTTTAATTAGTGTCACTATTATTC 60 
                      ******** *********** **  ** *****  ***** *  *       ****** * 
 
SA137/93A         AATAATTAAATTCCCTTTTCTCAATTTACACAAACATCATCACTTAGAAAGCACCAT--T 117 
SG511-Berlin       ATTGTTTAAATTCCCTCATCTTAACTTATAGAAACATTTCCTCAGTGCAAATACTGTGAT 120 
                      * *  ***********  *** ** *** * ******   * *   * **  **  *  * 
 
SA137/93A           GCT----TTTGTCTAA-TATGTACGATGAATCTGTATCCTCACTCAAAAAT
SG
  
                -35 region 
 SA137/93A          AGCGATAGCTTTCAACTCTGTAAGGTTCATTCATTGAATTGTAAGTTTAGATAAAGGCTA 232 
SG511-Berlin       ATTAATATCTTTCAACTATGTAAGATTCAAACATTGAATTGTAAGTTTAGATAAAGGCTA 
                     *   *** ********* ****** ****  ***************************** 
239 
 
-10 region              rbs        start codon vraD
 
 
SA137/93A          CTACTCCAAACATTATTTAAAATGAAATTAAATACAAAAGGAGTGAGACTATG 285 
SG511-Berlin       CTGTTCTACTTATTATTTAAAATGAATTTAAATACAAAAGGAGTGATACTATG 292 
                     **  ** *   *************** ******************* ******  
 
Figure 4.7: Nucleotide equence alignment of the promoter region of vraDE in S. aureus SA137/9 s 3A and  
ol 
quence: 
ion ine dalgarno 
G
S. aureus SG511-Berlin. The multiple sequence alignment was performed using the online analysis to
“ClustalW” (http://www.ebi.ac.uk/Tools/clustalw2/index.html). The -35 region (consensus se
T 0  (consensus sequence: T T ibosomal binding site (rbs/TGACA), the -1  reg A AAT) and the r sh
consensus sequence: AG AGGU) are underlined. “*” indicates identical nucleotides. 
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SA137/93A           MTILSVQHVSKTYGKKHTFQALKDINFDIQKGEFVAIMGPSGSGKTTLLNVLSSIDQISS 60 
SG511-Berlin       MTILSVQHVSKTYGKKHTFQALKDINFDIQKGEFVAIMGPSGSGKTTLLNVLSSIDQISS 60 
                    ************************************************************  
 
TVKENIMLPLSVQKMSKATME SA137/93A           GSVIANGQELNKLNQKALAKFRKESLGFIFQDYSILPTL 120 
 
SG511-Berlin       GSVIANGQELNKLNQKALAKFRKESLGFIFQDYSILPTLTVKENIMLPLSVQKMSKATME 120 
                    ************************************************************ 
 
SA 3A    ENYKAITTALGIYDLGN LS RT VH FADEPTGALDSKSAND 137/9         KYPSE GGQQQ AAARAF KPQII 180 
SG511-Berlin       ENYKAITTALGIYDLGNKYPSELSGGQQQRTAAARAFVHKPQIIFADEPTGALDSKSAND 180 
                    ************************************************************  
 
SA 3A    LL MN TIVMVTHDPVAASFAERV137/9         QRLEE KSFDT IMLKDGQIHTQLYQEGRSKQAFYEDIVH 240 
SG511-Berlin       LLQRLEEMNKSFDTTIVMVTHDPVAASFAERVIMLKDGQIHTQLYQEGRSKQAFYEDIVH 240 
                   ************************************************************ 
                inside                 outside 
SA137/93A           LQSVLGGVSNDI-MTFNHIVFKNLRQNLKHYAMYLFSLFFSIVLYFSFTTLQFTKGVNND 299 
SG511-Berlin       LQSVLGGVSNDI-MTFNHIVLKNLRQNLKHYAMYLFSLFFSIVLYFSFTTLQFTKGVNND 299 
                    ************ *******:***************************************  
           inside 
SA137/93A           DSMAIIKKGALVGSIFLFIIIVIFLMYANHLFVKRRTREFALFQLIGLTRQNILKMLALE 359 
SG511-Berlin       DSMAIIKKGALVGSIFLFIIIVIFLMYANHLFVKRRTREFALFQLIGLTRQNILKMLALE 359 
                    ************************************************************  
        outside 
SA137/93A           QMIVFLITGVVGVLCGIAGAQLLLSIVSKLMSLSINLSIHFEPMALVLTIFMLIIAYVLI 419 
SG511-Berlin       QMIVFIITGVVGVLCGIAGAQLLLSIVSKLMSLSINLSIHFEPMALVLTILMLIIAYILI 419 
                    *****:********************************************:******:**  
           inside             outside 
SA137/93A           LFKSALFLKRRSILSMMKDSIKTDATTAKVTTAEVISGVLGIAMIALGYYMATEMFGTFK 479 
SG511-Berlin       LFQSSLFLKRRSILSMMKDSVKTDVTTAKVTVIEVISGVLGIAMIALGYYMATEMFGTFK 479 
                    **:*:***************:***.******. ***************************  
              inside 
SA137/93A           ALTMAMTSPFIILFLTVVGAYLFFRSSVSLIFKTLKKSKNGRVSITDVVFTSSIMYRMKK 539 
SG511-Berlin       ALTMAMTSPFIILFLTVVGAYLFFRSSVSLIFKTLKKSKNGRVSITDVVFTSSIMYRMKK 539 
                    ************************************************************  
         outside 
SA 3A    NA IAIISAVTVTVLCFAALSKSNTDQTLTSMA137/9         MSLTI PNEFNVVATQDAKQFETKLSQQQ 599 
SG511-Berlin       NAMSLTIIAIISAVTVTVLCFAALSKSNTDQTLTSMAPNDFNVVASQDAQQFESKLSQQH 599 
 ***:***:*****:                     ***************************************:*****:
 
SA137/93A           ITFSKNAYETITVDNVNDQVITLENGSDSGRTNSILSANNKLTGNNAIITNTKSLPNIIN 659 
SG511-Berlin       ITFSKNYYETITVDNVKDQVITLENGSDSGRTNSILSANTKLTGNNAIITNTKSLPNVIN 659 
                     ****** *********:**********************.*****************:** 
 
SA137/93A           IHLNKDLVVKGTKNETFRVTQEDKGKVYPLNLSFNSPVIEVSPEKYQQLKTQNNVHTFYG 719 
SG511-Berlin       IHLNNDLVVKGTKNETFRVTQEDKDKVYPLNLSFNSPVIEVSPEKYQQLKTQNNVHTFYG 719 
                     ****:*******************.*********************************** 
 
SA137/93A           YDIKQTSQKEKAQAIAKQFGDKVITYDEMKKEVDATNGILIFVTSFLGLAFLVAAGCIIY 779 
SG511-Berlin       
 
YDIKQTSQKKKAQAIAKQFGDKIITYDDMKKEVDATNGILIFVTSFLGLAFLVAAGCIIY 779 
                    *********:************:****:******************************** 
          inside             outside  
SA137/93A           IKQMDETEDELSNFRILKRIGFTHTDMLKGLLLKITFNFGLPLLIAILHAVFAAIAFMKL 839 
S
 
G511-Berlin       IKQMDETEDELSNFRILKRIGFTHTDMLKGLLLKITFNFGLPLLIAILHAVFAAIAFMKL 839 
                    ************************************************************ 
                         inside  
SA137/93A           MGNISFMPVIVVIVVYTLIYITFALIAFVHSNKLIKKTI- 878 
SG511-Berlin       MGNISFMPVIIVIIVYTLIYIVFALIAFVHSNKLIKKTI- 878 
                     **********:**:*******.*****************  
 
Figure 4.8: Amino acid sequence alignment of VraDE in S. aureus SA137/93A and S. aureus SG511-
rformed using 
HMM server 
ted in grey. 
bstitution. 
Berlin. Multiple sequence alignment and determination of putative transmembrane helices were pe
the online analysis tool “ClustalW” (http://www.ebi.ac.uk/Tools/clustalw2/index.html) and the TM
v2.0 (http://www.cbs.dtu.dk/services/TMHMM-2.0/). Putative transmembrane helices are highligh
“*” indicates identical amino acids (aa), “:” conservative aa substitution, “.” semi-conservative aa su
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SA137/93A         MNHYIRTIGSMLILVYSMLAAFLFIDKVFVNIIYFQGMFYTQIFGIPVFLFLNLIIILLC 60 
SA137/93G         MNHYIRTIGSMLILVYSMLAAFLFIDKVFVNIIYFQGMFYTQIFGIPVFLFLNLIIILLC 60 
SG511-Berlin      MNHYIRTIGSMLILVYSMLAAFLFIDKVFVNIIYFQGMFYTQIFGIPVFLFLNLIIILLC 60 
Mu50              MNHYNRTIGSMLILVYSMLAAFLFIDKVFVNIIYFQGMFYTQIFGIPVFLFLNLIIILLC 60 
                  **** ******************************************************* 
 
SA137/93A         IIVGSVLAYKINQQNDWIKTQIERSMEGETVGINDQNIEIYSETLDLYHTLVPLNQELHK 120 
SA137/93G         IIVGSVLAYKINQQNDWIKTQIERSMEGETVGINDQNIEIYSETLDLYHTLVPLNQELHK 120 
SG511-Berlin      IIVGSVLAYKINQQNDWIKTQIERSMEGETVGINDQNIEIYSETLDLYHTLVPLNQELHK 120 
20 Mu50              IIVGSVLAYKINQQNDWIKTQIERSMEGETVGINDQNIEIYSETLDLYHTLVPLNQELHK 1
                  *****************************************************
 
******* 
ETKLEP 180 
ETKLEP 180 
ETKLEP 180 
KETKLEP 180 
RALLLHLRPLGLKDKSLGEGIKDLVIDLQKKVPMKVVHEI 240 
                 ************************************************************ 
A137/93A         QDFKVPKGIEDHLFRITQEAISNTLRHSNGTKVTVELFNKDDYLLLRIQDNGKGFNVDEK 300 
SA137/93A         LRLKTQNLTNENYNINDVKVKKIIEDERQRLARELHDSVSQQLFAASMMLSAIK
SA137/93G         LRLKTQNLTNENYNINDVKVKKIIEDERQRLARELHDSVSQQLFAASMMLSAIK
SG511-Berlin      LRLKTQNLTNENYNINDVKVKKIIEDERQRLARELHDSVSQQLFAASMMLSAIK
SAIMu50              LRLKTQNLTNENYNINDVKVKKIIEDERQRLARELHDSVSQQLFAASMML
                  ************************************************************ 
 
SA137/93A         PLDQQIPILEKMVQDSQLEMRALLLHLRPLGLKDKSLGEGIKDLVIDLQKKVPMKVVHEI 240 
SA137/93G         PLDQQIPILEKMVQDSQLEMRALLLHLRPLGLKDKSLGEGIKDLVIDLQKKVPMKVVHEI 240 
SG511-Berlin      PLDQQIPILEKMVQDSQLEM
Mu50              PLDQQIPILEKMVQDSQLEMRALLLHLRPLGLKDKSLGEGIKDLVIDLQKKVPMKVVHEI 240 
 
 
S
SA137/93G         QDFKVPKGIEDHLFRITQEAISNTLRHSNGTKVTVELFNKDDYLLLRIQDNGKGFNVDEK 300 
SG511-Berlin      QDFKVPKGIEDHLFRITQEAISNTLRHSNGTKVTVELFNKDDYLLLRIQDNGKGFNVDEK 300 
Mu50              QDFKVPKGIEDHLFRITQEAISNTLRHSNGTKVTVELFNKDDYLLLRIQDNGKGFNVDEK 300 
                  ************************************************************ 
 
SA137/93A         LEQSYGLKNMRERALEIGATFHIVSLPDSGTRIEVKAPLNKEDSYDD- 347 
SA137/93G         LEQSYGLKNMRERALEIGATFHIVSLPDSGTRIEVKAPLNKEDSYDD- 347 
SG511-Berlin      LEQSYGLKNMRERALEIGATFHIVSLPDSGTRIEVKAPLNKEDSYDD- 347 
Mu50              LEQSYGLKNMRERALEIGATFHIVSLPDSGTRIEVKAPLNKEDSYDD- 347 
                  ***********************************************  
 
Figure 4.9: Amino acid sequence alignment of VraS of S. aureus strain SA137/93A, strain SA137/93G, 
strain SG511-Berlin and strain Mu50.  The I5N amino acid substitution in VraS of S. aureus Mu50 is shaded 
in grey. “*” indicates identical amino acids. 
 
 
4.7 Comparative transcriptomics of S. aureus SG511-Berlin and S. aureus SA137/93A 
Since the expression pattern of S. aureus SG511-Berlin and S. aureus SA137/93A in the 
presence of mersacidin did not reveal significant differences among theses strains which 
could explain their divergent susceptibilities to mersacidin, the expression profiles of both 
strains were compared to each other in the absence of antibiotics using S. aureus microarrays. 
Here, mannifold differences in their transcriptional patterns were observed (Table 4.3 and 
Table S2 in the supplemental material). Due to the susceptibility of strain SG511-Berlin to 
methicillin, kanamycin, neomycin and erythromycin, resulting from the absence of the 
respective resistance determinants SCCmec, aadD and ermA, the transcripts of these genes 
were virtually absent in this strain compared to S. aureus SA137/93A. Furthermore, the 
divergent regulation of factors involved in biofilm formation and colonization was observed, 
e.g. atl and sirC (0.38- and 0.21-fold, respectively). Additionally, the transcript levels of the 
genes coding for the biosynthesis of the Cap5/8 microcapsule (<0.35-fold) and the urease 
synthesis cluster (<0.15-fold) were lower in SG511-Berlin compared to SA137/39A. In terms 
f global regulators, the sigB (0.3-fold) and agrC (0.08-fold) transcripts showed a lower level o
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in strain SG511-Berlin, while the level of rot gene transcript (4.32-fold) was higher compared 
train SG511-Berlin, since Rot has been shown to be a negative regulator for this gene cluster 
aid-Salim et al. 03). gr lier observations (Ja et al., 2007), the 
enes of the Yyc R w SG511-Ber 0.11-fold), which 
as been linked t pr e nt IS256 in the promoter region of 
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1 Relative transcript levels of S. aureus SG511-Berlin compared to  
            S. aureus  SA137/93A. 
 
 
N315 
ORF Gene Gene product function alue
1
SA0017 yycF response regulator 0.11 
SA0018 yycG two-component sensor histidine kinase 0.11 
SA0033 aadD kanamycin nucleotidyltransferase 
c  olysaccharide synthesis enzyme Cap5A 
enzyme Cap5B 
capC synthesis enzyme Cap8C 
thesis enzyme Cap5D 
charide synthesis enzyme Cap8E 
nthesis enzyme Cap5G 
 synthesis enzyme Cap5I 
ide synthesis enzyme Cap5J 
de synthesis enzyme Cap5K 
rotein 
S
f toxins Rot 4.32 
ene regulator C 0.08 
SA1869 sigB sigma factor B 0.30 
1984 asp23 alkaline shock protein 23 0.15 
0.02 
SA0038 mecA penicillin binding protein 2a 0.11 
SA0109 sirC lipoprotein 0.21 
SA0144 apA capsular p 0.26 
SA0145 capB capsular polysaccharide synthesis 0.18 
SA0146 capsular polysaccharide 0.22 
SA0147 capD capsular polysaccharide syn 0.19 
SA0148 capE capsular polysac 0.25 
SA0150 capG capsular polysaccharide sy 0.35 
SA0152 capI capsular polysaccharide 0.30 
SA0153 capJ capsular polysacchar 0.26 
SA0154 capK capsular polysacchari 0.22 
SA0616 vraF ABC transporter ATP-binding p 0.11 
SA0617 vraG ABC transporter permease 0.21 
SA0650 norA quinolone resistance protein 0.12 
SA0794 dltB DltB membrane protein 0.49 
SA0905 atl autolysin 0.38 
A1193 mprF lysyltransferase (MprF or FmtC) 0.40 
SA1583 rot repressor o
SA1843 agrC accessory g
SA
SA2082 ureA urease gamma subunit 0.07 
SA2083 ureB urease beta subunit 0.04 
SA2084 ureC urease alpha subunit 0.07 
SA2085 ureE urease accessory protein UreE 0.11 
SA2086 ureF urease accessory protein UreF 0.08 
SA2087 ureG urease accessory protein UreG 0.13 
SA2088 ureD urease accessory protein UreD 0.15 
SA2384 ermA rRNA methylase 0.02 
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Finally, a lower expression of the genes coding for the membrane protein DltB (0.49-fold), 
the lysyltransferase MprF (0.4-fold) and the ABC transporter VraFG (<0.21-fold) was 
observed in strain SG511-Berlin. The dltB, mprF and vraFG genes are controlled by the 
raRS TCRS, that has been proven to influence the susceptibility of S. aureus to 
 In  
ence might have a direct influence on the 
usceptibility of S. aureus SG511-Berlin to various antimicrobials. Noteworthy, the graXRS 
equence of S. aureus SA137/93A was identical to that of strain SA137/93G (data not shown) 
st homologous to the graXRS sequences of the S. aureus strains COL, USA300, 
of SG511-
2 (Holden et 
252 (see 
l to strain 
G
antimicrobial substances (Li et al., 2007a; Herbert et al., 2007; Meehl et al., 2007).
S. epidermidis, the graRS (also: apsRS; SA0614/15, of the genomic sequence of S. aureus 
N315) and SA0613 (graX; also: apsX) homologues have been shown to constitute a three-
component regulatory system and have been referred to as antimicrobial peptide sensing 
system (aps). The role of GraX is unclear, however, the protein is essential for signal 
transduction in S. epidermidis (Li et al., 2007b); its essentiality in S. aureus has not yet been 
ascertained by inactivation. 
 
4.8 Sequence analysis of graXRS of S. aureus SG511-Berlin and S. aureus SA137/93A 
In order to analyze the reasons for the divergent expression levels of dltB, mprF and vraFG in 
the S. aureus strains SG511-Berlin and SA137/93A, a 2.8 kb fragment of graXRS (SA0613-5) 
was sequenced in both strains. Besides several, mostly silent nucleotide exchanges, a thymine 
was inserted at position 190 of the sensor histidine kinase gene graS of strain SG511-Berlin 
compared to S. aureus SA137/93A and other S. aureus genomes of the NCBI database 
(http://www.ncbi.nlm.nih.gov/). As a direct consequence, this nucleotide insertion generates a 
stop codon at the amino acid (aa) position 64 (Fig. 4.11), thereby eliminating 283 aa of GraS, 
which is the entire cytoplasmic part of the membrane protein (Li et al., 2007a) that is 
responsible for the activation of the response regulator GraR. A defect GraS sensor histidine 
kinase, followed by an impaired signal transduction, might well be the reason for an altered 
dltB, mprF and vraFG expression and h
s
s
which was mo
Newman and NCTC8325. Aside from the nucleotide insertion, the graS sequence 
Berlin showed 100% sequence identity to the graS gene of S. aureus MRSA25
al., 2004). Since strain SG511-Berlin seems to be closely related to S. aureus MRSA
section 4.2 and 4.6), S. aureus MRSA252 was regarded as the appropriate contro
SG511-Berlin in the following experiments. 
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SA0613 (GraX) 
0 SA137/93A        MKPKVLLAGGTGYIGKYLSEVIENDAELFAISKYPDNKKTDDVEMTWIQCDIFHYEQVVA 6
LSEVIENDAELFAISKYPDNKKTDDVEMTWIQCDIFHYEQVVA 6SASG511-Berlin   MKPKVLLAGGTGYIGKY
                 *****************
  0 
******************************************* 
NSAKITQSSARDLTLIAADNFGRAAAINQVKKVIYIPGSRYDNE 120 
  FFIDPTKNSAKITQSSARDLTLIAADNFGRAAAINQVKKVIYIPGSRYDNE 120 
  ************************************************************ 
 80 
 0 
 
180 
 
FIDPTKSA137/93A        AMNQIDIAVF
   AMNQIDIAVSASG511-Berlin
               
 
SA137/93A        TIERLGAYGTPVETTNLVFKRSLVNVELQVSKYDDVRSTMKVVLPKGWTLKNVVNHFIAW 180 
SASG511-Berlin    TIERLGAYGTTVETTNLVFKRSLVNVELQVSKYDDVRSTMKVVLPKGWTLKNVVNHFIAW 1
                 **********.************************************************* 
 
SA137/93A        MGYTKGTFVKTEKSHDQFKIYIKNKVRPLAVFKIEETADGIITLILLSGSLVKKYTVNQG 240 
 40 SASG511-Berlin    MGYTKGTFVKTEKSHDQFKIYIKNKVRPLAVFKIVETADGIITLILLSGSLVKKYTVNQG 2
                 ********************************** ************************* 
 
SA137/93A        KLEFRLIKESAVVYIHLYDYIPRLFWPIYYFIQAPMQKMMIHGFEVDCRIKDFQSRLKSG 300 
 00 SASG511-Berlin    KLEFRLIKESSVVYIHLYDYIPRLFWPIYYFIQAPMQKMMIHGFEVDCRIKDFQSRLKSG 3
                 **********:************************************************* 
 
SA137/93A        ENMKYTKstop 307 
SASG511-Berlin     ENMKYTKstop 307 
   *******                
 
SA0614 (GraR) 
SA137/93A        MQILLVEDDNTLFQELKKELEQWDFNVAGIEDFGKVMDTFESFNPEIVILDVQLPKYDGF 60 
SASG511-Berlin    MQILLVEDDNTLFQELKKELEQWDFNVAGIEDFGKVMDTFESFNPEIVILDVQLPKYDGF 6
                 ************************************************************ 
 
SA137/93A        YWCRKMREVSNVPILFLSSRDNPMDQVMSMELGADDYMQKPFYTNVLIAKLQAIYRRVYE 120 
 20SASG511-Berlin    YWCRKMREVSNVPILFLSSRDNPMDQVMSMELGADDYMQKPFYTNVLIAKLQAIYRRVYE 1
                 ************************************************************ 
 
80 SA137/93A        FTAEEKRTLTWQDAVVDLSKDSIQKGDQTIFLSKTEMIILEILITKKNQIVSRDTIITAL 1
L SASG511-Berlin     FTAEEKRTLTWQDAVIDLSKDSIQKGDQTIFLSKTEMIILEILITKKNQIVSRDTIITA
                 ***************:******************************************** 
 
SA137/93A        WDDEAFVSDNTLTVNVNRLRKKLSEISMDSAIETKVGKGYMAHEstop 224 
SASG511-Berlin     WDDEAFVSDNTLTVNVNRLRKKLSEIGMDSAIETKVGKGYMAHEstop 224 
               **************************.*****************    
 
SA0615 (GraS) 
SA137/93A        MNNLKWVAYFLKSRMNWIFWILFLNFLMLGISLIDYDFPIDSLFYIVSLNLSLTMIFLLL 60 
SASG511-Berlin   MNNLKWVVYFLKSRKNWIFWILFLNILMLGISLIDYDFPIDSLFYIVSLNLSLTL
                 *******.****** **********:****************************:*
  IFLIL 60 
**:* 
 
137/93A        SA TYFKEVKLYKHFDKDKEIEEIKHKDLAETPFQRHTVDYLYRQISAHKEKVVEQQLQLNMH 120 
SASG511-Berlin     TFFstop----------------------------------------------------- 63 
                 *:*                                                          
 
SA137/93A        EQTITEFVHDIKTPVTAMKLLIDQEKNQERKQALLYEWSRINSMLDTQLYITRLESQRKD 180 
SASG511-Berlin     ------------------------------------------------------------ 
                                                                             
 
SA137/93A        MYFDYVSLKRMVIDEIQLTRHISQVKGIGFDVDFKVDDYVYTDIKWCRMIIRQILSNALK 240 
SASG511-Berlin     ------------------------------------------------------------ 
                                                                             
 
SA137/93A        YSENFNIEIGTELNDQHVSLYIKDYGRGISKKDMPRIFERGF
SASG511-Berlin     ------------------------------------------
TSTANRNETTSSGMGLYL 300 
------------------ 
                                                                             
 
SA137/93A        VNSVKDQLGIHLQVTSTVGKGTTVRLIFPLQNEIVERMSEVTNLSFstop 346 
SASG511-Berlin     ---------------------------------------------- 
 
Figure 4.11: Amino acid sequence alignment of GraXRS of S. aureus SA137/93A and S. aureus SG511-
Berlin. The first and second transmembrane segments of GraS are underlined and the extracellular loop as 
postulated by Li et al. (2007a) is presented in bold. In strain SG511-Berlin, the insertion of a thymine at position 
190 of graS generates a stop codon at the amino acid (aa) position 64 resulting in the deletion of 283 aa of the 
sensor histidine kinase representing the cytoplasmic, signal transducing part of the membrane protein. “*” 
indicates identical amino acids (aa), “:” conservative aa substitution, “.” semi-conservative aa substitution. 
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pTXgraS
8252 bp
SbfI - 21
PstI - 21
SphI - 27
PvuI - 1644
SpeI - 3850
NcoI - 3905
AclI - 3957
NheI - 4014
BmtI - 4018
EcoICRI - 4750
SacI - 4752
XmaI - 4758
SmaI - 4760
FspI - 4797
KasI - 5078
NarI - 5079
SfoI - 5080
BbeI - 5082
MluI - 5259
BclI - 5564
ApaLI - 5944
BspEI - 6341
BamHI - 6344
PacI - 6728
BspHI - 6820
NdeI - 7437
PmlI - 7988
repC
tet
graS
Xy
lR
lip
 electroporation (Schenk and Laddaga, 1992). As a second strategy, 2810 bp 
CR fragments comprising the graXRS genes were amplified from genomic DNA of  
. aureus MRSA252 (ORF SAR0668-70) and from genomic DNA of S. aureus N315 (ORF 
A0613-5), inserted into the XbaI and PstI restriction sites of XbaI/PstI-digested pCU1, 
ansformed into S. aureus RN4220 by electroporation and finally transduced into S. aureus 
S. aureus SG511-Berlin harbouring the pCU1 
erivatives or pTXgraS(N315) showed similar results in preliminary MIC testings towards 
ersacidin, only S. aureus SG511-Berlin carrying pTXgraS(MRSA252) was used for follow 
p experiments. 
4.9 Complementation of graS in S. aureus SG511-Berlin 
To analyze the effect of the nucleotide insertion in graS of strain SG511-Berlin, different 
mutants of this strain were constructed that carry the graS gene in trans under the control of a 
xylose-inducible promoter on the recombinant plasmid pTXgraS. To this end, a 1079 bp PCR 
fragment of the graS gene was amplified from genomic DNA of S. aureus MRSA252 (ORF 
SAR0670) and from genomic DNA of S. aureus N315 (ORF SA0615) as a control. The PCR 
fragments were subsequently inserted into the BamHI and MluI restriction sites of 
BamHI/MluI-digested pTX15, allowing the xylose-controlled expression of graS (Fig. 4.12). 
Ligation assays were transformed into S. aureus RN4220 and subsequently into S. aureus 
SG511-Berlin by
P
S
S
tr
SG511-Berlin by phage transduction. Since 
d
m
u
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Construction of the pTXgraS(MRSA252) expression plasmid. The expression plasmid 
pTXgraS(MRSA252) was generated by insertion of SAR0670 (graS) of S. aureus MRSA252 via the single 
BamHI and MluI restriction sites into the xylose-inducible expression vector pTX15. 
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4.10 Analysis of dltB and vraF gene expression by qRT-PCR in graS complemented  
S. aureus SG511-Berlin 
pUC19vraF
3622 bp
NdeI - 184
KasI - 235
NarI - 236
SfoI - 237
BbeI - 239
EcoRI - 396
EcoICRI - 404
SacI - 406
Acc65I - 408
KpnI - 412
XmaI - 412
SmaI - 414
BamHI - 417
XbaI - 423
EcoRV - 564
MfeI - 653
PsiI - 964
NheI - 1108
BmtI - 1112
BsrGI - 1212
PstI - 1375
SphI - 1381
PciI - 1742
ScaI - 3115
ZraI - 3555
AatII - 3557
vraF
bl
a
pUC19dltB
4022 bp
KasI - 235
NarI - 236
SfoI - 237
BbeI - 239
EcoRI - 396
EcoICRI - 404
SacI - 406
Acc65I - 408
KpnI - 412
XmaI - 412
SmaI - 414
BamHI - 417
XbaI - 423
PsiI - 544
ClaI - 979
BglII - 1368
PstI - 1775
SphI - 1781
HindIII - 1783
S  3515caI -
ZraI - 3955
AatII - 3957
dl
tB
bl
a
ince dltB and vraF expression of S. aureus has been shown to be dependent on the activation 
f GraS (Herbert et al., 2007; Li et al., 2007a; Meehl et al., 2007), qRT-PCR studies were 
erformed to control the graS-dependent dltB and vraF expression in the wildtype of  
. aureus SG511-Berlin, the empty vector control (pTX16) as well as the complemented 
utant carrying pTXgraS(MRSA252). For the construction of the external qRT-PCR plasmid 
tandards pUC19dltB and pUC19vraF, PCR fragments of dltB (1354bp, SA0794) and vraF 
61 bp, SA0616) were amplified by PCR from S. aureus MRSA252 genomic DNA and 
loned via single XbaI and PstI sites into the XbaI/PstI-digested pUC19 vector (Fig. 4.13). 
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Figure 4.13: Construction of the qRT-PCR standards pUC19dltB and pUC19vraF.  
 
 
The RNA used for dltB and vraF gene expression analysis was obtained under inducing 
onditions using the cationic AMP indolicidin to ensure a proper induction of GraS (Li et al., 
007a). Here, the complementation of graS resulted in a significant increase of dltB 
anscripts in S. aureus SG511-Berlin carrying pTXgraS(MRSA252) of more than fourfold 
ompared to the wildtype strain (Fig. 4.14A), indicating the functionality of the 
omplemented system. Further, vraF transcription was induced 1.5-fold compared to the 
wildtype strain (Fig. 4.14B). 
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strain SG511-Berlin resulted in a less negative cell surface charge compared to the wildtype 
at was indicated by a significantly lower amount of bound cytochrome c (~45%). Since the 
harge of the cell surface and the functionality of the GraRS TCRS have a crucial effect on 
e susceptibility of S. aureus to antimicrobial peptides (Peschel et al., 1999; Li et al., 2007a; 
erbert et al., 200 ; Meehl et a ), t eot tion raS of strain SG511-
erlin might account at least partly for its extensive susceptibility to icrobial agents. 
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Figure 4.15: Determination of the whole-cell surface charge. The whole-cell surface charge was measured 
nd to the cell wall of 
termination 
pared to the control strain 
MRSA252. Interestingly c entation of g  SG5 Berlin resulted in a 
significantly decreased su  to the lantibiotics m rsacidin, Pep5 and nisin, whereas 
the susceptibility to van idin and bacitracin was hardly changed.  
using a cytochrome c binding assay. The data show the relative amount of cytochrome c bou
the wildtype S. aureus SG511-Berlin (1), the pTX16 control (2), the pTXgraS(MRSA252) complemented strain 
(3) as well as S. aureus strain MRSA252 (4), strain RN1”HG” (5) and strain N315 (6) as additional controls. The 
data was calculated from the appropriate standard curve. Error bars represent the maximal deviations of the 
measurements from the respective mean value. *The data was obtained by a single measurement in LB broth. 
 
 
4.12 MIC determination of graS complemented S. aureus SG511-Berlin 
To analyze the role of the nucleotide insertion in graS in the susceptibility of S. aureus strain 
SG511-Berlin, the MICs of several antimicrobial agents were determined (Table 4.4). In order 
to maintain the experimental conditions of the dltB expression studies and the de
of the whole-cell surface charge, the bacteria were grown in half concentrated BHI broth. 
MIC values were read after 20 hours of growth. Here, the wildtype of strain SG511-Berlin 
was more susceptible to most of the tested substances com
, the omplem raS in 11-
sceptibility e
comycin, indolic
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Table 4.4: MIC deter f th wildtype ureus SG511-Berlin, the pTX16 control, the 
TXgraS(MRSA252) complemented strain and of S. aureus MRSA252 (additional control). Values [µg/ml] 
orrespond to the mean of at least three independent MIC determinations. 
 
has not yet been identified. BLAST analysis characterized SSP0470/SH0294 as a potential 
 
 
SG511 
wildtype 
 
SG511 
pTX16 
 
SG511 
pTXgraS 
 
MRSA 
252 
 
mination o e S. a
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Mersacidin 1 1 2.5 3.35 
Pep5 0.0095 0.0095 0.0205 0.2 
Nisin 2 2 4 4 
Vancomycin 0.55 0.58 0.6 0.4 
Indolicidin 1.33 1.33 1.83 >2 
Bacitracin 5 5 5 13 
 
 
 
 
 
 
 
 
 
 
4.13 Analysis of Tn551 insertion mutants with decreased susceptibility to mersacidin 
Compared to S. aureus, Staphylococcus simulans 22 is rather susceptible to antibiotics 
including mersacidin. In order to identify putative determinants that influence the 
susceptibility of different staphylococci to mersacidin and other antimicrobial agents, a library 
of Tn551 transposon insertion mutants of S. simulans 22 had been constructed earlier 
(Gabriele Bierbaum, IMMIP; unpublished data). In the present thesis, antimicrobial 
susceptibility testing and mapping of Tn551 transposon insertion was performed employing 
“clone 7” of the Tn551 insertion library of S. simulans 22. The MIC cultures were 
supplemented with erythromycin (20 µg/ml) to maintain the insertion of Tn551 but did not 
contain additional CaCl2 to increase the range of the bactericidal effect of mersacidin. Here, 
S. simulans 22 Tn551-7 was characterized by a significantly increased MIC in half 
concentrated Mueller-Hinton broth. After 24 hours of incubation, the MIC of S. simulans 22 
Tn551-7 was 50 µg/ml of mersacidin, whereas the control strain S. simulans 22 pI258 (vector 
control) had a MIC of 30 µg/ml. Interestingly, no effect was detectable when erythromycin 
was omitted. Mapping of the Tn551 transposon insertion in S. simulans 22 Tn551-7 revealed 
the location of Tn551 in the C-terminal region of a gene that is homologous to the 
hypothetical gene SSP0470 of the genome of Staphylococcus saprophyticus ATCC15305 
(NC007350) respectively SH0294 of the genome of Staphylococcus haemolyticus JCSC1435 
(NC007168) (Fig. 4.10). However, a gene homologous to SSP0470/SH0294 was not present 
in any sequenced S. aureus strain of the NCBI database and the function of SSP0470/SH0294 
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membrane protein and the C-terminal region of SSP0470/SH0294 showed ~50% homology to 
a permease domain of streptococci (data not shown). In S. saprophyticus ATCC15305 and  
S. haemolyticus JCSC1435, SSP0470/SH0294 are located directly upstream of the 
yrrolidone carboxylate peptidase gene pcp, which might therefore also be affected in  
. simulans 22 Tn551-7.  
p
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        >Primer Tn551-P1                          Primer Tn551-P2.2<          Primer Tn551-P2<ure 4.10: Mapping of Tn551 transposon insertion into S. simulans 22.  For primers see table 3.3.  
tment strategy 
ces a 
tidine and therefore an additional positive charge in a position that is occupied by 
tamine, glutamate or asparagine in other staphylococcal phage enzymes (Fig. 4.18). 
rt II – Evaluation of endolysins as novel biofilm trea
4 Sequence comparison of φ11 and φ12 endolysins 
e endolysin sequences of the bacteriophages φ11 (ORF 53, 1473 bp, accession number 
_004615) and φ12 (ORF 49, 1455 bp, accession number NC_004616) were blasted against 
 NCBI protein database. Both endolysins are modular enzymes which consist of three 
tinct domains coding for an N-terminal CHAP-domain with hydrolytic function (cysteine, 
tidine-dependent amidohydrolases/peptidases), a central amidase-domain (N-acetyl-
ramyl-L-alanine amidase) and a C-terminal SH3b domain, which is involved in cell wall 
ognition (Baba and Schneewind, 1996) (Fig. 4.16). In spite of their similar domain 
hitecture, these endolysins show low sequence identity and similarity (26.9% and 39% 
pectively; Fig. 4.17). Additionally, the protein sequences of the φ11 and φ12 endolysins 
re further analyzed using BLAST to identify homologous proteins of other bacteriophages 
ble 4.5). Both endolysins were characterized by high protein sequence identities with 
stly conservative amino acid substitutions compared to homologous genes of other 
teriophages (Sass, 2005). However, the protein sequence of the φ12 endolysin contained a 
que amino acid exchange at position 260 in the amidase domain which introdu
SSP0470  SSP0469
~2200 bp 
~1400 bp 
    tag 
(SSP1100) (SH0294)
SSP0468 Transposon Tn551 
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Figure 4.16: Schematic representation of the
φ11 endolysin: 
φ12 endolysin: 
 protein domain architecture of the φ11 and φ12 endolysins. 
he protein sequences of both endolysins were analyzed using the online analysis tool “CDART” (Conserved 
omain Architecture Retrieval Tool; http://www.ncbi.nlm.nih.gov/Structure/lexington/lexington.cgi). Each 
dolysin consists of three conserved domains.
 
 
PGGYCDYTEVMLQDGHVWVGYTWE-GQRYYLPIRT 471 
NNATIKYDGAYCINGYRWITYIANSGQRRYIATGE 467 
.. :   :  ..  .*  .   :*: *: *  : *** *:.    
 
T
D
en
 
φ11-ORF53      MSIIMEVATMQAKLTKNEFIEWLKTSEGKQFNVDLWYGFQCFDYANAGWKVLFGLLLKGL 60 
49 φ12-ORF49      -----------MLITKNQAEKWFDNSLGKQFNPDLFYGFQCYDYANMFFMIATGERLQGL 
                          :***:  :*:..* ***** **:*****:****  : :  *  *:**   
 
φ11-ORF53      GAKDIPFAN--NFDGLATVYQNTPDFLAQPGDMVVFGSNYGAGYGHVAWVIEATLDYIIV 118 
109 φ12-ORF49      YAYNIPFDNKARIEKYGQIIKNYDSFLPQKLDIVVFPSKYGGGAGHVEIVESANLNTFTS 
              * :*** *  .::  . : :*  .**.*  *:*** *:**.* ***  * .*.*: :     
 
φ11-ORF53      YEQNWLGGGWTDGIEQPGWGWEKVTRRQHAYDFPMWFIRPNFKSETAPRSVQSPTQAPKK 178 
167 φ12-ORF49      FGQNWNGKGWTNGVAQPGWGPETVTRHVHYYDDPMYFIRLNFPDKVSVG--DKAKSVIKQ 
             : *** * ***:*: ***** *.***: * ** **:*** ** .:.:    :..... *:   
 
φ11-ORF53      ETAKPQPKAVELKIIKDVVKGYDLPKRGSNPKGIVIHNDAGSKGATAEAYRNGLVNAPLS 238 
227 φ12-ORF49      ATAKKQAVIKPKKIMLVAGHGYNDPGAVGNGTNERDFIRKYITPNIAKYLRHAGHEVALY 
              *** *.     **:  . :**: *   .* ..   .     .   *:  *:.  :..*    
 
φ11-ORF53      RLEAGIAHSYVSGNTVWQALDESQVGWHTANQIGNKYYYGIEVCQSMGADNATFLKNEQA 298 
287 φ12-ORF49      GGSSQSQDMYQDTAYGVNVGNNKDYGLYWVKSHGYDIVLEIHLDAAGESASGGHVIISSQ 
               .:   . * .     :. ::.: * : .:. * .    *.:  :  : .. .:  ..    
 
φ11-ORF53      TFQECARLLKKWGLPANRNTIRLHNEFTSTSCPHRSSVLHTGFDPVTRGLLPEDKRLQLK 358 
347 φ12-ORF49      FNADTIDKSIQDVIKNNLGQIRGVTPRNDLLNVNVSAEININYRLSELGFITNKNDMDWI 
                :      :  :  * . **  .  ..    : *: :: .:     *::.:.: ::     
 
φ11-ORF53      ----DYFIKQIRAYMDGKIPVATVSN--ESSASSNTVKPVASAWKRNKYGTYYMEESARF 412 
407 φ12-ORF49      KKNYDLYSKLIAGAIHGKPIGGLVAGNVKTSAKNQKNPPVPAGYTLDKNNVPYKKETGYY 
                 * : * * . :.**   . *:.  ::**..:.  **.:.:. :* .. * :*:. :   
 
φ11-ORF53      TNGNQPITVRKVGPFLSCPVGYQFQ
TNSRITGVLPφ12-ORF49      TVANVKGNNVRDGYS
               * .*   .  : *   
φ11-ORF53      WNGSAPPNQILGDLWGEIS 490 
φ12-ORF49      VDKAGNRISSFGKFSTI-- 484 
                : :.   . :*.: 
 
Figure 4.17: Amino acid sequence alignment of the φ11 and φ12 endolysins. The protein sequence alignment 
s identical amino acids (aa), 
:” conservative aa substitution, “.” semi-conservative aa substitution. 
of both endolysin sequences reveals a low sequence identity of 26.9%. “*” indicate
“
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Table 4.5: Bacteriophage proteins homologous to the φ11 or the φ12 endolysin. 
 
Bacteriophage proteins homologous to the φ11 endolysin: 
1. ORF 007 of staphylococcus phage 29 (AAX91726); protein sequence identity of 99% 
2. ORF NWMN1039 of staphylococcus phage phiNM2 (BAF67311); protein sequence identity of 98% 
. ORF SAV0913 of the prophage φMu1 of S. aureus Mu50 (BAB57075); protein sequence identity of  97% 
otein sequence identity of 97% 
% 
. Amidase of phage MSSA476 (CAG42730); protein sequence identity of 97% 
. Amidase of phage L54a of S. aureus COL (AAW38858); protein sequence identity of 95% 
. Amidase of phage φSLT of S. aureus MRSA252 (YP040898); protein sequence identity of 95% 
3. ORF 007 of staphylococcus phage 69 (AAX90762); protein sequence identity of 98% 
4. ORF 006 of staphylococcus phage 92 (AAX91937); protein sequence identity of 98% 
5. ORF 007 of staphylococcus phage 55 (AAX91649); protein sequence identity of 98% 
6. ORF 007 of staphylococcus phage 52a (AAX91801); protein sequence identity of 98% 
7
8. ORF 006 of staphylococcus phage 88 (AAX91865); pr
9. Amidase of staphylococcus phage 80alpha (AAB39699); protein sequence identity of 91
 
Bacteriophage proteins homologous to the φ12 endolysin: 
1. ORF 007 of staphylococcus phage 47 (AAX91198); protein sequence identity of 100% 
2. Amidase of phage φSA2MW of S. aureus MW2 (BAB95245); protein sequence identity of 98% 
3
4
5
 
 
 
φ12           241 AYGVNVGNNKDYGLYWVKSHGYDIVLEIHLDAAGESASGGHVIISSQFNADTIDKSIQDV 300 
φSA2MW         241 AYGVNVGNNKDYGLYWVKSQGYDIVLEIHLDAAGESASGGHVIISSQFNADTIDKSIQDV 300 
phageMSSA476     241 AYGVNVGNNKDYGLYWVKSQGYDIVLEIHLDAAGENASGGHVIISSQFNADTIDKSIQDV 300 
L54a        241 AYGVNVGNKKDYGLYWVKSQGYDIVLEIHLDAAGESASGGHVIISSQFNADTIDKSIQDV 300 
φSLT       241 AYGVNVGNKKDYGLYWVKSQGYDIVLEIHLDAAGESASGGHVIISSQFNADTIDKSIQDV 300 
                       ********:*****
 
*****:***************.************************ 
Figure 4.18: Amino acid substitution at position 260 of the φ12 endolysin. “*” indicates identical amino acids 
a), “:” conservative aa substitution, “.” semi-conservative aa substitution. The aa substitution of the φ12 
constructed separately (Fig. 4.19A). In addition, the cell wall binding module was deleted 
(a
endolysin at position 260 is shaded in grey. 
 
 
4.15 Cloning and overexpression of C-terminal six-His-tagged φ11 and φ12 endolysins 
The endolysin genes of the bacteriophages φ11 and φ12 were amplified by PCR from 
genomic DNA of S. aureus NCTC8325, using the primers listed in table 3.3. In order to test 
the activity of the φ11 endolysin subunits, the endopeptidase unit (φ11endo, amino acid [aa] 
1-180) and the amidase unit (φ11ami, aa 180-371) as well as each unit plus the cell wall 
binding domain (φ11endo/CBD, aa 1-180/371-490, and φ11ami/CBD, aa 180-490) were 
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1                        180/181                      370/371   490
D-alanyl-glycyl endopeptidase (endo)
N-acetylmuramyl-L-alanine amidase (ami)
φ11 endolysin
modules
φ11 full-length
φ11 endo/ami
φ11 endo
φ11 endo/CBD
φ11 ami
φ11 ami/CBD
SDS-cell walls
S. simulans 22
Heat-killed
staphylococci
Staphylococcal
biofilms
Cell wall binding domain (CBD)
+++                      ++                     ++
+++                      --- ---
--- --- ---
++                       --- ---
--- --- ---
++                       --- ---
Lytic activity: 
A.                                                              B.
+++ (strong), ++ (medium), --- (no activity)
s controlled 
y SDS-PAGE analysis (Fig. 4.20). Protein purification was also performed with cells 
arbouring the empty vector and the eluate served as control in the activity tests.  
from the φ11 endolysin (φ11endo/ami, aa 1-371). The amplification products were cloned into 
the multiple cloning site of the expression vector pET22b∆pelB (Sass, 2005), a pET22b 
derivative that has been deleted of the pelB leader sequence to inhibit protein transport to the 
periplasm of the expression host, except for φ11ami and φ11ami/CBD which were cloned into 
pET22b using the NdeI restriction site and thereby deleting the pelB leader sequence of 
pET22b. The resulting plasmids, pETer∆11 and pETer∆12 (Sass, 2005) as well as 
pETendo11, pETendoCBD11, pETami11, pETamiCBD11 and pETendo/ami11 were used to 
overexpress each endolysin and the single subunits of the φ11 enzyme as C-terminal six-His-
tagged fusion protein. After subcloning of the plasmids in E. coli JM109, E. coli Bl21(DE3) 
was used as a host for expression of each six-His-tagged endolysin. Expression cultures were 
grown in LB broth containing ampicillin (40 µg/ml) to an OD600 of 0.6. Then protein 
expression was induced by addition of IPTG to a final concentration of 1 mM. Expression 
cultures were harvested after 4 hours followed by protein purification steps under native 
conditions via Ni-NTA affinity chromatography. Purity of the protein eluates wa
b
h
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Recombinant murein hydrolases of the staphylococcal phage φ11. A. Schematic overview of
the φ11 endolysin modules illustrating the constructs tested in this thesis. The φ11 endolysin ures a modular 
design which consists of an N-terminal endopeptidase domain (endo), a central amidase domain (ami) and a C
 
 feat
-
rminal cell wall binding domain (CBD). The full-length and deletion constructs of the φ11 endolysin were 
verexpressed as six-His-fusion proteins. B. Lytic activity of the staphylococcal phage φ11 endolysin domains. 
te
o
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Figure 4. 0: SDS-PAGE analysis containing φ12 and φ11 endolysins and derived proteins purified by  
Ni-NTA affinity chromatography. The purified proteins were analyzed by 15% SDS-PAGE and stained with 
PageBlue
2
as prestained protein molecular weight 
arker; lane 1, φ12 endolysin (full-length); lane 2, φ11 endolysin (full-length); lane 3, φ11endo/ami; lane 4, φ11 
ndo/CBD; lane 5, φ11 ami/CBD; lane 6, φ11 endo; lane 7, φ11 ami. 
ml), the lytic 
ctivity was determined as before. In contrast to the full-length protein (Fig. 4.22), the 
eletion variants of the φ11 enzyme were hardly active against heat-killed cells. 
 
TM protein staining solution (Fermentas) according to the manufacturer`s instructions. Lane M1, 
Fermentas Page RulerTM unstained protein ladder; lane M2, Ferment
m
e
 
 
4.16 Analysis of the lytic activities of the φ11 endolysin modules 
The lytic activities of the full-length φ11 endolysin and its deletion variants (each applied in a 
concentration of 20 µg/ml) were examined photometrically at 600 nm employing purified 
SDS cell walls of S. simulans 22 (Bierbaum and Sahl, 1987) resuspended in incubation buffer 
[50 mM Tris-HCl, 100 mM NaCl; pH 7.5] to an OD600 of ~0.3 (Fig. 4.21). All lysis 
experiments were performed in triplicate. The full-length enzyme showed efficient lysis of the 
peptidoglycan compared to the control (empty vector eluate) and both, the endopeptidase and 
the amidase module plus cell wall binding domain (φ11endo/CBD and φ11ami/CBD), were 
active and able to lyse cell walls. Furthermore, the φ11 enzyme without the cell wall binding 
domain hydrolyzed S. simulans 22 cell walls. However, the full length enzyme was more 
active than the isolated subdomains and only the combination of φ11endo/CBD and 
φ11ami/CBD (20 µg/ml each) restored full lytic activity. The effect of the truncation was even 
more pronounced with whole cells. To this end, cells of S. aureus NCTC8325 were grown 
overnight, diluted in incubation buffer to an OD600 of approximately 0.3 and pasteurized for 
10 minutes at 80°C. After addition of equivalent amounts of endolysin (20 µg/
a
d
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Figure 4.21: Activity of the domains of the multifunctional φ11 endolysin. The lytic activities of the purified 
enzyme samples of the full-length and truncated φ11 endolysin (20 µg/ml each) were examined using purified 
cell walls of S. simulans 22. The full-length enzyme (▲) as well as the φ11 enzyme without the cell wall binding 
domain (φ11endo/ami; T) were able to lyse the substrate efficiently compared to the protein eluate of the empty 
vector control (●). The truncated enzymes φ11endo (□) and φ11ami (◊) did not show noteworthy lytic activity. 
The truncated enzymes containing the cell wall binding domain φ1
0 5 10 15 20
time [min]
1endoCBD (■) and φ11amiCBD (♦) showed 
nhanced lytic activity but still worked less effective than the full length enzyme. The lytic activity could be 
stored by the parallel use of φ11endoCBD and φ11amiCBD (∆).  
e. 
his phenomenon was earlier described by Takano et al. (2000) who investigated the 
fluence of synthetic peptides derived from the S. aureus major autolysin Atl on autolysis. 
e
re
 
 
4.17 Activities of the φ11 and φ12 endolysins on different staphylococcal strains 
Next, the lytic activities of the φ11 and φ12 endolysins on whole cells of several 
staphylococcal strains were analyzed. In addition to S. aureus NCTC8325, the full-length φ11 
endolysin rapidly lysed heat-killed cells of S. aureus Wood 46, S. aureus Cowan I, S. aureus 
Newman, S. epidermidis O-47 and S. simulans 22 (Fig. 4.22). Its lytic activity was equivalent 
to that of highly purified lysostaphin (5 µg/ml). Interestingly, the φ11 enzyme without cell 
wall binding domain (φ11endo/ami) did not hydrolyze whole staphylococcal cells. Unlike 
φ11, the φ12 endolysin was not able to hydrolyze heat-killed cells of S. aureus Wood 46,  
S. aureus Cowan I or S. aureus Newman. However, after addition of the φ12 endolysin an 
increase in optical density of the cultures was observed (Sass, 2005). This was accompanied 
and most probably caused by an aggregation of the cells that was macroscopically visibl
T
in
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Figure 4.22: The φ11 endolysin lyses whole cells of several staphylococci. Light scattering data showed that 
the φ11 endolysin (▲; 20 µg/ml) rapidly decreased the optical density of heat-inactivated S. aureus NCTC8325, 
S. aureus Wood 46, S. aureus Cowan I, S. aureus Newman, S. epidermidis O-47 and S. simulans 22 cultures 
compared to the protein eluate of the empty vector control (●). Its lytic activity was comparable to the effect 
observed after addition of lysostaphin (■; 5 µg/ml), which is a highly efficient glycyl-glycine endopeptidase. 
deletion of the cell wall targeting domain, the φ11 enzyme (φ11endo/ami, ∆; 20 µg/ml) showed a 
s. 
 
a concentration of 15 µg/ml) was examined photometrically at 600 nm employing heat-
After 
significantly reduced activity, which indicates a fundamental role of the CBD for efficient cell lysi
 
4.18 Site-directed mutagenesis and overexpression of mutated φ12 endolysin 
Since the φ12 endolysin was characterized by an amino acid substitution at position 260 in the 
amidase domain, a single point mutation (T780G) was introduced into the nucleotide 
sequence of pETer∆12 by site-directed mutagenesis to generate pETer∆12mut (Fig. 4.23). 
This T780G nucleotide exchange results in a mutated φ12 endolysin (φ12mut) in which the 
histidine of the φ12 endolysin at position 260 is exchanged to the glutamine present in 
homologous sequences from the NCBI database (Fig. 4.18). The pETer∆12mut plasmid was 
then used to overexpress the φ12mut endolysin as C-terminal six-His-tagged fusion protein 
(Fig. 4.24) as aforementioned. The lytic activity of the purified φ12mut endolysin (applied in 
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xchange of the φ12mut endolysin does not provide lytic activity on whole cells of S. aureus. 
 
01 
inactivated S. aureus NCTC8325 cells (Fig. 4.25) as described above. Here, the φ12mut 
endolysin was not able to hydrolyze heat-inactivated cells. Thus, the H260Q amino acid
e
 
         251  D   Y   G   L   Y   W   V   K   S   H   G   Y   D   I   V   L   E  267 
φ12      761 GAT TAT GGC TTA TAT TGG GTT AAA TCA CAT GGG TAT GAC ATT GTT CTA GAG 8
φ12mut   761 GAT TAT GGC TTA TAT TGG GTT AAA TCA CAG GGG TAT GAC ATT GTT CTA GAG 801 
             *** *** *** *** *** *** *** *** *** **  *** *** *** *** *** *** *** 
         251  D   Y   G   L   Y   W   V   K   S   Q   G   Y   D   I   V   L   E  267 
 
 
 
Figure 4.23: Site-directed mutagenesis of the φ12 endolysin. “*” indicates identical nucleotides. The T780G 
ucleotide exchange and the resulting H260Q amino acid substitution of the φ12 endolysin are indicated in bold. n
 
 
 
 
time [min]
 
 
 
 
 
 
 
 
Figure 4.24: SDS-PAGE analysis of the φ12mut endolysin purified by Ni-NTA affinity chromatography. 
Lane M, unstained protein molecular weight marker; la
116  kDa 
66.2 kDa
45  kDa 
35  kDa 
M    1      2      3
φ12mut
ne 1, φ12mut endolysin (eluate 1); lane 2, φ12mut 
ndolysin (eluate 2); lane 3, φ12mut endolysin (eluate 3). e
 
 
 
 
 
 
 
 
 
 
Figure 4.25: Lysis assay of the φ12mut endolysin. The lysis assay was performed using heat-inactivated cells 
of S. aureus NCTC8325. The φ12mut endolysin (■) and the φ11 endolysin (▲; positive control) were applied in 
a concentration of 15 µg/ml and lysis was examined photometrically at 600 nm. The protein eluate of the empty 
vector control () was used as a negative control.  
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4.19 Staphylococcal biofilm assay on artificial surfaces 
To determine the influence of the φ11 and φ12 endolysins on staphylococcal biofilms, a 
modified biofilm plate assay was employed (Fig. 4.19B and Fig. 4.26). Here, the φ12 
endolysin showed no hydrolytic activity on biofilms of S. aureus NCTC8325 and S. aureus 
Newman. In contrast, after addition of the φ12 endolysin an enhanced staining of the biofilms 
was noticed. This effect is consistent with the results of the experiments performed with heat-
inactivated cells and may be explained by a murein hydrolase-mediated adhesion of 
staphylococci (Heilmann et al., 1997; Heilmann et al., 2003). In contrast, the purified φ11 
endolysin was able to eliminate biofilms of S. aureus NCTC8325 and S. aureus Newman with 
an efficiency that was comparable to or slightly lower than that of lysostaphin. However, 
there was no effect on biofilms of S. epidermidis O-47. 
 
.  TSB               |      Tris-HCl-Puffer     |   5 µg lysostaphin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26: 
2005) and S. 
Newman with
not dissolved 
the S. aureus 
 
 
 A. 
10 µg φ11 |          20 µg φ12 |   5 µg lysozyme
TSB               |      Tris-HCl-Puffer     |   5 µg lysostaphinB. 
10 µg φ11 |         20 µg φ12 |   5 µg lysozymeCcontrol |    12 µg φ11 |           5 µg 
pET∆pelB endolysin lysostaphin
Biofilm plate assay of S. aureus NCTC8325 (A) (Sass, 2005), S. aureus Newman (B) (Sass, 
epidermidis O-47 (C).  The φ11 endolysin lysed biofilms of S. aureus NCTC8325 and S. aureus 
 an efficiency comparable to that of lysostaphin. However, biofilms of S. epidermidis O-47 were 
by the φ11 endolysin. In contrast, addition of the φ12 endolysin resulted in enhanced staining of 
biofilms. 
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4.20 Analysis of the biofilm nature of S. aureus NCTC8325 and S. epidermidis O-47 
The φ11 endolysin was able to hydrolyze heat-killed cells of S. aureus NCTC8325 and  
S. epidermidis O-47 (Fig. 4.22). However, it was only able to dissolve biofilms of S. aureus 
NCTC8325 while S. epidermidis O-47 biofilms remained unaffected (Fig. 4.26). To explore 
the reasons for this differentiation, the nature of S. aureus NCTC8325 and S. epidermidis  
O-47 biofilms was analyzed by incubation with proteinase K or sodium metaperiodate in the 
modified biofilm plate assay (Fig. 4.27). Biofilms that predominantly consist of PIA  
(β-1,6-linked N-acetylglucosamine) are dissolved by incubation with sodium metaperiodate 
and protein biofilms are dissolved by proteinase K treatment. S. epidermidis O-47 biofilms 
were only dissolved by sodium metaperiodate treatment which indicates that this biofilm is 
exclusively polysaccharide mediated. In contrast, neither sodium metaperiodate nor 
proteinase K treatment could completely eradicate biofilms of S. aureus NCTC8325 grown in 
TSB broth which suggests that an elevated portion of proteinogenous biofilm is present along 
with a biofilm mediated by the characteristic polysaccaride PIA. 
 
 
S. aureus 
NCTC8325 
S. epidermidis     
O-47 
   H2O                 Na-meta           proteinase 
P                          periodate                  K 
 
 
 
 
 
 
 
 
 
Figure 4.27: Biofilm nature of S. aureus NCTC8325 and S. epidermidis O-47. Neither sodium metaperiodate 
nor proteinase K treatment could completely eradicate biofilms of S. aureus NCTC8325 grown in TSB broth. In 
contrast, S. epidermidis O-47 biofilms were dissolved by sodium metaperiodate treatment. 
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5 Discussion 
Infections caused by S. aureus and S. epidermidis still play a major role in human and animal 
disease. Considering the increased emergence of staphylococci and other microorganisms that 
are resistant to current treatment strategies, there is an urgent need to expand our knowledge 
on how bacteria respond to antibiotic treatment and develop resistance mechanisms that help 
to persist during host infection. To ensure the control of bacterial infections in future, new 
treatment strategies need to be explored that target actively growing and non-growing cells. 
 
5.1 The lantibiotic mersacidin is a strong inducer of the cell wall stress response of 
Staphylococcus aureus 
One objective of this work was to study the response of S. aureus to the lantibiotic 
mersacidin, in order to reveal insights into the mechanisms that S. aureus might use to 
establish reduced susceptibility towards this antimicrobial peptide. To this end, the 
transcriptional responses of the S. aureus strains SA137/93A (heterogenic VISA / MRSA) 
and SA137/93G (VISA / MSSA, a laboratory mutant of strain SA137/93A) (Reipert et al., 
2003) as well as of the susceptible strain S. aureus SG511-Berlin were studied. 
Previous gene expression studies of Kuroda et al. and Utaida et al. concerning the S. aureus 
responses to the cell wall-active substances vancomycin (Kuroda et al., 2003), oxacillin, 
bacitracin and D-cycloserine (Utaida et al., 2003) had identified a cell wall stress stimulon, 
which seems to be predominantly regulated by the VraSR two-component regulatory system 
(TCRS). Members of this stimulon comprise the vraSR genes together with genes related to 
the cell wall metabolism of S. aureus like murZ, uppS, bacA, pbp2, sgtB and genes related to 
protein metabolism. Recently, McAleese et al. described a core cell wall stress stimulon of 17 
genes by merging their own results, that had been recorded in the presence of vancomycin, 
together with the results of Kuroda et al. and Utaida et al. (Kuroda et al., 2003; Utaida et al., 
2003; McAleese et al., 2006). In conclusion, the cell wall stress stimulon is characterized 
through a comprehensive response that involves manifold cellular processes. This general cell 
wall stress response seems to be conserved among Gram-positive bacteria (Jordan et al., 
2008). Most recently, the transcriptional profile of the S. aureus response to the lantibiotic 
nisin has become available (Muthaiyan et al., 2008). Nisin acts by lipid II-based pore 
formation and inhibition of cell wall biosynthesis (Wiedemann et al., 2001). The S. aureus 
response to nisin (~3 x MIC) was relatively moderate and an induction of the cell wall stress 
stimulon was not observed. 
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In the presence of the lantibiotic mersacidin, the induction of the VraSR-triggered cell wall 
stress stimulon was one of the most striking events of gene regulation (Table 4.1 and Table 
4.2) and included 71 genes of the 161 cell wall stress stimulon members (Utaida et al., 2003). 
Similarly, 35 genes out of the 46 genes of the VraSR regulon (Kuroda et al., 2003) were 
upregulated after exposure to mersacidin (Table 5.1). Furthermore, 16 out of the 17 members 
of the core cell wall stress stimulon (McAleese et al., 2006) were differentially expressed after 
mersacidin treatment. The vraSR genes and several cell wall biosynthesis genes were strongly 
upregulated, which included the putative monofunctional glycosyltransferase gene sgtB, the 
transpeptidase/transglycosylase gene pbp2 and the UDP-N-acetylglucosamine  
1-carboxylvinyl transferase gene murZ, as well as tcaA and drp35. The predominant induction 
of the glutamate (gltB, rocA) and lysine (asd, dapAB, dhoM, lysA) amino acid biosynthesis 
pathways might also support cell wall biosynthesis, since glutamate and lysine represent 
essential components of the peptidoglycan precursor lipid II. In fact, the disruption of the dap 
operon or the lysA gene has been shown to be involved in a decrease of oxacillin resistance 
and growth attenuation of S. aureus (de Lencastre et al., 1999; Wiltshire and Foster, 2001). 
Especially in strain SA137/93A, mersacidin treatment induced the transcription of the bacA 
and uppS genes, which are involved in lipid II carrier regeneration and synthesis. Expecting 
the carrier level to be a limiting factor when lipid II is blocked by mersacidin, an enhanced 
availability of carriers might be beneficial for peptidoglycan synthesis. In accordance with 
peptidoglycan biosynthesis inhibition, gene expression for cell wall lytic enzymes (atl, 
SA0423, SA2100) was negatively affected. In terms of membrane trafficking, the 
oligopeptide transport system genes oppBCDF and the components of the phosphotransferase 
system (PTS) were upregulated. While an increased expression of the PTS may boost the 
import of glucose to supply additional energy, the induction of OppBCDF might support cell 
wall biosynthesis by the acquisition of essential amino acids. 
Another prominent category of the cell wall stress stimulon is formed by genes related to 
protein metabolism (Utaida et al., 2003). Upregulation was recorded for the chaperone genes 
prsA, groEL and dnaK as well as the chaperone/protease genes of the Clp-family (caseinolytic 
proteases) like clpC, clpP, cplB and clpL, which are also part of the S. aureus response to 
heat-shock, vancomycin stress and acid shock (Anderson et al., 2006; Kuroda et al., 2003; 
Bore et al., 2007). The upregulation of genes related to protein metabolism might indicate an 
accumulation of damaged or inactive proteins upon mersacidin treatment which has also been 
observed after treatment with oxacillin or bacitracin (Utaida et al., 2003).  
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1 Kuroda et al. (2003) 
2 Significant changes of gene expression were determined by implementing SAM (significance analysis of 
microarrays; http://www-stat.stanford.edu/~tibs/SAM/) (Tusher et al., 2001). Fold change in transcript level 
indicated as mean of the “median of ratios” compared to control cells. Fold change in bold = classified as 
"significantly" regulated in this strain by SAM. 
 
 
Table 5.1: Significant induction of the VraSR-dependent cell wall stress response of S. aureus1 by mersacidin 
Fold change2
SA137/93A SA137/93G SG511
N315 
ORF Gene Gene product Product function 
(0.5xMIC) (0.5xMIC) (0.15xMIC) (1xMIC)
        
SA0531 proP proline/betaine transporter homologue Protein transport and binding 2.4 2.7  0.6 
SA0536  hypothetical protein  30.2 17.1 8.5 26.6 
SA0608  hypothetical protein  2.7 3.8  9.2 
SA0825 spsA type-I signal peptidase Protein secretion 2.2 1.4  3.9 
SA0909 fmtA FmtA, autolysis and  
methicillin resistance-related protein 
Pathogenic factors 9.3 3.8 6.3 6.3 
SA0914  hypothetical protein, similar to chitinase B  14.2 3.9  15.3 
SA0931  hypothetical protein  4.9 3.2  6.2 
SA1183 opuD glycine betaine transporter Protein transport and binding 0.9 0.5  0.5 
SA1255  PTS system, glucose-specific enzyme  
IIA component 
Protein transport and binding 4.7 10.7 2.6 13.1 
SA1282 recU recombination protein U homologue DNA recombination 3.6 2.5 2.2 2.5 
SA1283 pbp2 penicillin-binding protein 2 Cell wall related genes 3.4 2.3 2.7 3.5 
SA1476  hypothetical protein  11.5 11.3 6.5 15.9 
SA1548  hypothetical protein, similar to acylglycerol- 
3-phosphate-O-acyltransferase homologue 
Metabolism of lipids 0.7 0.5  0.6 
SA1549  heat-shock protein homologue, similar to  
serine proteinase 
Adaptation to atypical conditions 7.1 4.6 3.9 5.6 
SA1657  conserved hypothetical protein  1.3 2.3  0.9 
SA1659 prsA peptidyl-prolyl cis/trans isomerase homologue Protein folding 10.8 18.1 10.0 33.3 
SA1691 sgtB hypothetical protein, similar to  
penicillin-binding protein 1A/1B 
Cell wall related genes 13.1 8.8 4.8 9.7 
SA1700 vraR two-component response regulator RNA synthesis - Regulation 13.3 8.0 7.3 17.3 
SA1701 vraS two-component sensor histidine kinase Sensors (signal transduction) 11.7 8.9 5.8 17.0 
SA1702  conserved hypothetical protein  10.4 9.4 4.4 12.2 
SA1703  hypothetical protein  31.6 24.8 6.8 45.4 
SA1711  hypothetical protein, similar to  
DNA-damage inducible protein P 
DNA replication, modification, repair 2.2 1.6  3.4 
SA1712  conserved hypothetical protein  24.7 21.0 5.0 29.4 
SA1926 murZ UDP-N-acetylglucosamine 1- 
carboxylvinyl transferase 2 
Cell wall related genes 3.2 4.4 3.9 6.1 
SA2103  hypothetical protein, similar to lyt  
divergon expression attenuator LytR 
RNA synthesis - Regulation 6.4 6.1 4.4 8.0 
SA2113  hypothetical protein  14.9 11.8 4.9 11.4 
SA2146 tcaA TcaA protein  3.3 1.6 2.2 4.0 
SA2220  conserved hypothetical protein  7.0 12.2 3.7 21.4 
SA2221  hypothetical protein  25.6 18.3 5.2 42.7 
SA2222  hypothetical protein, similar to TcaB Protein transport and binding 1.2 0.6  1.0 
SA2296  hypothetical protein, similar to  
transcriptional regulator MerR 
RNA synthesis - Regulation 8.1 10.4 3.9 5.5 
SA2297  hypothetical protein, similar to  
GTP-pyrophosphokinase 
Nucleotide, nucleic acid metabolism 9.1 14.1 3.9 10.3 
SA2298  conserved hypothetical protein  1.8 2.2  1.9 
SA2413  sulfite reductase flavoprotein (NADPH) Metabolism of sulfur 1.7 2.2  2.3 
SA2480 drp35 drug responsive protein 35  2.7 3.4 2.8 2.8 
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In fact, increased degradation of aberrant proteins may provide additional amino acids to 
support a cell wall damage-induced response. The strong induction of the acetyl-CoA  
C-acetyltransferase gene vraB, which is involved in the degradation of amino acids and in 
lipid metabolism, might be an additional indicator in this context.  
Since incubation with 0.5 x MIC of mersacidin was sufficient to massively induce the cell 
wall stress response, the gene expression profile of strain SA137/93G was further examined at 
even lower concentrations using DNA microarrays (Table 5.1 and Table S2 in the 
supplemental material). Incubation with 0.15 x MIC (4 µg/ml, 2.175 µM) of mersacidin was 
sufficient to significantly alter the expression of 19 out of 46 genes of the VraSR regulon 
(Kuroda et al., 2003) (Table 5.1) and 12 out of 17 genes belonging to the core cell wall stress 
stimulon (McAleese et al., 2006). These results show, that inhibitory antibiotic concentrations 
are not an obligatory requirement for the induction of the cell wall stress stimulon as it is the 
case for e.g. vancomycin and oxacillin (McAleese et al., 2006; Wootton et al., 2005; 
McCallum et al., 2006). Compared to 0.5 x MIC, the response was reduced after employing 
0.15 x MIC in strain SA137/93G, suggesting a dose-dependent effect on gene expression. 
To verify the induction of the cell wall stress response by the autoregulatory VraSR TCRS 
(Yin et al., 2006), overexpression of the sensor histidine kinase gene vraS was further 
analyzed via qRT-PCR (Fig. 4.5A). In the presence of 0.5 x MIC of mersacidin, a strong 
induction of vraS transcription (16- to 26-fold) was observed in all strains tested. Even  
0.15 x MIC of mersacidin considerably induced vraS gene transcription in strain SA137/93G 
(5.6-fold) and strain SG511-Berlin (3.4-fold) (strain SA137/93A not tested). As a control, 
strain SA137/93G was incubated with subinhibitory concentrations of vancomycin (4 µg/ml, 
2.75 µM, 0.5 x MIC). Here, no induction was visible by qRT-PCR. This is also confirmed by 
earlier studies of other groups who employed multiple MICs (8 to 10 x MICs) of cell wall 
affecting agents like vancomycin, oxacillin or bacitracin to induce the cell wall stress 
response (Kuroda et al., 2003; Utaida et al., 2003; McAleese et al., 2006), while low 
inhibitory or subinhibitory concentrations of vancomycin or oxacillin did not lead to an 
induction (McAleese et al., 2006; Wootton et al., 2005; McCallum et al., 2006). Likewise, an 
induction of the cell wall stress response could not be observed for the lantibiotic nisin at 
inhibitory concentrations (Muthaiyan et al., 2008). Nisin acts by fast depolarization of the cell 
membrane as a cause of lipid II-based pore formation rather than by inhibition of cell wall 
biosynthesis (Wiedemann et al., 2004; Wiedemann et al., 2001). Thus, the bacteria will be 
rapidly inactivated by nisin which prevents an adequate response to cell wall damage through 
the VraSR-stimulon. Hence, mersacidin turned out to be a strong inducer of the cell wall 
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stress response in S. aureus compared to other substances like vancomycin, oxacillin, 
bacitracin and nisin.  
The VISA strains SA137/93A and SA137/93G are characterized by a cell wall with an 
increased thickness, which is also formed in the absence of antibiotics (Reipert et al., 2003). 
Actually, vancomycin intermediate resistance partly relies on an increase in cell wall material 
(Cui et al., 2000; Cui et al., 2003; Reipert et al., 2003), which might result from an activated 
cell wall metabolism. In previous studies by Christiane Szekat and Gabriele Bierbaum (Sass 
et al., 2008a), the influence of an increased cell wall thickness on the action of mersacidin was 
tested (Fig. 5.1). To this end, S. aureus cells with increased amounts of peptidoglycan were 
obtained by incubation in resting medium (RM) for two hours. Cell wall resting medium 
allows the biosynthesis of excess cell wall material, while the absence of essential amino 
acids prohibits growth. Controls were performed in RM devoid of glucose (RM-g), which is 
necessary for synthesis of extra cell wall material (Cui et al., 2000; Shockman et al., 1961). 
After incubation of the cells in RM or RM-g, the susceptibility to mersacidin was tested. 
Vancomycin served as control. In the case of mersacidin, the incubation in the presence of 
glucose did not decrease the susceptibility of S. aureus SG511-Berlin and of the VISA strains 
SA137/93A and SA137/93G (Fig. 5.1), whereas the efficacy of vancomycin was always 
lower against cells that had been incubated in the presence of glucose. In strain SG511-Berlin, 
mersacidin was even more effective than vancomycin, which was not the case for the strains 
SA137/93A and SA137/93G. These results demonstrate that the cell wall thickness does not 
impact on the antibiotic efficacy of mersacidin. Thus, the induction of the cell wall stress 
response at low mersacidin concentrations may be partly explained by the differences that 
characterize the interactions of mersacidin and vancomycin with the cell envelope: While 
mersacidin and vancomycin both target lipid II, vancomycin acts by binding to the D-alanyl-
D-alanine terminus of the peptide side chain of lipid II. In a thickened cell wall, increased 
amounts of free D-alanyl-D-alanine termini provide false target sites for vancomycin binding. 
This results in a decreased diffusion velocity of vancomycin through the cell wall, the 
“clogging effect” (Cui et al., 2000), and only those vancomycin molecules that are not trapped 
in the cell wall will reach lipid II. In contrast to vancomycin, mersacidin complexes the sugar 
phosphate head group of the peptidoglycan precursor lipid II, which is only present in the 
membrane and experiments with radiolabelled mersacidin have confirmed that it does not 
bind to isolated cell walls (Brötz et al., 1998). Additionally, in in vitro cell wall biosynthesis 
systems, the effective concentration of mersacidin is in the same range as that of vancomycin 
(Brötz et al., 1997). 
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Figure 5.1: Influence of the cell wall thickness on the efficacy of mersacidin. The influence of an increased 
cell wall thickness on the efficacy of mersacidin was studied for the S. aureus strains SA137/93A (A), 
SA137/93G (B) and SG511-Berlin (C) (Sass et al., 2008a). To this end, S. aureus cells were incubated in resting 
medium supplemented with glucose (RM+g), which allows the synthesis of increased amounts of peptidoglycan, 
or in the absence of glucose (RM-g), which prevents synthesis of extra cell wall material. The data represent the 
optical density (600 nm) of RM-preincubated S. aureus cells after treatment with different concentrations of 
mersacidin. Vancomycin served as a control. (S) mersacidin/RM+g; (U) mersacidin/RM-g; () 
vancomycin/RM+g; () vancomycin/RM-g. 
 
 
Discussion     81 
Therefore, although nearly similar molar concentrations (2.175 µM mersacidin (0.15 x MIC) 
and 2.75 µM vancomycin (0.5 x MIC)) of the two antibiotics were used in the induction 
assays, less vancomycin than mersacidin molecules may have been available at the cell 
membrane for the binding of lipid II. This effect could explain why higher concentrations of 
vancomycin have to be employed in order to induce the cell wall stress response and why 
lower initial concentrations of mersacidin may be sufficient for an effective induction of 
VraSR. 
A comparison of the transcript levels of vraSR of all tested strains showed that the levels did 
not vary significantly between the strains (Fig. 4.5A). Since the vraSR genes have been found 
to be more highly expressed in S. aureus Mu50 (VISA) compared to VSSA (Kuroda et al. 
2003), which has been linked to the I5N substitution of the vraS gene (Fig. 4.9), the VraSR 
TCRS has been proposed to be involved in the VISA-type resistance mechanism via 
contribution to cell wall thickening (Kuroda et al., 2000; McAleese et al., 2006) and the 
deletion of the vraSR locus has been described to influence the development of resistance 
towards glycopeptides and β-lactams (Kuroda et al., 2003). However, the cell wall stress 
response was similarly induced upon mersacidin treatment in the VISA strains SA137/93A 
and SA137/93G as well as in the susceptible strain SG511-Berlin in our studies, all strains 
showed equal basal transcript levels and the vraS nucleotide sequences of these strains 
showed 100% identity. Interestingly, the induction of VraSR did not depend on the absolute 
concentration of mersacidin in the medium but seemed to be triggered by the stress itself, 
since 0.5 µg/ml of mersacidin massively induced the cell wall stress response in the 
susceptible strain SG511-Berlin (here 0.5 µg/ml correspond to 0.5 x MIC mersacidin;  
Fig. 4.5A), while vraS transcription levels were not significantly affected in strain 
SA137/93G (for this strain 0.5 µg/ml correspond to 0.02 x MIC mersacidin). Therefore, the 
VraSR TCRS might have evolved as a damage-sensing system that is indirectly induced as a 
cause of cell wall damage rather than a drug sensing system that recognizes the drug itself at 
defined concentrations. This is also indicated by findings showing that VraSR responds to 
various cell wall-active antibiotics as well as other conditions of cell wall stress like 
suboptimal transcript levels of murF and pbp2 (Sobral et al., 2007; Gardete et al., 2006). In 
this regard, the bacitracin-dependent induction of the LiaRS TCRS in Bacillus subtilis, a close 
homologue of VraSR, also indicated a damage-sensing mechanism (Rietkötter et al., 2008). 
This supports the idea of VraSR being a common accelerator system of peptidoglycan 
synthesis (Kuroda et al., 2003), which reacts to perturbations of cell wall integrity. 
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In conclusion, mersacidin strongly induces the cell wall stress response of S. aureus even at 
very low concentrations as compared to other antibiotics like nisin, vancomycin, bacitracin or 
oxacillin, thereby reflecting its unique mode of action. The results presented here underline 
the important role of lipid II in this context and demonstrate that the induction of the cell wall 
stress response is not in every case dependent on inhibitory concentrations of cell wall-active 
substances. Interestingly, the cell wall stress response was similarly induced in S. aureus 
strains with different susceptibilities to antimicrobial agents, e.g. mersacidin, and therefore 
other mechanisms may account for the altered resistance of certain strains to mersacidin and 
similar antimicrobial peptides. Nevertheless, since the cell wall stress response comprises the 
increased expression of cell wall biosynthesis genes, it appears to be an inherent mechanism 
of growing cells to counteract the effect of antibiotics like mersacidin that target cell wall 
biosynthesis. 
 
5.2 Effect of the VraDE ABC transporter on the decreased susceptibility to mersacidin 
The presence of mersacidin significantly influenced the regulation of several genes coding for 
hypothetical ABC transporters such as SA0192, vraFG and vraDE (Table 4.1 and Table 4.2). 
Indeed, the most prominent event of gene regulation involved the upregulation of vraDE  
(40 to 70-fold in the microarray studies) (Table 4.1). The induction of vraDE gene 
transcription was further verified via qRT-PCR (Fig. 4.5B). Upon incubation with 0.5 x MIC, 
vraDE expression was induced 76 to 79-fold in strain SA137/93A and SA137/93G, 
respectively. In the susceptible strain SG511-Berlin, the transcript level of the vraDE genes 
rose almost 1700-fold upon incubation with mersacidin. This transporter has been previously 
shown to be inducible by vancomycin and cationic AMPs (Kuroda et al., 2000; Li et al., 
2007a; Sass et al., 2008b) and seems to be involved in the increased resistance towards 
bacitracin and the human β-defensin 3 (hBD3) in S. aureus (Sass et al., 2008b). However, the 
regulation underlying vraDE induction has not been identified yet. The VraSR TCRS does not 
seem to be solely involved in the upregulation of vraDE transcription as knock-out mutations 
of the respective gene locus did not lead to an altered expression of the vraDE genes (Kuroda 
et al., 2003). The upregulation to such an extent might indicate that VraDE plays a critical 
role in the staphylococcal defense against mersacidin, especially since resistance is conferred 
by an ABC transporter in the producer strain of mersacidin (Guder et al., 2002).  
To test whether VraDE is able to transport mersacidin out of the cell membrane and therefore 
supports a resistance phenotype, the growth behaviour and MICs of a vraE knock-out mutant 
of S. aureus SG511-Berlin (Sass et al., 2008b) and its parent strain were examined in the 
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presence of the lantibiotic. Since S. aureus SG511∆vraE had displayed significantly reduced 
resistance to bacitracin and the lantibiotics nisin and Pep5 (Sass et al., 2008b), VraDE was 
considered to be functional in the parent strain. Unexpectedly, S. aureus SG511∆vraE did not 
show increased susceptibility towards mersacidin neither in growth curve recordings nor in 
MIC studies. Sequencing of the vraDE genes including the promoter region revealed, that the 
-35 and the -10 region as well as the ribosomal binding site and the vraD gene were highly 
conserved in strains SA137/93A and SG511-Berlin (100% sequence identity) and that the 
vraE gene showed 95.7% sequence identity with mostly conservative amino acid 
substitutions. Therefore, VraDE is unlikely to contribute to mersacidin resistance, presumably 
because it is unable to transport the lantibiotic. This could be due to the properties of 
mersacidin which is globular, neutral and non-membrane disturbing. Since VraDE has been 
shown to predominantly transport linear, cationic, membrane interacting compounds, it might 
be unable to faciliate the transport of other antimicrobials as also shown for chloramphenicol 
and oxacillin (Sass et al., 2008b). However, it cannot be ruled out that the knockout 
phenotype is indiscernible through the activity of another ABC transporter. In conclusion, 
mersacidin represents a molecule that seems not to be a substrate for the multidrug resistance 
transporter VraDE which apparently functions in the first line bacterial counter strategy 
against bacitracin and cationic toxic compounds.  
 
5.3 A native graS mutation supports the susceptibility of Staphylococcus aureus strain 
SG511-Berlin to antimicrobial peptides 
The rather susceptible S. aureus strain SG511-Berlin represents a standard strain for 
antimicrobial susceptibility testing and has been used as a model for basic research on 
staphylococci (Brötz et al., 1997; Maidhof et al., 1989; Pag et al., 2008; Sass et al., 2008b; de 
Jonge et al., 1993; Naumann and Labischinski, 1990). While studying the influence of the 
lantibiotic mersacidin on the expression profiles of S. aureus (see section 5.1), strain SG511-
Berlin was characterized by an increased susceptibility to mersacidin, which, however, could 
not be traced to differences in the transcriptional response pattern of strain SG511-Berlin 
upon mersacidin treatment compared to the other S. aureus strains tested. 
In order to identify the factors which are responsible for the increased susceptibility of strain 
SG511-Berlin to antimicrobials like mersacidin, the expression profile of strain SG511-Berlin 
was compared with the more resistant strain SA137/93A in the absence of antibiotics. Here, a 
different expression of the genes coding for the membrane proteine DltB, the lysyltransferase 
MprF and the ABC transport system VraFG was observed. DltB contributes to the alanylation 
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of the cell wall by the transport and incorporation of activated D-alanine into the teichoic 
acids, while MprF catalyses the lysinylation of phosphatidylglycerol. Both, DltB and MprF, 
confer a more positive net charge to the cell surface, thereby preventing the binding of 
cationic AMPs to the cytoplasmic membrane (Peschel et al., 1999; Peschel et al., 2001). 
Furthermore, the dltB, mprF and vraFG genes have been shown to be positively controlled by 
the TCRS GraRS in S. aureus (Herbert et al., 2007; Meehl et al., 2007). The vraFG genes are 
even encoded downstream of graRS and therefore constitute a typical bacteriocin immunity 
regulon of grampositive bacteria comprising a TCRS with an adjacent ABC transporter 
(Jordan et al., 2008). Actually, the GraRS regulatory unit has recently been proposed as an 
antimicrobial peptide sensing system (aps) in S. aureus and S. epidermidis (Li et al., 2007a; 
Li et al., 2007b) and in fact its influence on the susceptibility of S. aureus to antimicrobials 
has been described (Peschel et al., 2000; Peschel et al., 1999; Meehl et al., 2007; Kraus et al., 
2008; Howden et al., 2008; Neoh et al., 2008). In addition, GraRS seems to interact with other 
global regulators of S. aureus to influence factors involved in biofilm formation (dltB, atl) and 
colonization (atl, sirC, cap5/8) (Herbert et al., 2007). Interestingly, our results showed that 
these proteins were also characterized by a lower expression level in S. aureus SG511-Berlin 
compared to S. aureus SA137/93A. 
Sequence analysis of the graS gene in strain SG511-Berlin revealed a native nucleotide 
insertion that generates a stop codon at amino acid position 64 which leads to the deletion of 
82% of GraS, which is the entire cytoplasmic part of the sensor histidine kinase. As expected, 
this deletion had a direct influence on the expression of dltB and is accompanied by a more 
negative surface charge of strain SG511-Berlin compared to other S. aureus strains that could 
be reversed by the reconstitution of graS. Finally, the graS-reconstituted strain SG511-Berlin 
also showed significantly decreased susceptibility to the lantibiotics mersacidin, nisin and 
Pep5. Although the GraRS TCRS is not induced upon mersacidin treatment (see section 
4.3.6), these results demonstrate that GraS contributes to an inherent defense mechanism of  
S. aureus towards mersacidin. A similar phenomenon has been shown for human beta 
defensin 3, which, although it does not induce GraRS in S. aureus significantly, is susceptible 
to the resistance mechanisms controlled by the GraRS system (Li et al., 2007a). GraRS is 
activated by positively charged peptides (Li et al., 2007a) as e.g. nisin and indolicidin. The 
cationic peptides nisin and Pep5 accumulate in the cell wall by binding to the teichoic and 
lipoteichoic acids by an ionic interaction. At least with Pep5, the inhibition of this 
accumulation results in complete loss of activity (Sahl et al., 1985; Bierbaum and Sahl, 1987; 
Sahl and Brandis, 1983). Therefore, the activity of these peptides is diminished by the 
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incorporation of positively charged D-alanine residues into the teichoic acids that is due to 
DltB expression (Peschel et al., 1999). In contrast, mersacidin, which prevents the 
transglycosylation reaction of peptidoglycan biosynthesis by complexing the peptidoglycan 
precursor lipid II (Brötz et al., 1998), does not carry a net positive charge and does not bind to 
isolated cell walls in buffer (Brötz et al., 1998). However, the activity of mersacidin is 
enhanced in the presence of calcium ions (Barrett et al., 1992; Schneider et al., 2000), and the 
binding of calcium ions may impart a positive net charge to the complex which would 
facilitate the interaction with the negatively charged cell wall polymers as well as with the 
negatively charged head group of lipid II (Hsu et al., 2003). Furthermore, although the 
specific transport functions of VraFG have not yet been ascertained, mersacidin or the 
mersacidin calcium complex could also be removed from the bacterial cell and membrane via 
this transport system, thereby preventing its accumulation at the site of peptidoglycan 
biosynthesis. Further studies are needed to define the mode by which GraRS controls 
resistance towards mersacidin. 
The GraRS system has additionally been implicated to have a central role in conferring 
resistance to the glycopeptide antibiotic vancomycin in S. aureus (Meehl et al., 2007) and 
even single nucleotide exchanges in graR as well as graS have been demonstrated to support 
resistance to vancomycin (Howden et al., 2008; Neoh et al., 2008). However, a significant 
increase in vancomycin resistance after complementation of graS in S. aureus SG511-Berlin 
could not be detected. This could be due to the genetic background of strain SG511-Berlin 
that might not be adequate for establishing a significant gain in vancomycin resistance, since 
the closely related S. aureus MRSA252, which bears a functional GraS, shows an even lower 
vancomycin MIC. 
In conclusion, a native graS mutation directly influences the cell surface properties and 
concomitantly the susceptibility of S. aureus SG511-Berlin to antimicrobial substances like 
mersacidin, nisin and Pep5. Besides the VraSR system (see section 5.1), the GraRS system 
represents a second intrinsic resistance mechanism of actively growing cells that reacts to 
antimicrobial agents. Taking this into account, it is desireable to develop new antibacterial 
treatment strategies that circumvent the influence of the intrinsic resistance mechanisms of 
actively growing cells. Noteworthy, GraRS is more than an antimicrobial peptide sensing 
system as it also interacts with global regulators and influences biofilm formation, 
colonization and autolysis, i.e. it represents an important factor in controlling the vital 
functions of S. aureus. These facts should be considered upon further use of strain SG511-
Berlin as a standard strain for antimicrobial susceptibility testing and basic research purposes. 
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5.4 Role of “SSP0470:Tn551” in the increased resistance of S. simulans 22 to mersacidin 
Tn551 transposon mutagenesis of S. simulans 22 had been previously performed by Gabriele 
Bierbaum (IMMIP; unpublished data) to identify factors which potentially influence the 
susceptibility of staphylococci to antimicrobials like mersacidin. By this means, a Tn551 
insertion mutant of S. simulans 22 had been isolated that showed a significant difference in its 
susceptibility to mersacidin compared to the wild type strain. In the present work, mapping of 
the Tn551 transposon insertion in the genome of  S. simulans 22 revealed its location in the  
C-terminal region of the hypothetical gene SSP0470 (of the genomic sequence of  
S. saprophyticus ATCC15305). A BLAST analysis was performed and characterized 
SSP0470 as a potential membrane protein with low homology to streptococcal permeases. 
Curiously, in contrast to other described resistance markers, the susceptibility of S. simulans 
22 to mersacidin decreases when SSP0470 is disrupted by Tn551. This is similar to previous 
observations concerning the S. aureus gene tcaA (Maki et al., 2004). These studies linked an 
increased glycopeptide resistance of selected S. aureus strains, including strain SA137/93G, 
to the inactivation of the tcaA gene. TcaA is a membrane protein whose biochemical 
functions still need to be determined. Maki et al. presumed that induction of tcaA transcription 
in the presence of cell wall-active antibiotics, as described by Utaida et al. (2003), would 
increase the susceptibility to teicoplanin, thereby creating a selective pressure for the 
inactivation of tcaA in the presence of the glycopeptide teicoplanin. The mode by which 
SSP0470 influences the susceptibility to mersacidin is yet unclear and further studies are 
needed to characterize its role as a resistance determinant. Interestingly, a gene homologous to 
SSP0470 is not present in any sequenced S. aureus strain of the NCBI database to date. 
Compared to S. aureus, S. simulans 22 is quite susceptible to antimicrobial agents and 
therefore is a favoured organism for antimicrobial susceptibility testing and routine 
examinations. Perhaps, SSP0470 is one of the factors that account for the different 
susceptibility characteristics among the different staphylococci.  
 
5.5 Lytic activity of recombinant phage φ11 and φ12 endolysins on whole cells and 
biofilms of Staphylococcus aureus 
Staphylococcal biofilms on indwelling devices are difficult to treat due to their inherent 
antibiotic resistance (Costerton et al., 1987; Donlan and Costerton, 2002; O'Grady et al., 
2002; Geisel et al., 2001; Mah and O'Toole, 2001; Stewart, 2002). Especially, persister cells 
contribute to biofilm resistance (Roberts and Stewart, 2005; Anderson and O'Toole, 2008), 
since these non-growing cells appear to escape from the action of antibiotics that target the 
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bacterial metabolism. In this context, it is important to develop alternative treatment strategies 
that target actively growing cells as well as non-growing persister cells to combat 
staphylococcal biofilm infections in future. Phage lysins, or endolysins, have received 
noticeable attention as possible antimicrobial agents against Gram-positive bacteria and have 
been applied to a variety of pathogens, such as Bacillus anthracis (Low et al., 2005), 
Streptococcus pneumoniae (Entenza et al., 2005) and S. aureus (O'Flaherty et al., 2005). 
Endolysins are active against non-growing and dead cells as well as living, planktonic cells 
(O'Flaherty et al., 2005; Entenza et al., 2005), however, their ability to lyse the complex 
structure of staphylococcal biofilms has not yet been investigated. In this approach, the lysis 
genes of the bacteriophages φ11 and φ12 of S. aureus NCTC8325 were cloned and 
heterologously overexpressed in E. coli for subsequent analysis of the lytic activity of the 
enzymes and their single subdomains on cell walls, whole cells and biofilms of staphylococci 
(Sass and Bierbaum, 2007). Here, the full-length φ11 endolysin efficiently hydrolyzed 
purified peptidoglycan of S. simulans 22 and both, the endopeptidase and the amidase module 
plus cell wall binding domain (φ11endo/CBD and φ11ami/CBD), were active and able to lyse 
cell walls (Fig. 4.21). However, the full length φ11 endolysin was more active than the 
isolated subdomains and only the combination of φ11endo/CBD and φ11ami/CBD restored 
full lytic activity. Hence, the two catalytic domains of the enzyme have to be combined with 
each other to cleave the cell wall of intact cells. Thus, the φ11 endolysin seems to belong to a 
group of endolysins which act as multifunctional hydrolases (Bateman and Rawlings, 2003). 
Recently, the lytic enzyme of phage φWMY of Staphylococcus warneri M (LysWMY) was 
reported to show strong similarities in its domain architecture to the φ11 endolysin (Yokoi et 
al., 2005). In contrast to the φ11 endolysin, LysWMY retained its full activity even when 
both, the amidase and cell wall binding domain had been deleted. This result indicates that a 
combined action of different domains does not seem to be an obligatory characteristic even 
among closely related murein hydrolases. Noteworthy, purified cell walls were a much more 
sensitive substrate for the enzymes than heat-killed cells, since they showed the residual 
activities of the single subdomains much more clearly. In spite of this, the φ12 endolysin did 
not show any activity with S. simulans 22 cell walls (Sass, 2005). 
Furthermore, substrate recognition mediated by the cell wall binding domain, which is 
homologous to the C-terminal domain of lysostaphin (Loessner et al., 1998), appeared to be 
necessary for high catalytic efficiency of the φ11 endolysin. Lytic activity of the φ11 
endolysin on heat-killed staphylococcal cells was abolished after deletion of the cell wall 
binding domain (φ11endo/ami), while it retained nearly all of its lytic activity on SDS cell 
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walls. The single domains, φ11endo and φ11ami, showed significantly reduced lytic activity 
on SDS cell walls in the absence of the cell wall binding domain. These findings are similar to 
the results obtained with lysostaphin and ALE-1, a glycyl-glycine endopeptidase homologous 
to lysostaphin. After the deletion of their C-terminal cell wall targeting domains (Baba and 
Schneewind, 1996; Lu et al., 2006), which mediate the binding to cross-linked peptidoglycan 
and recognise the [Gly]5 interpeptide crossbridge (Lu et al., 2006; Gründling and Schneewind, 
2006), lysostaphin and ALE-1 showed a significant reduction in lytic activity on autoclaved 
staphylococci or viable cells, respectively. Our results suggest that a similar targeting 
mechanism exists for the φ11 endolysin and that, in this respect, the phage enzyme closely 
resembles its staphylococcal counterparts. 
The lytic activities of the φ11 and φ12 endolysins were also tested on whole cells of S. aureus 
NCTC8325, S. aureus Wood 46, S. aureus Cowan I, S. aureus Newman, S. epidermidis O-47 
and S. simulans 22. Here, the full-length φ11 endolysin was characterized by rapid hydrolysis 
of heat-inactivated staphylococcal cells which was equivalent to the activity of lysostaphin. 
Unlike φ11, the φ12 endolysin was not able to hydrolyze heat-inactivated staphylococci. After 
addition of the φ12 endolysin an increase in optical density of the cultures was observed 
which was accompanied and most probably caused by an aggregation of the cells that was 
macroscopically visible (Sass, 2005). This phenomenon has been described previously 
(Takano et al., 2000) by investigating the influence of synthetic peptides derived from the  
S. aureus major autolysin Atl on autolysis. Sequence comparison with the homologous 
amidase-3 domains of the S. aureus phages φSA 2MW, L54a, φSLT, PVL, 96, 3a, 53, 77, 
ROSA, φETA and amidases of Staphylococcus haemolyticus JCSC1435 and Staphylococcus 
epidermidis RP62a identified an amino acid exchange at position 260 in the amidase-3 
domain of the φ12 endolysin. This exchange introduces a histidine and therefore an additional 
positive charge in a position that is occupied by glutamine, glutamate or asparagine in the 
other staphylococcal enzymes. To analyze the reasons for the ineffectiveness of the φ12 
endolysin, a mutated φ12 endolysin was constructed in which the histidine at position 260 was 
exchanged to glutamine. Unexpectedly, the φ12mut endolysin was still incapable to hydrolyze 
heat-inactivated staphylococci. Thus, in our test systems, the φ12 endolysin as well as the 
φ12mut endolysin are unable to exert efficient hydrolytic activity on staphylococcal 
peptidoglycan, while retaining the ability to bind the cell wall. The substrate binding ability of 
the enzyme may then lead to the enhanced adhesion between the cells. In vivo, the 
ineffectiveness of the φ12 endolysin would mean severe disadvantages for phage φ12. A 
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phage, that owns an endolysin which is incapable to properly hydrolyze the cell wall of the 
bacterial host, would be dependent on other mechanisms, e.g. other phages, to escape from 
the bacterial cell after activation of the phage lytic cycle. This could explain, why phage φ12 
commonly exists as a lysogenic phage in S. aureus NCTC8325 together with the phages φ11 
and φ13. Nevertheless, it cannot be excluded that an inadequate folding of the six-His-tagged 
φ12 endolysin is involved in the loss of hydrolytic activity. 
In this work, the activity of the endolysins was also tested against staphylococcal biofilms. 
Bacterial biofilm formation is part of a survival strategy to resist suboptimal environmental 
conditions such as limited nutrient availability or lethal concentrations of antibiotics. 
Antimicrobial agents often show significantly reduced effects on biofilms, which is thought to 
be due to several biofilm-inherent properties. For example, a slow growth rate impedes the 
action of antibiotics (Duguid et al., 1992b; Stewart, 2002) and evidence is emerging that the 
sessile cells in biofilms live in an altered metabolic state (Beenken et al., 2004; Resch et al., 
2005). Furthermore, the diffusion velocity of antibiotics is limited within biofilms. A reduced 
rate of antibiotic penetration leads to a gradually increasing concentration of the antibiotic in 
the deeper layers of a biofilm which permits adaptation of the biofilm cells to the antibiotic by 
stress-induced metabolic and transcriptional changes (Jefferson et al., 2005). Additionally, 
non-growing persister cells circumvent the action of conventionally used antibiotics that 
predominantly act on the metabolism of actively growing cells (Anderson and O'Toole, 2008; 
Roberts and Stewart, 2005). Here, the purified φ11 endolysin was able to eliminate biofilms 
of S. aureus NCTC8325 and S. aureus Newman. So far, no other phage lysin has been 
reported to disrupt staphylococcal biofilms. However, S. epidermidis biofilms remained 
unaffected, although whole cells of S. epidermidis were susceptible to the action of the φ11 
endolysin. The φ11 endolysin most probably destabilizes the biofilm structure by fast lysis of 
sessile cells, which are embedded in the extracellular matrix or at the interface of the matrix 
and surface, whereupon the biofilm is dissolved. Another possibility could be an influence of 
the intrinsic nature of the biofilm. Neither Na-meta-periodate nor proteinase K treatment 
could completely eradicate biofilms of S. aureus NCTC8325 which suggests that an elevated 
portion of proteinogenous biofilm is present along with a biofilm mediated by the 
characteristic polysaccaride PIA. PIA consists of β-1,6-linked N-acetylglucosamine residues 
(Götz, 2002) and is not the target of the φ11 murein hydrolase. In contrast to S. aureus 
NCTC8325, S. epidermidis O-47 biofilms are exclusively polysaccaride-mediated and were 
not dissolved by the φ11 enzyme. Therefore, the different natures of the biofilm matrices 
tested here could be an explanation for the varying efficacy of the φ11 endolysin.  
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In conclusion, the combined action of the endopeptidase and amidase domains of the φ11 
endolysin allowed the efficient hydrolysis of whole cells and biofilms of S. aureus. 
Additionally, cell wall targeting appeared to be a prerequisite for maximum activity. 
Considering the huge clinical relevance of staphylococcal biofilms in terms of human 
diseases, the endolysins may constitute a novel strategy to treat actively growing cells and 
non-growing persister cells in order to combat S. aureus nosocomial infections that are 
mediated by biofilm formation on medical devices.  
 
5.6 Perspectives 
S. aureus infections remain difficult to treat due to their ability to persist during host invasion. 
Today, there is an urgent need for a better understanding of how bacteria develop resistance to 
antibiotics and new treatment strategies need to be explored to control bacterial infections. 
In this work, the lantibiotic mersacidin has been characterized as a strong inducer of the cell 
wall stress response of S. aureus and the GraRS (aps) antimicrobial peptide sensing system of 
S. aureus could be identified as a resistance determinant to mersacidin and other lantibiotics. 
However, further studies are needed to gain deeper insights into the mechanism that S. aureus 
uses to resist antibiotic treatment. In this context, the selective inactivation of the dltB, mprF 
and vraFG genes of a more resistant strain, e.g. S. aureus SA137/93G, could specify the mode 
by which the GraRS system controls a resistance mechanism against mersacidin. Despite the 
fact, that the inactivation of the VraDE ABC transporter genes did not have an influence on 
the susceptibility of S. aureus to mersacidin in this work, it cannot be excluded that the 
differences in mersacidin susceptibility are based on a transport mechanism. Here, 
biochemical characterization of VraFG, VraDE and related transporters will test this 
hypothesis and may provide directions for circumventing the activity of resistance 
transporters through structural modification of antibiotics. However, the factors presented in 
this work may only be partly responsible for the different susceptibilities among 
staphylococci and new techniques must be employed to understand the lifestyle of S. aureus, 
its constitutive and inducible resistance factors. This work underlined the importance of a 
fundamental knowledge on bacterial genomics, since single variations of the nucleotide 
sequences may have a hugh impact on the bacterial phenotype. In this context, the recent 
introduction of pyrosequencing techniques now allows for the convenient sequencing of 
whole bacterial genomes. Combined with elaborate bioinformatic analysis tools, which enable 
the rapid analysis of entire genomes, S. aureus wild type strains or laboratory mutants of 
interest could be screened for variations in their nucleotide sequences that may influence the 
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susceptibility of S. aureus and other staphylococci to antibiotics. Hereupon, genes of interest 
should be selectively inactivated or alternatively be overexpressed to study their contribution 
to antibiotic resistance and to evaluate desireable properties of new antimicrobial agents. 
Further studies on the response and resistance of S. aureus to mersacidin and other antibiotics 
should also comprise the analysis of the S. aureus proteome. While the genomic data provides 
the building blocks for the S. aureus way of life, the bacterial proteome would present a 
snapshot of the actual state of the cell and, therefore, would allow to understand the 
mechanisms that S. aureus uses to evade antimicrobial treatment. 
In this work, the φ11 endolysin was used to efficiently treat S. aureus biofilms in vitro. 
Nevertheless, further studies need to be conducted to characterize the φ11 endolysin and to 
ascertain its putative contribution to a new biofilm treatment strategy in order to overcome the 
restrictions of antibiotics that target only actively growing cells. Here, it would also be 
interesting to analyze the S. aureus response to the φ11 endolysin on a transcriptional and 
proteomic level to evaluate a putative gain of resistance towards these group of antimicrobial 
compounds. The φ11 endolysin could further be coupled to GFP (green fluorescent protein) to 
study the binding mechanism of the protein to staphylococcal cells. Furthermore, the cell 
wall-binding domain could be exchanged to one of another murein hydrolase to possibly gain 
activity against cells that were previously not affected by the φ11 endolysin, e.g. biofilms of 
S. epidermidis. Additionally, site-directed mutagenesis could be employed to improve the 
activity of the φ11 endolysin or to detect amino acid residues that are essential for its lytic 
activity. Finally, in vivo studies have to be performed to confirm the potential of endolysins to 
counteract infections caused by S. aureus. 
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Table S1: Genes with significantly altered expression of S. aureus SA137/93G upon mersacidin treatment1
N315 ORF Gene  Gene product function 
Fold change2 
SA137/93G 
(0.15 x MIC) 
Cell wall
SA0205  hypothetical protein, similar to lysostaphin precursor  2.16 
SA1691 sgtB hypothetical protein, similar to penicillin-binding protein 1A/1B  4.79 
SA2481  conserved hypothetical protein  2.57 
Transport/binding proteins and lipoproteins
SA0192  hypothetical protein, similar to ABC transporter ATP-binding protein  11.96 
SA0567  hypothetical protein, similar to iron (III) ABC transporter permease protein  0.27 
SA1255  PTS system, glucose-specific enzyme II, A component  2.60 
SA1478  hypothetical protein, similar to transporter PAB2175 from Pyrococcus abyssi  3.19 
SA2112  hypothetical protein, similar to sodium-dependent transporter  0.37 
SA2492 vraD hypothetical protein, similar to ABC transporter  34.28 
SA2493 vraE hypothetical protein, similar to ABC transporter (permease)  35.07 
Sensors (signal transduction)
SA1701 vraS two-component sensor histidine kinase  5.84 
Metabolism related genes
SA0515  hypothetical protein, similar to deoxypurine kinase  0.18 
SA0534 vraB acetyl-CoA c-acetyltransferase  4.62 
SA1301 ndk nucleoside diphosphate kinase  0.44 
SA1925  conserved hypothetical protein  3.50 
SA2297  hypothetical protein, similar to GTP-pyrophosphokinase  3.91 
DNA replication, RNA and protein synthesis
SA0442 holB probable DNA polymerase III, delta prime subunit  0.22 
SA1195 msrR peptide methionine sulfoxide reductase regulator MsrR  3.63 
SA1659 prsA peptidyl-prolyl cis/trans isomerase homologue 9.97 
SA1700 vraR two-component response regulator  7.27 
SA2296  hypothetical protein, similar to transcriptional regulator, MerR family  3.94 
Adaption to atypical conditions
SA1549  hypothetical protein, similar to serine proteinase, heat-shock protein htrA  3.94 
Pathogenic factors (toxins and colonization factors)
SA0519 sdrC Ser-Asp rich fibrinogen-binding, bone sialoprotein-binding protein  0.50 
SA0909 fmtA FmtA, autolysis and methicillin resistant-related protein  6.28 
SA2006  hypothetical protein, similar to MHC class II analog  2.76 
Hypothetical proteins
SA0275  conserved hypothetical protein  0.61 
SA0329  conserved hypothetical protein  0.36 
SA0358  conserved hypothetical protein  11.08 
SA0364  hypothetical protein  0.28 
SA0467  conserved hypothetical protein  0.36 
SA0517  conserved hypothetical protein  0.43 
SA0535 vraC hypothetical protein  4.24 
SA0536  hypothetical protein  8.58 
SA0591  hypothetical protein  4.15 
SA1256  conserved hypothetical protein  2.83 
SA1419  conserved hypothetical protein  0.37 
SA1476  hypothetical protein  6.52 
SA1702  conserved hypothetical protein  4.42 
SA1703  hypothetical protein  6.82 
continued on following page
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Table S1 - Continued 
N315 ORF Gene  Gene product function 
Fold change2 
SA137/93G 
(0.15 x MIC) 
SA1712  conserved hypothetical protein  5.03 
SA2113  hypothetical protein  4.91 
SA2146 tcaA TcaA protein  2.20 
SA2195  conserved hypothetical protein  1.75 
SA2220  conserved hypothetical protein  3.66 
SA2221  hypothetical protein  5.24 
SA2238  conserved hypothetical protein  1.99 
SA2480 drp35 Drp35  2.84 
SAS025  hypothetical protein  1.91 
 
1 Significant changes of gene expression were determined by implementing SAM (significance analysis of 
microarrays; http://www-stat.stanford.edu/~tibs/SAM/) (Tusher et al., 2001). 
2 Fold change in transcript level indicated as mean of the “median of ratios” compared to control cells. 
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Table S2: Comparative gene expression analysis  of S. aureus strain SG511-Berlin versus strain SA137/93A 
N315 ORF Gene  Gene product function 
Fold change 
SG511-Berlin/ 
SA137/93A 1
Cell wall    
SA0038 mecA penicillin binding protein 2a 0.11 
SA0265 lytM peptidoglycan hydrolase  0.38 
SA1935 hmrA similar to amidase (HmrA)  0.40 
SA2199 fmhA fmhA protein  7.00 
Transformation competence
SA0705  hypothetical protein, similar to comF operon protein 1  0.48 
Transport/binding proteins and lipoproteins  
SA0099  hypothetical protein, similar to transmembrane efflux pump protein  0.14 
SA0106 lctP L-lactate permease homologue  0.16 
SA0109 sirC lipoprotein  0.21 
SA0183 glcA PTS enzyme II (EC 2.7.1.69), glucose-specific, factor IIA homologue  4.27 
SA0197  hypothetical protein, similar to ABC transporter ATP-binding protein  0.18 
SA0198 oppF oligopeptide transport ATP-binding protein  2.05 
SA0294  hypothetical protein, similar to branched-chain amino acid uptake carrier  0.45 
SA0295  hypothetical protein, similar to outer membrane protein precursor  2.97 
SA0325 glpT glycerol-3-phosphate transporter  2.45 
SA0368  hypothetical protein, similar to proton/sodium-glutamate symport protein  5.14 
SA0420  hypothetical protein, similar to ABC transporter ATP-binding protein  0.21 
SA0421  hypothetical protein, similar to ABC transporter permease protein  0.18 
SA0422  hypothetical protein, similar to lactococcal lipoprotein  0.22 
SA0531 proP proline/betaine transporter homologue  0.35 
SA0541  hypothetical protein, similar to cationic amino acid transporter  0.32 
SA0566  hypothetical protein, similar to iron-binding protein  2.34 
SA0589  hypothetical protein, similar to ABC transporter ATP-binding protein  8.99 
SA0616 vraF ABC transporter ATP-binding protein  0.11 
SA0617 vraG ABC transporter permease  0.21 
SA0691  lipoprotein, similar to ferrichrome ABC transporter  0.33 
SA0769  ABC transporter ATP-binding protein homologue  0.32 
SA0794 dltB DltB membrane protein  0.49 
SA0845 oppB oligopeptide transport system permease protein  0.47 
SA0848 oppF oligopeptide transport system ATP-binding protein OppF homologue  0.43 
SA0928  hypothetical protein, similar to cation ABC transporter  17.55 
SA0956  hypothetical protein, similar to Mn2+-transport protein  0.11 
SA1042 pyrP uracil permease  7.49 
SA1140 glpF glycerol uptake facilitator  2.89 
SA1183 opuD glycine betaine transporter  2.16 
SA1341  hypothetical protein, similar to export protein SpcT protein  2.46 
SA1505 lysP lysine-specific permease  2.12 
SA1592  aesenical pump membrane protein homologue  2.30 
SA1634  truncated hypothetical protein [Pathogenicity island SaPIn3] 0.31 
SA1699  hypothetical protein, similar to transporter  0.23 
SA1958  hypothetical protein, similar to transposase for IS232  0.40 
SA1962 mtlA PTS system, mannitol specific IIA component  0.17 
SA1972  hypothetical protein, similar to multidrug transporter  0.20 
SA1978  hypothetical protein, similar to ferrichrome ABC transporter (permease)  0.43 
SA1987  glycine betaine transporter opuD homologue  0.18 
SA2061  hypothetical protein  2.20 
SA2081  hypothetical protein, similar to urea transporter  0.32 
SA2094  hypothetical protein, similar to Na+/H+ antiporter  0.26 
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Table S2 - Continued 
N315 ORF Gene  Gene product function 
Fold change 
SG511-Berlin/ 
SA137/93A 1
SA2135  hypothetical protein, similar to sodium/glutamate symporter  4.34 
SA2148  hypothetical protein, similar to membrane protein  0.23 
SA2167 scrA PTS system, sucrose-specific IIBC component  2.86 
SA2200  hypothetical protein, similar to ABC transporter, ATP binding subunit  3.93 
SA2201  hypothetical protein, similar to ABC transporter, permease protein  2.91 
SA2202  hypothetical protein, similar to ABC transporter  3.30 
SA2242  conserved hypothetical protein  0.19 
SA2243  hypothetical protein, similar to ABC transporter ATP-binding protein  0.16 
SA2300  hypothetical protein, similar to glucarate transporter  4.03 
SA2302  hypothetical protein, similar to ABC transporter  4.48 
SA2303  hypothetical protein, similar to membrane spanning protein  5.44 
SA2314  hypothetical protein, similar to ABC transporter ATP-binding protein  0.45 
SA2326 ptsG PTS system, glucose-specific IIABC component  3.40 
SA2339  hypothetical protein, similar to antibiotic transport-associated protein  5.64 
SA2345  hypothetical protein, similar to mercuric ion-binding protein  2.20 
SA2396  hypothetical protein, similar to amino acid transporter  0.40 
SA2489  hypothetical protein, similar to high-affinity nickel-transport protein  0.31 
Sensors (signal transduction)
SA0018 vicK two-component sensor histidine kinase  0.11 
SA0039 mecR1 methicillin resistance protein  0.08 
SA0615 graS hypothetical protein, similar to two-component sensor histidine kinase 0.36 
SA1158  hypothetical protein, similar to two-component sensor histidine kinase  0.36 
SA1653 TRAP signal transduction protein TRAP  0.06 
SA1843 agrC accessory gene regulator C  0.08 
Membrane bioenergetics (electron transport chain and ATP synthase)  
SA0366 ahpC alkyl hydroperoxide reductase subunit C  2.19 
SA0578  hypothetical protein, similar to NADH dehydrogenase  0.39 
SA0579  hypothetical protein, similar to Na+/H+ antiporter  0.33 
SA0580  hypothetical protein, similar to Na+/H+ antiporter  0.27 
SA0583  hypothetical protein, similar to Na+/H+ antiporter  0.35 
SA0799  hypothetical protein, similar to NADH dehydrogenase  2.06 
SA0910  hypothetical protein, similar to quinol oxidase polypeptide IV QoxD  3.53 
SA0911 qoxC Quinol oxidase polypeptide III QoxC  2.95 
SA0912 qoxB Quinol oxidase polypeptide I QoxB  3.20 
SA0913  hypothetical protein, similar to quinol oxidase polypeptide II QoxA  2.59 
SA1904 atpC FoF1-ATP synthase epsilon subunit  2.02 
Cell division    
SA0249 scdA cell division and morphogenesis-related protein  2.59 
SA0724  hypothetical protein, similar to cell-division inhibitor  0.25 
SA0905 atl autolysin, N-acetylmuramyl-L-alanine amidase and glucosaminidase  0.38 
Sporulation    
SA2498  hypothetical protein, similar to DNA-binding protein Spo0J-like homologue  2.76 
Metabolism of carbohydrates and related molecules - Specific pathways  
SA0242  hypothetical protein, similar to xylitol dehydrogenase  2.19 
SA0510 araB probable L-ribulokinase  2.01 
SA0528  hypothetical protein, similar to hexulose-6-phosphate synthase  0.31 
SA0562 adh1 alcohol dehydrogenase I  46.70 
SA0605  hypothetical protein, similar to dihydroxyacetone kinase  2.43 
SA0658  hypothetical protein, similar to plant-metabolite dehydrogenases  0.41 
SA0669  hypothetical protein, similar to para-aminobenzoate synthase component I 0.23 
SA0670  hypothetical protein, similar to para-aminobenzoate synthase component I  0.27 
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Table S2 - Continued 
N315 ORF Gene  Gene product function 
Fold change 
SG511-Berlin/ 
SA137/93A 1
SA0946 pdhD dihydrolipoamide dehydrogenase component of pyruvate dehydrogenase E3  0.30 
SA0994 sdhC succinate dehydrogenase cytochrome b-558  2.07 
SA0995 sdhA succinate dehydrogenase flavoprotein subunit  2.35 
SA1736 aldH aldehyde dehydrogenase  0.21 
SA1913 mnaA UDP-GlcNAc 2-epimerase  0.41 
SA1924  hypothetical protein, similar to aldehyde dehydrogenase  0.40 
SA1963 mtlD mannitol-1-phosphate 5-dehydrogenase  0.22 
SA1965 glmM phosphoglucosamine-mutase  0.43 
SA2102  formate dehydrogenase homologue  0.29 
SA2119  hypothetical protein, similar to dehydrogenase  0.21 
SA2155  hypothetical protein, similar to malate:quinone oxidoreductase  2.01 
SA2204  phosphoglycerate mutase, pgm homologue  5.58 
SA2260  hypothetical protein, similar to glucose 1-dehydrogenase  0.28 
SA2342  hypothetical protein, similar to O-acetyltransferase  4.73 
SA2346  hypothetical protein, similar to D-specific D-2-hydroxyacid dehydrogenase ddh 0.33 
SA2394  hypothetical protein, similar to alpha-acetolactate decarboxylase  2.12 
SA2395  L-lactate dehydrogenase  2.24 
SA2402  acetate-CoA ligase  0.42 
Metabolism of amino acids and related molecules  
SA0098  hypothetical protein, similar to aminoacylase  0.14 
SA0176  hypothetical protein, similar to N-acetylglutamate 5-phosphotransferase  0.42 
SA0344 metE 5-methyltetrahydropteroyltriglutamate-homocysteine methyltransferase  0.27 
SA0346  hypothetical protein, similar to cystathionine beta-lyase  0.39 
SA0347  hypothetical protein, similar to cystathionine gamma-synthase  0.36 
SA0418 cysM cysteine synthase homologue  0.36 
SA0471 cysK cysteine synthase (o-acetylserine sulfhydrylase) homologue  3.27 
SA0508  hypothetical protein, similar to glycine C-acetyltransferase  2.14 
SA0668  hypothetical protein, similar to anthranilate synthase component II 0.26 
SA0672  hypothetical protein, similar to urea amidolyase  0.40 
SA0902  HisC homologue  0.49 
SA1164 dhoM homoserine dehydrogenase  0.40 
SA1165 thrC threonine synthase  0.44 
SA1200 trpG anthranilate synthase component II  0.39 
SA1201 trpD anthranilate phosphoribosyltransferase  0.35 
SA1202 trpC indole-3-glycerol phosphate synthase  0.45 
SA1203 trpF phosphoriborylanthranilate isomerase  0.45 
SA1204 trpB tryptophan synthase beta chain  0.46 
SA1205 trpA tryptophan synthase alpha chain  0.47 
SA1343  hypothetical protein, similar to tripeptidase  0.42 
SA1365  glycine dehydrogenase (decarboxylating) subunit 2 homologue  0.40 
SA1545 serA D-3-phosphoglycerate dehydrogenase  0.47 
SA1585  proline dehydrohenase homologue  0.47 
SA1814  hypothetical protein, similar to succinyl-diaminopimelate desuccinylase  0.32 
SA1859 ilvB acetolactate synthase large subunit  0.40 
SA1861 ilvC alpha-keto-beta-hydroxylacil reductoisomerase  0.28 
SA1862 leuA 2-isopropylmalate synthase  0.38 
SA1863 leuB 3-isopropylmalate dehydrogenase  0.43 
SA1864 leuC 3-isopropylmalate dehydratase large subunit  0.38 
SA1865 leuD 3-isopropylmalate dehydratase small subunit  0.41 
SA2082 ureA urease gamma subunit  0.07 
SA2083 ureB urease beta subunit  0.04 
continued on following page
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Table S2 - Continued 
N315 ORF Gene  Gene product function 
Fold change 
SG511-Berlin/ 
SA137/93A 1
SA2084 ureC urease alpha subunit  0.07 
SA2085 ureE urease accessory protein UreE  0.11 
SA2086 ureF urease accessory protein UreF  0.08 
SA2087 ureG urease accessory protein UreG  0.13 
SA2088 ureD urease accessory protein UreD  0.15 
SA2095  hypothetical protein, similar to D-octopine dehydrogenase  0.40 
SA2098  hypothetical protein, similar to glycerate dehydrogenase  2.59 
SA2125  hypothetical protein, similar to formiminoglutamase  0.27 
SA2341 rocA 1-pyrroline-5-carboxylate dehydrogenase  2.51 
SA2347  hypothetical protein, similar to aspartate aminotransferase  0.38 
SA2425 arcC carbamate kinase  3.17 
Metabolism of nucleotides and nucleic acids  
SA0016 purA adenylosuccinate synthase  2.34 
SA0022  hypothetical protein, similar to 5'-nucleotidase  2.56 
SA0687 nrdF ribonucleoside-diphosphate reductase minor subunit  0.41 
SA0917 purK phosphoribosylaminoimidazole carboxylase carbon dioxide-fixation chain PurK 0.36 
SA0918 purC phosphoribosylaminoimidazolesuccinocarboxamide synthetase homologue 0.40 
SA0920 purQ phosphoribosylformylglycinamidine synthase I PurQ  0.20 
SA0921 purL phosphoribosylformylglycinamidine synthetase PurL  0.23 
SA0922 purF phosphoribosylpyrophosphate amidotransferase PurF  0.25 
SA0923 purM phosphoribosylformylglycinamidine cyclo-ligase PurM  0.23 
SA0924 purN phosphoribosylglycinamide formyltransferase  0.26 
SA0925 purH bifunctional purine biosynthesis protein PurH  0.19 
SA0926 purD phosphoribosylamine--glycine ligase PurD  0.39 
SA0927  conserved hypothetical protein  16.03 
SA1043 pyrB aspartate transcarbamoylase chain A  8.36 
SA1044 pyrC dihydroorotase  10.04 
SA1045 pyrAA carbamoyl-phosphate synthase small chain  8.50 
SA1046 pyrAB carbamoyl-phosphate synthase large chain  8.64 
SA1047 pyrF orotidine-5-phosphate decarboxylase  8.68 
SA1048 pyrE orotate phosphoribosyltransferase  8.93 
SA1172  hypothetical protein, similar to GMP reductase  2.06 
SA1260 thyA thymidylate synthase  0.47 
SA1938 pdp pyrimidine nucleoside phosphorylase  3.45 
SA2127  hypothetical protein, similar to ribose 5-phosphate isomerase (rpi)  2.70 
Metabolism of lipids   
SA0036  glycerophosphoryldiester phosphodiesterase homologue  0.12 
SA0572  hypothetical protein, similar to esterase/lipase  0.15 
SA0869 fabI trans-2-enoyl-ACP reductase  0.40 
SA0969  hypothetical protein, similar to glycerophosphoryl diester phosphodiesterase  0.49 
SA1434  acetyl-CoA carboxylase (biotin carboxylase subunit), accC homologue  0.25 
SA1435  hypothetical protein, similar to acetyl-CoA carboxylase, accB homologue  0.25 
SA1542  hypothetical protein, similar to glycerophosphoryl diester phosphodiesterase  0.43 
SA2333 mvaA hydroxymethylglutaryl-CoA reductase  2.27 
SA2349 crtM squalene synthase  0.39 
SAS044  4-oxalocrotonate tautomerase  2.23 
Metabolism of coenzymes and prosthetic groups  
SA0241  hypothetical protein, similar to 4-diphosphocytidyl-2C-methyl-D-erythritol synthase  2.20 
SA0317  hypothetical protein, similar to dihydroflavonol-4-reductase  0.47 
SA0898 menB naphthoate synthase  2.05 
SA1491 hemL glutamate-1-semialdehyde 2,1-aminomutase  2.18 
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N315 ORF Gene  Gene product function 
Fold change 
SG511-Berlin/ 
SA137/93A 1
SA1492 hemB delta-aminolevulinic acid dehydratase  2.20 
SA1493 hemD uroporphyrinogen III synthase  3.32 
SA1495 hemX hemA concentration negative effector hemX  3.19 
SA1496 hemA glutamyl-tRNA reductase  2.24 
SA1586 ribH 6,7-dimethyl-8-ribityllumazine synthase  0.40 
SA1587 ribA riboflavin biosynthesis protein  0.36 
SA1588 ribB riboflavin synthase alpha chain  0.36 
SA2070 moaB molybdopterin precursor biosynthesis moaB  0.48 
DNA replication, modification and repair, recombination, packaging and segregation  
SA0027 repB truncated replication protein for plasmid  0.08 
SA0028 repB truncated replication protein for pUB110 plasmid  0.04 
SA0029 pre plasmid recombination enzyme  0.04 
SA0577  hypothetical protein, similar to FimE recombinase  0.23 
SA1189 parC topoisomerase IV subunit A  2.06 
SA1489 tag DNA-3-methyladenine glycosidase  2.44 
SA1806  probable ATP-dependent helicase [Bacteriophage phiN315] 0.09 
RNA synthesis and modification  
SA0017 vicR response regulator  0.11 
SA0097  hypothetical protein, similar to transcription regulator AraC/XylS family  0.07 
SA0104  hypothetical protein, similar to transcription regulator GntR family  0.21 
SA0108 sarH1 staphylococcal accessory regulator A homologue  0.11 
SA0142  hypothetical protein, similar to DNA-binding protein  7.00 
SA0322  hypothetical protein, similar to transcription regulator  2.69 
SA1041 pyrR pyrimidine operon repressor chainA  3.49 
SA1465 tgt tRNA-guanine transglycosylase  0.49 
SA1583 rot repressor of toxins Rot  4.32 
SA1591  arsenical resistance operon repressor homologue  3.57 
SA1678  transcription regulator Fur family homologue  2.25 
SA1805  repressor homologue [Bacteriophage phiN315] 0.28 
SA1869 sigB sigma factor B  0.30 
SA1870 rsbW anti-sigmaB factor  0.26 
SA1961  hypothetical protein, similar to transcription antiterminator BglG family  0.25 
SA1999  hypothetical protein, similar to regulatory protein, SIR2 family  0.37 
SA2089 sarR staphylococcal accessory regulator A homologue  3.28 
SA2147 tcaR TcaR transcription regulator  0.43 
SA2384 ermA rRNA methylase Erm(A)  0.02 
SA2424  hypothetical protein, similar to transcription regulator Crp/Fnr family protein  2.91 
Protein synthesis, modification and folding  
SA0009 serS seryl-tRNA synthetase  2.28 
SA0330  hypothetical protein, similar to ribosomal-protein-serine N-acetyltransferase  0.40 
SA0815  peptidyl-prolyl cis-trans isomerase homologue  2.63 
SA0855 trpS tryptophanyl-tRNA synthetase  0.36 
SA1039 lsp lipoprotein signal peptidase  2.04 
SA1116 rpsO 30S ribosomal protein S15  2.51 
SA1697  hypothetical protein, similar to protein-tyrosine phosphatase  0.49 
SA1717  glutamyl-tRNAGln amidotransferase subunit C  0.44 
SA1725  Staphopain, Cysteine Proteinase  2.27 
SA1856  hypothetical protein, similar to glycoprotein endopeptidase  0.48 
SA1917  hypothetical protein, similar to phosphatase  2.39 
Adaption to atypical conditions
SA0144 capA capsular polysaccharide synthesis enzyme Cap5A  0.26 
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N315 ORF Gene  Gene product function 
Fold change 
SG511-Berlin/ 
SA137/93A 1
SA0145 capB capsular polysaccharide synthesis enzyme Cap5B  0.18 
SA0146 capC capsular polysaccharide synthesis enzyme Cap8C  0.22 
SA0147 capD capsular polysaccharide synthesis enzyme Cap5D  0.19 
SA0148 capE capsular polysaccharide synthesis enzyme Cap8E  0.25 
SA0149 capF capsular polysaccharide synthesis enzyme Cap5F  0.30 
SA0150 capG capsular polysaccharide synthesis enzyme Cap5G  0.35 
SA0151 capH capsular polysaccharide synthesis enzyme O-acetyl transferase Cap5H  0.49 
SA0152 capI capsular polysaccharide synthesis enzyme Cap5I  0.30 
SA0153 capJ capsular polysaccharide synthesis enzyme Cap5J  0.26 
SA0154 capK capsular polysaccharide synthesis enzyme Cap5K  0.22 
SA0155 capL capsular polysaccharide synthesis enzyme Cap5L  0.44 
SA0156 capM capsular polysaccharide synthesis enzyme Cap5M  0.37 
SA0157 capN capsular polysaccharide synthesis enzyme Cap5N  0.44 
SA0158 capO capsular polysaccharide synthesis enzyme Cap8O  0.39 
SA0659  hypothetical protein, similar to CsbB stress response protein  0.36 
SA0723 clpP ATP-dependent Clp protease proteolyticsubunit homologue  2.02 
SA0755  hypothetical protein, similar to general stress protein 170  0.35 
SA1941 dps general stress protein 20U  2.54 
SA1984 asp23 alkaline shock protein 23, ASP23  0.15 
SA2175  hypothetical protein, similar to small heat shock protein  0.36 
SA2336 clpL ATP-dependent Clp proteinase chain clpL  0.16 
Detoxification    
SA0033 aadD kanamycin nucleotidyltransferase  0.02 
SA0132  hypothetical protein, similar to tetracyclin resistance protein  0.43 
SA0551  mercuric reductase homologue  0.43 
SA0650 norA quinolone resistance protein  0.12 
SA0681  hypothetical protein, similar to multidrug resistance protein  0.19 
SA2385 ant(9) O-nucleotidylltransferase 0.10 
Phage-related functions
SA1759  lytic enzyme [Bacteriophage phiN315] 0.37 
SA1765  hypothetical protein [Bacteriophage phiN315] 0.29 
SA1787  hypothetical protein [Bacteriophage phiN315] 0.43 
SA1810 int integrase [Bacteriophage phiN315] 2.05 
Transposon and IS elements
SA0034  transposase for IS-like element  0.05 
SA0762 tnpA transposase A for Tn554  0.45 
SA1483 tnpB transposase B for Tn554  0.31 
SA1603  truncated transposase  2.17 
SA1623  truncated transposase [Pathogenicity island SaPIn3] 0.34 
SA2289 tnp transposase  0.23 
SA2383  hypothetical protein  0.21 
SA2386 tnpC transposition regulatory protein tnpC transposon Tn554 0.23 
SA2387 tnpB transposition regulatory protein tnpB transposon Tn554 0.18 
SA2388 tnpA transposition regulatory protein tnpA transposon Tn554 0.15 
SAS069  hypothetical protein, similar to transposase for IS232  2.48 
Pathogenic factors (toxins and colonization factors)  
SA0270  hypothetical protein, similar to secretory antigen precursor SsaA  5.72 
SA0276  conserved hypothetical protein, similar to diarrheal toxin  0.45 
SA0309 geh glycerol ester hydrolase  0.44 
SA0357  hypothetical protein, similar to exotoxin 2  0.17 
SA0519 sdrC Ser-Asp rich fibrinogen-binding, bone sialoprotein-binding protein  9.39 
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SA137/93A 1
SA0521 sdrE Ser-Asp rich fibrinogen-binding, bone sialoprotein-binding protein  12.15 
SA0587  lipoprotein, streptococcal adhesin PsaA homologue  13.65 
SA0744 ssp extracellular ECM and plasma binding protein  0.42 
SA0841  hypothetical protein, similar to cell surface protein Map-w  2.02 
SA1004  hypothetical protein, similar to fibrinogen-binding protein  0.48 
SA1430  hypothetical protein, similar to enterotoxin A precursor  3.54 
SA1629 splC serine protease SplC [Pathogenicity island SaPIn3] 0.50 
SA1642 seg extracellular enterotoxin type G precursor [Pathogenicity island SaPIn3] 4.55 
SA1643 sen enterotoxin SeN [Pathogenicity island SaPIn3] 3.39 
SA1644 yent2 enterotoxin YENT2 [Pathogenicity island SaPIn3] 2.25 
SA1645 yent1 enterotoxin Yent1 [Pathogenicity island SaPIn3] 3.27 
SA1648 seo enterotoxin SeO [Pathogenicity island SaPIn3] 2.40 
SA1812  hypothetical protein, similar to synergohymenotropic toxin precursor 0.48 
SA1898  hypothetical protein, similar to SceD precursor  0.16 
SA1973  hypothetical protein, similar to hemolysin III  0.42 
SA2093 ssaA secretory antigen precursor SsaA homologue  2.04 
SA2097  hypothetical protein, similar to secretory antigen precursor SsaA  0.34 
SA2290 fnbB fibronectin-binding protein homologue  0.10 
SA2291 fnb fibronectin-binding protein homologue  0.16 
SA2423 clfB clumping factor B  2.41 
SA2430 aur zinc metalloproteinase aureolysin  2.53 
Miscellaneous   
SA0083  conserved hypothetical protein  0.35 
SA0231  hypothetical protein, similar to flavohemoprotein  3.16 
SA1193 mprF oxacillin resistance-related MprF (FmtC) protein  0.40 
SA1559  hypothetical protein, similar to smooth muscle caldesmon  0.32 
SA1617  hyp. protein, similar to nuclear antigen, Kaposi's sarcoma-associated herpesvirus 3.32 
SA1709  hypothetical protein, similar to ferritin  2.88 
Hypothetical proteins   
SA0019  conserved hypothetical protein  0.14 
SA0020  conserved hypothetical protein  0.47 
SA0024  hypothetical protein  0.08 
SA0025  hypothetical protein  0.10 
SA0037  conserved hypothetical protein  0.11 
SA0043  conserved hypothetical protein  0.45 
SA0078  hypothetical protein  0.17 
SA0079  conserved hypothetical protein  0.18 
SA0080  conserved hypothetical protein  0.16 
SA0084  hypothetical protein, similar to homo sapiens CGI-44 protein, PRO1975 protein  0.17 
SA0085  conserved hypothetical protein  0.04 
SA0088  hypothetical protein  0.19 
SA0089  hypothetical protein, similar to DNA helicase  0.21 
SA0092  hypothetical protein  0.02 
SA0093  hypothetical protein  0.07 
SA0094  hypothetical protein  0.21 
SA0095  hypothetical protein  0.02 
SA0096  hypothetical protein  0.05 
SA0100  conserved hypothetical protein  0.22 
SA0101  hypothetical protein  0.49 
SA0129  hypothetical protein  7.68 
SA0141  hypothetical protein  2.58 
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SA137/93A 1
SA0203  hypothetical protein  0.32 
SA0221  hypothetical protein  3.94 
SA0228  hypothetical protein  4.27 
SA0269  hypothetical protein  13.63 
SA0271  conserved hypothetical protein  18.12 
SA0278  hypothetical protein  0.49 
SA0279  hypothetical protein  0.41 
SA0280  hypothetical protein  0.41 
SA0281  conserved hypothetical protein  0.10 
SA0282  conserved hypothetical protein  0.10 
SA0283  hypothetical protein  0.12 
SA0284  hypothetical protein  0.07 
SA0286  conserved hypothetical protein  0.23 
SA0287  conserved hypothetical protein  0.08 
SA0288  conserved hypothetical protein  0.11 
SA0289  conserved hypothetical protein  0.22 
SA0290  conserved hypothetical protein  0.22 
SA0291  hypothetical protein  2.89 
SA0292  hypothetical protein  5.58 
SA0308  conserved hypothetical protein  0.39 
SA0326  conserved hypothetical protein  0.31 
SA0327  conserved hypothetical protein  0.27 
SA0345  conserved hypothetical protein  0.33 
SA0355  hypothetical protein, similar to hypothetical protein virulence plasmid pXO1-38  0.34 
SA0359  conserved hypothetical protein  0.28 
SA0360  conserved hypothetical protein  0.37 
SA0370  conserved hypothetical protein  4.49 
SA0372  hypothetical protein  3.83 
SA0395  hypothetical protein [Pathogenicity island SaPIn2] 0.36 
SA0401 lpl5 hypothetical protein [Pathogenicity island SaPIn2] 3.04 
SA0402 lpl6 hypothetical protein [Pathogenicity island SaPIn2] 0.46 
SA0478  conserved hypothetical protein  2.45 
SA0509  conserved hypothetical protein  0.05 
SA0518  conserved hypothetical protein  2.15 
SA0529  conserved hypothetical protein  0.23 
SA0552  hypothetical protein  2.05 
SA0554  conserved hypothetical protein  0.37 
SA0555  conserved hypothetical protein  0.48 
SA0556  conserved hypothetical protein  2.99 
SA0570  hypothetical protein  2.39 
SA0588  conserved hypothetical protein  13.07 
SA0609  conserved hypothetical protein  0.42 
SA0636  conserved hypothetical protein  0.49 
SA0637  conserved hypothetical protein  0.39 
SA0651  hypothetical protein  0.31 
SA0673  conserved hypothetical protein  0.46 
SA0701  conserved hypothetical protein  2.68 
SA0704  conserved hypothetical protein  2.65 
SA0707  conserved hypothetical protein  2.04 
SA0710  conserved hypothetical protein  4.37 
SA0725  conserved hypothetical protein  0.43 
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SA137/93A 1
SA0739  conserved hypothetical protein  4.96 
SA0752  hypothetical protein  0.44 
SA0768  conserved hypothetical protein  0.42 
SA0770  conserved hypothetical protein  0.31 
SA0771  conserved hypothetical protein  0.34 
SA0772  conserved hypothetical protein  0.36 
SA0773  conserved hypothetical protein  0.42 
SA0779  hypothetical protein  2.66 
SA0789  conserved hypothetical protein  0.43 
SA0800  conserved hypothetical protein  2.11 
SA0801  conserved hypothetical protein  2.57 
SA0804  conserved hypothetical protein  3.82 
SA0805  conserved hypothetical protein  2.12 
SA0833  conserved hypothetical protein  0.29 
SA0872  conserved hypothetical protein  2.62 
SA0873  conserved hypothetical protein  3.36 
SA0903  conserved hypothetical protein  0.41 
SA0906  conserved hypothetical protein  0.48 
SA0908  conserved hypothetical protein  0.39 
SA0919  conserved hypothetical protein  0.32 
SA0929  conserved hypothetical protein  18.84 
SA0933  hypothetical protein  0.39 
SA0955  hypothetical protein  0.50 
SA0999  conserved hypothetical protein  0.45 
SA1002  hypothetical protein  2.80 
SA1040  conserved hypothetical protein  2.32 
SA1049  hypothetical protein  11.12 
SA1133  conserved hypothetical protein  0.35 
SA1154  conserved hypothetical protein  0.45 
SA1168  hypothetical protein  2.51 
SA1250  conserved hypothetical protein  0.26 
SA1252  conserved hypothetical protein  0.50 
SA1265  conserved hypothetical protein  0.39 
SA1295  conserved hypothetical protein  0.36 
SA1320  hypothetical protein  0.15 
SA1321  hypothetical protein  0.18 
SA1331  conserved hypothetical protein  0.47 
SA1335  conserved hypothetical protein  2.29 
SA1419  conserved hypothetical protein  0.49 
SA1432  conserved hypothetical protein  0.28 
SA1433  conserved hypothetical protein  0.21 
SA1436  conserved hypothetical protein  0.19 
SA1437  conserved hypothetical protein  0.20 
SA1497  conserved hypothetical protein  2.01 
SA1544  hypothetical protein, similar to soluble hydrogenase 42 kD subunit  0.21 
SA1573  hypothetical protein  0.40 
SA1582  conserved hypothetical protein  0.46 
SA1590  hypothetical protein  0.47 
SA1595  hypothetical protein  0.23 
SA1596  hypothetical protein  0.13 
SA1597  hypothetical protein  0.10 
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SA1618  conserved hypothetical protein  3.29 
SA1619  hypothetical protein  2.94 
SA1639  hypothetical protein [Pathogenicity island SaPIn3] 0.36 
SA1641  hypothetical protein [Pathogenicity island SaPIn3] 3.83 
SA1692  conserved hypothetical protein  0.30 
SA1768  hypothetical protein [Bacteriophage phiN315] 2.37 
SA1770  hypothetical protein [Bacteriophage phiN315] 2.15 
SA1773  hypothetical protein [Bacteriophage phiN315] 2.19 
SA1774  hypothetical protein [Bacteriophage phiN315] 2.80 
SA1802  hypothetical protein [Bacteriophage phiN315] 0.45 
SA1803  hypothetical protein [Bacteriophage phiN315] 0.34 
SA1823  hypothetical protein [Pathogenicity island SaPIn1] 4.58 
SA1824  hypothetical protein [Pathogenicity island SaPIn1] 3.25 
SA1838  conserved hypothetical protein  0.24 
SA1839  hypothetical protein, similar to SdrH  0.48 
SA1849  conserved hypothetical protein  2.11 
SA1850  conserved hypothetical protein  2.83 
SA1918  conserved hypothetical protein  2.19 
SA1932  hypothetical protein, similar to hypothetical protein T13D8.31 - Arabidopsis thaliana  2.12 
SA1934  hypothetical protein  0.46 
SA1946  conserved hypothetical protein  0.09 
SA1971  hypothetical protein  0.19 
SA1976  conserved hypothetical protein  3.70 
SA1985  hypothetical protein  0.09 
SA1986  hypothetical protein  0.07 
SA2101  conserved hypothetical protein  0.18 
SA2106  hypothetical protein, similar to protein of pXO2-46  0.15 
SA2113  hypothetical protein  0.35 
SA2133  conserved hypothetical protein  2.18 
SA2143  conserved hypothetical protein  2.51 
SA2195  conserved hypothetical protein  0.35 
SA2196  conserved hypothetical protein  0.23 
SA2218  hypothetical protein  3.70 
SA2262  conserved hypothetical protein  0.09 
SA2265  hypothetical protein  0.28 
SA2271  hypothetical protein  0.36 
SA2272  hypothetical protein  0.25 
SA2315  conserved hypothetical protein  0.37 
SA2329  conserved hypothetical protein  3.29 
SA2350  conserved hypothetical protein  0.45 
SA2355  conserved hypothetical protein  0.12 
SA2359  hypothetical protein  0.33 
SA2366  conserved hypothetical protein  0.27 
SA2367  conserved hypothetical protein  0.18 
SA2371  conserved hypothetical protein  2.68 
SA2372  hypothetical protein  2.76 
SA2373  hypothetical protein  3.31 
SA2374  conserved hypothetical protein  0.28 
SA2377  conserved hypothetical protein  2.63 
SA2407  conserved hypothetical protein  2.15 
SA2432  conserved hypothetical protein  0.25 
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SA2449  hypothetical protein  0.46 
SA2450  hypothetical protein  0.41 
SA2451  hypothetical protein  0.40 
SA2452  conserved hypothetical protein  0.48 
SA2479  conserved hypothetical protein  0.48 
SA2480 drp35 Drp35  2.45 
SA2483  hypothetical protein  0.31 
SA2488  hypothetical protein  0.34 
SA2491  conserved hypothetical protein  0.46 
SAS001  conserved hypothetical protein  0.48 
SAS058  hypothetical protein  2.02 
 
1 Fold change in transcript level of at least 2-fold is indicated as mean of the “median of ratios”. 
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